0000105770-22-000054.txt : 20221027 0000105770-22-000054.hdr.sgml : 20221027 20221027162138 ACCESSION NUMBER: 0000105770-22-000054 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221027 DATE AS OF CHANGE: 20221027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 221337598 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-Q 1 wst-20220930.htm 10-Q wst-20220930
0000105770--12-312022Q3false00001057702022-01-012022-09-3000001057702022-10-17xbrli:shares00001057702022-07-012022-09-30iso4217:USD00001057702021-07-012021-09-3000001057702021-01-012021-09-30iso4217:USDxbrli:shares00001057702022-09-3000001057702021-12-3100001057702020-12-3100001057702021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2022-07-012022-09-30xbrli:pure0000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:BiologicsCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberwst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:PharmaCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:HighValueComponentsMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:DeliveryDevicesMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AmericasMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2021-01-012021-09-300000105770srt:AsiaPacificMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300000105770srt:AsiaPacificMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000105770srt:AsiaPacificMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300000105770srt:AsiaPacificMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300000105770us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-3000001057702013-06-300000105770wst:SmartDoseMember2022-09-300000105770wst:TermLoanDue2024Member2022-09-300000105770wst:TermLoanDue2024Member2021-12-310000105770wst:SeniorNotesDue2022Member2022-09-300000105770wst:SeniorNotesDue2022Member2021-12-310000105770wst:SeniorBNotesDue2024Member2022-09-300000105770wst:SeniorBNotesDue2024Member2021-12-310000105770wst:SeniorCNotesDue2027Member2022-09-300000105770wst:SeniorCNotesDue2027Member2021-12-310000105770wst:RevolvingCreditFacilityDue2024Member2022-02-280000105770wst:RevolvingCreditFacilityDue2024Member2022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:DomesticLineOfCreditMember2022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:ForeignLineOfCreditMember2022-03-310000105770wst:RevolvingCreditFacilityDue2024Member2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberwst:ApplicableMarginMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:FederalFundsEffectiveSwapRateMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-03-012022-03-310000105770us-gaap:BaseRateMemberwst:RevolvingCreditFacilityDue2024Membersrt:MinimumMember2022-03-012022-03-310000105770us-gaap:BaseRateMemberwst:RevolvingCreditFacilityDue2024Membersrt:MaximumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMember2022-03-012022-03-31wst:instancewst:fiscal_quarter0000105770wst:Revolvingcreditfacilitydue2024Member2022-09-300000105770wst:Revolvingcreditfacilitydue2024Memberus-gaap:LetterOfCreditMember2022-09-300000105770us-gaap:ForwardContractsMembercurrency:SGD2022-09-30iso4217:SGD0000105770us-gaap:ForwardContractsMembercurrency:USD2022-09-300000105770us-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000105770us-gaap:LongMemberus-gaap:ForeignExchangeForwardMembercurrency:USDus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000105770us-gaap:ForeignExchangeForwardMembercurrency:USDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2022-09-30iso4217:EUR0000105770currency:JPYus-gaap:LongMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-30iso4217:JPY0000105770currency:JPYus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2022-09-300000105770us-gaap:LongMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2022-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGDus-gaap:ShortMember2022-09-300000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USDus-gaap:NetInvestmentHedgingMember2019-12-310000105770currency:JPYus-gaap:CrossCurrencyInterestRateContractMember2022-09-300000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USD2022-09-300000105770us-gaap:OptionMember2017-11-012022-09-30utr:bbl0000105770us-gaap:OptionMember2022-01-012022-09-300000105770us-gaap:OptionMember2022-09-30iso4217:USDwst:bbl0000105770us-gaap:ForeignCurrencyGainLossMember2022-07-012022-09-300000105770us-gaap:ForeignCurrencyGainLossMember2021-07-012021-09-300000105770us-gaap:ForeignCurrencyGainLossMember2022-01-012022-09-300000105770us-gaap:ForeignCurrencyGainLossMember2021-01-012021-09-300000105770us-gaap:FairValueHedgingMember2022-07-012022-09-300000105770us-gaap:FairValueHedgingMember2022-01-012022-09-300000105770us-gaap:FairValueHedgingMember2021-07-012021-09-300000105770us-gaap:FairValueHedgingMember2021-01-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2022-07-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2021-07-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2022-07-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2021-07-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-07-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2021-07-012021-09-300000105770us-gaap:CashFlowHedgingMember2022-07-012022-09-300000105770us-gaap:CashFlowHedgingMember2021-07-012021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000105770us-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000105770us-gaap:NetInvestmentHedgingMember2021-07-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2022-01-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2021-01-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2022-01-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2021-01-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2022-01-012022-09-300000105770us-gaap:CashFlowHedgingMemberus-gaap:TreasuryLockMember2021-01-012021-09-300000105770us-gaap:CashFlowHedgingMember2022-01-012022-09-300000105770us-gaap:CashFlowHedgingMember2021-01-012021-09-300000105770us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-09-300000105770us-gaap:NetInvestmentHedgingMember2022-01-012022-09-300000105770us-gaap:NetInvestmentHedgingMember2021-01-012021-09-300000105770wst:NetSalesMember2022-07-012022-09-300000105770wst:NetSalesMember2021-07-012021-09-300000105770wst:NetSalesMember2022-01-012022-09-300000105770wst:NetSalesMember2021-01-012021-09-300000105770us-gaap:CostOfSalesMember2022-07-012022-09-300000105770us-gaap:CostOfSalesMember2021-07-012021-09-300000105770us-gaap:CostOfSalesMember2022-01-012022-09-300000105770us-gaap:CostOfSalesMember2021-01-012021-09-300000105770us-gaap:InterestExpenseMember2022-07-012022-09-300000105770us-gaap:InterestExpenseMember2021-07-012021-09-300000105770us-gaap:InterestExpenseMember2022-01-012022-09-300000105770us-gaap:InterestExpenseMember2021-01-012021-09-300000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2022-07-012022-09-300000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2021-07-012021-09-300000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2022-01-012022-09-300000105770us-gaap:ForeignCurrencyGainLossMemberus-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2021-01-012021-09-300000105770us-gaap:NondesignatedMember2022-07-012022-09-300000105770us-gaap:NondesignatedMember2021-07-012021-09-300000105770us-gaap:NondesignatedMember2022-01-012022-09-300000105770us-gaap:NondesignatedMember2021-01-012021-09-300000105770us-gaap:FairValueInputsLevel1Member2022-09-300000105770us-gaap:FairValueInputsLevel2Member2022-09-300000105770us-gaap:FairValueInputsLevel3Member2022-09-300000105770us-gaap:ForeignExchangeContractMember2022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2022-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2022-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2022-09-300000105770us-gaap:CurrencySwapMember2022-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2022-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2022-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2022-09-300000105770us-gaap:FairValueInputsLevel1Member2021-12-310000105770us-gaap:FairValueInputsLevel2Member2021-12-310000105770us-gaap:FairValueInputsLevel3Member2021-12-310000105770us-gaap:ForeignExchangeContractMember2021-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2021-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2021-12-310000105770us-gaap:CurrencySwapMember2021-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2021-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2021-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2021-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:TreasuryLockMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000105770us-gaap:CommonStockMember2021-12-310000105770us-gaap:AdditionalPaidInCapitalMember2021-12-310000105770us-gaap:TreasuryStockCommonMember2021-12-310000105770us-gaap:RetainedEarningsMember2021-12-310000105770us-gaap:RetainedEarningsMember2022-01-012022-03-3100001057702022-01-012022-03-310000105770us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000105770us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000105770us-gaap:CommonStockMember2022-03-310000105770us-gaap:AdditionalPaidInCapitalMember2022-03-310000105770us-gaap:TreasuryStockCommonMember2022-03-310000105770us-gaap:RetainedEarningsMember2022-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100001057702022-03-310000105770us-gaap:RetainedEarningsMember2022-04-012022-06-3000001057702022-04-012022-06-300000105770us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000105770us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000105770us-gaap:CommonStockMember2022-06-300000105770us-gaap:AdditionalPaidInCapitalMember2022-06-300000105770us-gaap:TreasuryStockCommonMember2022-06-300000105770us-gaap:RetainedEarningsMember2022-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000001057702022-06-300000105770us-gaap:RetainedEarningsMember2022-07-012022-09-300000105770us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000105770us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000105770us-gaap:CommonStockMember2022-09-300000105770us-gaap:AdditionalPaidInCapitalMember2022-09-300000105770us-gaap:TreasuryStockCommonMember2022-09-300000105770us-gaap:RetainedEarningsMember2022-09-300000105770us-gaap:CommonStockMember2020-12-310000105770us-gaap:AdditionalPaidInCapitalMember2020-12-310000105770us-gaap:TreasuryStockCommonMember2020-12-310000105770us-gaap:RetainedEarningsMember2020-12-310000105770us-gaap:RetainedEarningsMember2021-01-012021-03-3100001057702021-01-012021-03-310000105770us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000105770us-gaap:TreasuryStockCommonMember2021-01-012021-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000105770us-gaap:CommonStockMember2021-03-310000105770us-gaap:AdditionalPaidInCapitalMember2021-03-310000105770us-gaap:TreasuryStockCommonMember2021-03-310000105770us-gaap:RetainedEarningsMember2021-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100001057702021-03-310000105770us-gaap:RetainedEarningsMember2021-04-012021-06-3000001057702021-04-012021-06-300000105770us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000105770us-gaap:TreasuryStockCommonMember2021-04-012021-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000105770us-gaap:CommonStockMember2021-06-300000105770us-gaap:AdditionalPaidInCapitalMember2021-06-300000105770us-gaap:TreasuryStockCommonMember2021-06-300000105770us-gaap:RetainedEarningsMember2021-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000001057702021-06-300000105770us-gaap:RetainedEarningsMember2021-07-012021-09-300000105770us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000105770us-gaap:TreasuryStockCommonMember2021-07-012021-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000105770us-gaap:CommonStockMember2021-09-300000105770us-gaap:AdditionalPaidInCapitalMember2021-09-300000105770us-gaap:TreasuryStockCommonMember2021-09-300000105770us-gaap:RetainedEarningsMember2021-09-300000105770us-gaap:PerformanceSharesMember2022-01-012022-09-300000105770us-gaap:PerformanceSharesMember2022-09-300000105770us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-07-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-07-012021-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000105770country:US2022-07-012022-09-300000105770country:US2021-07-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-07-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000105770us-gaap:ForeignPlanMember2022-07-012022-09-300000105770us-gaap:ForeignPlanMember2021-07-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-01-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-01-012021-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000105770country:US2022-01-012022-09-300000105770country:US2021-01-012021-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-09-300000105770us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000105770us-gaap:ForeignPlanMember2022-01-012022-09-300000105770us-gaap:ForeignPlanMember2021-01-012021-09-300000105770wst:A2020RestructuringPlanMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2020-07-310000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MaximumMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMember2020-07-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2021-12-310000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2021-12-310000105770wst:A2020RestructuringPlanMember2021-12-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2022-01-012022-09-300000105770wst:A2020RestructuringPlanMember2022-01-012022-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:OtherRestructuringMember2022-09-300000105770wst:A2020RestructuringPlanMember2022-09-30wst:segment0000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000105770wst:PackagingSystemsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000105770wst:DeliverySystemsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770us-gaap:IntersegmentEliminationMember2022-07-012022-09-300000105770us-gaap:IntersegmentEliminationMember2021-07-012021-09-300000105770us-gaap:IntersegmentEliminationMember2022-01-012022-09-300000105770us-gaap:IntersegmentEliminationMember2021-01-012021-09-300000105770us-gaap:OperatingSegmentsMember2022-07-012022-09-300000105770us-gaap:OperatingSegmentsMember2021-07-012021-09-300000105770us-gaap:OperatingSegmentsMember2022-01-012022-09-300000105770us-gaap:OperatingSegmentsMember2021-01-012021-09-300000105770us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000105770us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000105770us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000105770us-gaap:CorporateNonSegmentMember2021-01-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania23-1210010
 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
530 Herman O. West Drive, Exton, PA
19341-0645
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.          Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                      Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑ Accelerated filer☐
Non-accelerated filer
☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                      ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
As of October 17, 2022, there were 74,032,987 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS
  Page
 
ITEM 1. 
 
 
 
 
 
ITEM 2.
ITEM 3.
ITEM 4.
   
 
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 6.
   
   

2
PART I. FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)

 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Net sales$686.9 $706.5 $2,178.2 $2,100.8 
Cost of goods and services sold418.9 418.3 1,304.1 1,225.6 
Gross profit268.0 288.2 874.1 875.2 
Research and development13.6 13.1 42.6 39.1 
Selling, general and administrative expenses66.3 91.9 231.2 264.8 
Other (income) expense (Note 15)1.9 1.8 (4.0)3.0 
Operating profit186.2 181.4 604.3 568.3 
Interest expense2.2 1.8 6.2 5.6 
Interest income(1.5)(0.4)(2.2)(0.7)
Other nonoperating expense (income)49.3 (1.1)49.1 (3.6)
Income before income taxes136.2 181.1 551.2 567.0 
Income tax expense20.4 12.0 85.8 73.0 
Equity in net income of affiliated companies(4.8)(6.5)(17.5)(20.1)
Net income$120.6 $175.6 $482.9 $514.1 
Net income per share:   
Basic$1.62 $2.37 $6.49 $6.95 
Diluted$1.59 $2.31 $6.36 $6.78 
Weighted average shares outstanding:    
Basic74.4 74.1 74.4 74.0 
Diluted75.7 76.0 75.9 75.8 

See accompanying notes to condensed consolidated financial statements.
3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Net income$120.6 $175.6 $482.9 $514.1 
Other comprehensive loss, net of tax:   
Foreign currency translation adjustments, net of tax of $1.1, $0.1, $3.8 and $1.8, respectively
(76.0)(24.2)(162.5)(46.9)
Defined benefit pension and other postretirement plan adjustments, net of tax of $14.6, $0.2, $15.5, and $0.4, respectively
13.6 0.4 16.4 1.1 
Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively
(0.1)— (0.2)— 
Net (loss) gain on derivatives, net of tax of $0.0, $(0.4), $(0.8) and $(0.4), respectively
(0.1)1.3 (2.6)0.7 
Other comprehensive loss, net of tax(62.6)(22.5)(148.9)(45.1)
Comprehensive income$58.0 $153.1 $334.0 $469.0 

See accompanying notes to condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)September 30,
2022		December 31,
2021
ASSETS  
Current assets:  
Cash and cash equivalents$729.0 $762.6 
Accounts receivable, net485.3 489.0 
Inventories413.1 378.4 
Other current assets106.2 112.0 
Total current assets1,733.6 1,742.0 
Property, plant and equipment2,232.9 2,215.0 
Less: accumulated depreciation and amortization1,163.9 1,157.5 
Property, plant and equipment, net1,069.0 1,057.5 
Operating lease right-of-use assets86.6 69.3 
Investments in affiliated companies188.6 207.7 
Goodwill104.0 109.9 
Intangible assets, net18.1 23.0 
Deferred income taxes63.0 48.5 
Pension and other postretirement benefits1.2 16.7 
Other noncurrent assets52.7 39.2 
Total Assets$3,316.8 $3,313.8 
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$2.2 $44.2 
Accounts payable188.9 232.2 
Pension and other postretirement benefits2.3 2.4 
Accrued salaries, wages and benefits66.7 116.3 
Income taxes payable29.9 26.3 
Operating lease liabilities13.3 9.3 
Other current liabilities153.4 163.4 
Total current liabilities456.7 594.1 
Long-term debt207.2 208.8 
Deferred income taxes16.6 4.9 
Pension and other postretirement benefits35.2 40.5 
Operating lease liabilities77.2 63.0 
Deferred compensation benefits19.2 28.9 
Other long-term liabilities33.9 38.2 
Total Liabilities846.0 978.4 
Commitments and contingencies (Note 17)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
— — 
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.2 million, respectively
18.8 18.8 
Capital in excess of par value230.6 249.0 
Retained earnings2,913.1 2,456.7 
Accumulated other comprehensive loss(308.5)(159.6)
Treasury stock, at cost (1.3 million and 1.1 million shares, respectively)
(383.2)(229.5)
Total Equity2,470.8 2,335.4 
Total Liabilities and Equity$3,316.8 $3,313.8 
See accompanying notes to condensed consolidated financial statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Nine Months Ended
September 30,
 20222021
Cash flows from operating activities:  
Net income$482.9 $514.1 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation86.8 84.6 
Amortization2.7 3.3 
Stock-based compensation17.0 27.5 
Pension settlement charge50.8 0.7 
Contingent consideration payments in excess of acquisition-date liability(1.4)(1.0)
Other non-cash items, net(16.3)(17.5)
Changes in assets and liabilities
(129.3)(188.5)
Net cash provided by operating activities493.2 423.2 
Cash flows from investing activities:  
Capital expenditures(189.7)(176.9)
Other, net(3.7)1.2 
Net cash used in investing activities(193.4)(175.7)
Cash flows from financing activities:  
Repayments of long-term debt(43.7)(1.1)
Debt issuance costs(1.3)— 
Dividend payments(40.0)(37.8)
Proceeds from stock-based compensation awards17.1 23.1 
Employee stock purchase plan contributions6.1 5.7 
Shares purchased under share repurchase programs(202.9)(137.1)
Shares repurchased for employee tax withholdings(19.4)(14.7)
Net cash used in financing activities(284.1)(161.9)
Effect of exchange rates on cash(49.3)(13.1)
Net (decrease) increase in cash and cash equivalents(33.6)72.5 
Cash, including cash equivalents at beginning of period762.6 615.5 
Cash, including cash equivalents at end of period$729.0 $688.0 

See accompanying notes to condensed consolidated financial statements.
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1:  Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.

Note 2:  New Accounting Standards

Recently Adopted Standards

In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements.

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We adopted this guidance during the quarter and its adoption did not have a material impact on our financial statements.

Note 3:  Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

7
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Biologics
41 %
40 %
42 %
40 %
Generics
 18 %
18 %
18 %
17 %
Pharma
24 %
24 %
24 %
24 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
High-Value Product Components
54 %
55 %
56 %
54 %
High-Value Product Delivery Devices
6 %
5 %
5 %
4 %
Standard Packaging
23 %
22 %
23 %
23 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Americas
53 %
45 %
48 %
45 %
Europe, Middle East, Africa
38 %
45 %
43 %
45 %
Asia Pacific
9 %
10 %
9 %
10 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2021$14.6 
Contract assets, September 30, 2022
18.3 
Change in contract assets - increase (decrease)$3.7 
Deferred income, December 31, 2021$(61.3)
Deferred income, September 30, 2022
(52.0)
Change in deferred income - decrease (increase)$9.3 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2022, $23.6 million of revenue was recognized that was included in deferred income at the beginning of the year.
8

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2022, there was $3.2 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $2.3 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.


Note 4:  Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2022202120222021
Net income$120.6 $175.6 $482.9 $514.1 
Weighted average common shares outstanding74.4 74.1 74.4 74.0 
Dilutive effect of equity awards, based on the treasury stock method
1.3 1.9 1.5 1.8 
Weighted average shares assuming dilution75.7 76.0 75.9 75.8 

During the three months ended September 30, 2022 and 2021, there were 0.2 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.0 million antidilutive shares outstanding during the nine months ended September 30, 2022 and 2021, respectively.

In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2022.

During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the program at a cost of $202.9 million, or an average price of $360.03 per share.

Note 5:  Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2022		December 31,
2021
Raw materials$179.0 $153.8 
Work in process79.0 63.5 
Finished goods155.1 161.1 
 $413.1 $378.4 

9
Note 6:  Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating lease cost$3.7 $3.3 $10.4 $9.5 
Short-term lease cost0.3 0.4 1.1 0.9 
Variable lease cost2.3 1.1 4.7 3.3 
Total lease cost$6.3 $4.8 $16.2 $13.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.7 $2.9 $10.0 $9.2 
Right-of-use assets obtained in exchange for new operating lease liabilities$14.0 $— $29.5 $0.8 

As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term for operating leases was 8.9 and 10.7 years, respectively.

As of September 30, 2022 and December 31, 2021, the weighted average discount rate was 3.27% and 3.58%, respectively.

10
Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20222021
2022 (remaining period as of)$4.2 $11.5 
202315.9 10.7 
202414.9 10.0 
202512.8 8.2 
202611.6 7.3 
Thereafter45.0 38.7 
104.4 86.4 
Less: imputed lease interest(13.9)(14.1)
Total lease liabilities$90.5 $72.3 

Note 7:  Affiliated Companies

At September 30, 2022 and December 31, 2021, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $177.2 million and $201.2 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $11.4 million and $6.5 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $33.6 million and $131.2 million for the three and nine months ended September 30, 2022, respectively, as compared to $34.0 million and $119.6 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the payable balance due to affiliates was $20.8 million and $25.5 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.6 million and $10.2 million, respectively, for the three and nine months ended September 30, 2022, as compared to $2.8 million and $8.8 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the receivable balance due from affiliates was $1.8 million and $2.3 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2021 Annual Report for additional details.

11
Note 8:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2022, with the exception of the Series A notes which is as of December 31, 2021.
($ in millions)September 30,
2022		December 31,
2021
Term Loan, due December 31, 2024 (4.53%)
$83.8 $85.5 
Series A notes, due July 5, 2022 (3.67%)
— 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
209.8 253.5 
Less: unamortized debt issuance costs0.4 0.5 
Total debt209.4 253.0 
Less: current portion of long-term debt2.2 44.2 
Long-term debt, net$207.2 $208.8 


Credit Facility

In March 2022, we amended and extended the existing credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve month period in the aggregate through an increase in the revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions.

At September 30, 2022, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2022, we were in compliance with all of our debt covenants.

12
Term Loan

At September 30, 2022, we had $83.8 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $81.6 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Please refer to Note 10, Debt, to the consolidated financial statements in our 2021 Annual Report for additional details regarding our debt agreements.

Note 9:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of September 30, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD13.5 — 11.8 
Yen5,686.2 23.8 20.6 
SGD68.7 33.7 15.6 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2022, the notional amount of the cross-currency swap is ¥9.2 billion ($83.8 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2022, we purchased several series of call options for a total of 823,536 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.
13

As of September 30, 2022, we had outstanding contracts to purchase 259,559 barrels of crude oil from September 2022 to June 2024, at a weighted-average strike price of $109.84 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2022 and December 31, 2021.

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Fair Value Hedges:
Hedged item (intercompany loan)
$(14.1)$(5.9)$(35.4)$(11.0)Other (income) expense
Derivative designated as hedging instrument
14.1 5.9 35.4 11.0 Other (income) expense
Amount excluded from effectiveness testing
2.2 0.9 4.4 2.1 Other (income) expense
Total$2.2 $0.9 $4.4 $2.1 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 and 2021 were $1.1 million, $2.8 million, and $0.6 million, $1.9 million, respectively.

14
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$(0.4)$(0.2)$0.5 $0.1 Other (income) expense
Total$(0.4)$(0.2)$0.5 $0.1 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.7 $0.1 $(0.5)$0.1 Net sales
Foreign currency hedge contracts(1.5)1.4 1.0 (0.3)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.8)$1.5 $0.6 $(0.1) 
Net Investment Hedges:     
Cross-currency swap$4.3 $0.6 $— $— Other (income) expense
Total$4.3 $0.6 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$0.3 $(0.6)$(0.7)$0.9 Other (income) expense
Total$0.3 $(0.6)$(0.7)$0.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$1.1 $(0.5)$(1.1)$0.9 Net sales
Foreign currency hedge contracts(4.9)(1.4)2.5 1.2 Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(3.8)$(1.9)$1.6 $2.3  
Net Investment Hedges:     
Cross-currency swap$13.2 $6.0 $— $— Other (income) expense
Total$13.2 $6.0 $— $—  
15

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales$(0.5)$0.1 $(1.1)$0.9 
Cost of goods and services sold1.0 (0.3)2.5 1.2 
Interest expense0.1 0.1 0.2 0.2 
Other (income) expense0.5 0.1 (0.7)0.9 

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Commodity call options$(1.5)$0.5 $1.6 $1.6 Other (income) expense
Total$(1.5)$0.5 $1.6 $1.6 

For the three and nine months ended September 30, 2022 and 2021, there was no material ineffectiveness related to our hedges.

Note 10:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

16
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.3 $12.3 $— $— 
Foreign currency contracts22.6 — 22.6 — 
Cross-currency swap20.5 — 20.5 — 
Commodity call options1.3 — 1.3 — 
 $56.7 $12.3 $44.4 $— 
Liabilities:    
Contingent consideration$4.9 $— $— $4.9 
Deferred compensation liabilities12.6 12.6 — — 
Foreign currency contracts8.8 — 8.8 — 
 $26.3 $12.6 $8.8 $4.9 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$15.5 $15.5 $— $— 
Foreign currency contracts14.8 — 14.8 — 
Cross-currency swap4.4 — 4.4 — 
Commodity call options1.7 1.7 
 $36.4 $15.5 $20.9 $— 
Liabilities:    
Contingent consideration$3.7 $— $— $3.7 
Deferred compensation liabilities16.1 16.1 — — 
Foreign currency contracts3.4 — 3.4 — 
 $23.2 $16.1 $3.4 $3.7 

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other (income) expense in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.

17
Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2022, the estimated fair value of long-term debt was $202.2 million compared to a carrying amount of $207.2 million. At December 31, 2021, the estimated fair value of long-term debt was $217.9 million and the carrying amount was $208.8 million.

Note 11:  Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income 0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive (loss) income before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive (loss) income3.2 — 0.5 — 3.7 
Other comprehensive (loss) income, net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)











18
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2022202120222021
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(0.1)$1.2 $(1.1)Net sales
Foreign currency contracts(1.2)0.4 (2.9)(1.9)Cost of goods and services sold
Foreign currency contracts(0.7)(0.9)1.1 (2.1)Other (income) expense
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(1.5)(0.7)(0.9)(5.4)
Tax benefit (expense)0.4 0.7 — 2.2 
Net of tax$(1.1)$— $(0.9)$(3.2)
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$— $0.1 $— $0.2 (a)
Actuarial gains (losses)1.1 0.1 1.1 (0.1)(a)
Settlements(27.6)— (28.8)(0.7)(a)
Other— — (0.4)— 
Total before tax(26.5)0.2 (28.1)(0.6)
Tax benefit (expense)14.2 (0.1)14.6 0.1 
Net of tax$(12.3)$0.1 $(13.5)$(0.5)
Total reclassifications for the period, net of tax$(13.4)$0.1 $(14.4)$(3.7)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
19
Note 12: Shareholders’ Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive income, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 

20
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 

21
Note 13:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2022, there were 1,692,482 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2022, we granted 116,820 stock options at a weighted average exercise price of $366.15 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $96.63 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.8%; expected life of 5.6 years based on prior experience; stock volatility of 25.1% based on historical data; and a dividend yield of 0.2%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2022, we granted 31,597 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $364.54 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2022, we granted 4,987 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $354.65 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Stock-based compensation expense was $6.0 million and $17.0 million for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, stock-based compensation expense was $11.4 million and $27.5 million, respectively.

Note 14:  Benefit Plans

The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$0.3 $0.1 $— $— $0.3 $0.1 
Interest cost0.5 1.6 0.1 — 0.6 1.6 
Expected return on assets(0.8)(2.9)— — (0.8)(2.9)
Amortization of prior service credit— — — (0.1)— (0.1)
Recognized actuarial losses (gains)0.3 0.5 (0.4)(0.3)(0.1)0.2 
Settlements49.6 — — — 49.6 — 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)
22
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$49.6 $(0.9)$(0.3)$(0.4)$49.3 $(1.3)
International plans0.3 0.2 — — 0.3 0.2 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$1.0 $0.9 $— $— $1.0 $0.9 
Interest cost3.7 4.5 0.1 0.1 3.8 4.6 
Expected return on assets(5.4)(9.0)— — (5.4)(9.0)
Amortization of prior service credit— 0.1 — (0.3)— (0.2)
Recognized actuarial losses (gains)1.0 1.5 (1.1)(1.2)(0.1)0.3 
Settlements50.8 0.7 — — 50.8 0.7 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$50.3 $(2.4)$(1.0)$(1.4)$49.3 $(3.8)
International plans0.8 1.1 — — 0.8 1.1 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating expense (income), which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for the U.S. pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

23
Note 15:  Other (Income) Expense

Other (income) expense consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Restructuring and related charges$— $0.4 $(1.6)$2.5 
Fixed asset impairments and loss on sale of equipment1.4 0.2 1.5 0.6 
Contingent consideration1.5 0.1 2.6 0.9 
Foreign exchange transaction (gains) losses(2.2)0.4 (4.6)(2.5)
Other items1.2 0.7 (1.9)1.5 
Total other (income) expense$1.9 $1.8 $(4.0)$3.0 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $5 million to $6 million, with annualized savings in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $5.2 million in restructuring and related charges associated with this plan.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2021$2.8 $0.5 $3.3 
(Credits) Charges(1.4)(0.2)(1.6)
Cash payments(0.6)(0.2)(0.8)
Balance, September 30, 2022$0.8 $0.1 $0.9 

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Other Items

During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2021, we recorded a gain of $0.5 million and $1.6 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our hedging activity.

During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a net loss in our cost investment activity of $1.8 million, inclusive of an impairment charge of $2.2 million for one of the Company's cost investments.

24
Note 16:  Income Taxes

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $20.4 million and $12.0 million for the three months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.0% and 6.6%, respectively. The provision for income taxes was $85.8 million and $73.0 million for the nine months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.6% and 12.9%, respectively.

The increase in effective tax rate for the three months ended September 30, 2022 and 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.0 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans,. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.0 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.

The increase in effective tax rate for the nine months ended September 30, 2022 and 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.3 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans,. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.3 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.

Note 17:  Commitments and Contingencies

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2021 Annual Report.

Note 18:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

25
The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales:    
Proprietary Products$567.0 $577.0 $1,822.0 $1,708.0 
Contract-Manufactured Products120.0 129.7 356.5 393.2 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.4)
Consolidated net sales$686.9 $706.5 $2,178.2 $2,100.8 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating profit (loss):
Proprietary Products$188.6 $195.5 $615.9 $594.3 
Contract-Manufactured Products14.7 16.8 48.0 51.9 
Total business segment operating profit$203.3 $212.3 $663.9 $646.2 
Corporate and Unallocated
Stock-based compensation expense$(6.0)$(11.4)$(17.0)$(27.5)
Corporate general costs (1)(10.9)(18.1)(43.6)(45.5)
Unallocated Items:
Restructuring and related charges— (0.3)1.6 (2.5)
Amortization of acquisition-related intangible assets (2)(0.2)(0.2)(0.6)(0.6)
Cost investment activity— (0.9)— (1.8)
Total Corporate and Unallocated(17.1)(30.9)(59.6)(77.9)
Total consolidated operating profit$186.2 $181.4 $604.3 $568.3 
Interest expense (income) and other nonoperating expense (income), net50.0 0.3 53.1 1.3 
Income before income taxes$136.2 $181.1 $551.2 $567.0 

26
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other (Income) Expense, for further discussion of these items.

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2021 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2021 Annual Report and in Part II, Item 1A of this Form 10-Q.

Throughout this section, references to “Notes” refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position. For a reconciliation of each non-U.S. GAAP financial measure to the most directly comparable U.S. GAAP financial measure, refer to the "2022 Financial Performance Summary" section.









27
Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world.
Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

Impact of COVID-19 and other Macroeconomic Factors

West has been actively monitoring the COVID-19 pandemic and its impact globally. Our primary objectives have remained the same throughout the pandemic: to support the safety of our team members and their families and continue to support patients around the world. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. Our capital and financial resources, including overall liquidity, remain strong. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.

However, we cannot predict the impact of the progression of the COVID-19 pandemic on future results due to a variety of factors, including the continued good health of our employees, the ability of suppliers to continue to operate and deliver, the ability of West and its customers to maintain operations, continued access to transportation resources, the changing needs and priorities of customers, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. We will continue to closely monitor the COVID-19 pandemic in order to ensure the safety of our people and our ability to serve our customers and patients worldwide.

Through the nine months ended September 30, 2022, the war between Russia and Ukraine has not had a material impact on the Company’s business, financial condition or results of operations as we do not have manufacturing operations or significant commercial relationships in either country. However, the Company is closely monitoring the broader impact that this war has on availability of raw materials, logistics and access to European energy sources.











28

2022 Financial Performance Summary

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2022:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2022 GAAP
$186.2 $20.4 $120.6 $1.59 
Unallocated items:
Pension settlement (2)
— 20.0 29.6 0.39 
Amortization of acquisition-related intangible assets (3)
0.2 0.1 0.7 0.01 
Tax law changes (5)
— (3.2)3.2 0.04 
Three months ended September 30, 2022 adjusted amounts (non-U.S. GAAP)
$186.4 $37.3 $154.1 $2.03 

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2022 GAAP
$604.3 $85.8 $482.9 $6.36 
Unallocated items:
Restructuring and severance related charges (1)
(1.6)(0.4)(1.2)(0.01)
Pension settlement (2)
— 20.3 30.5 0.40 
Amortization of acquisition-related intangible assets (3)
0.6 0.1 2.1 0.03 
Royalty acceleration (4)
— 1.3 (1.3)(0.02)
Tax law changes (5)
— (3.2)3.2 0.04 
Nine months ended September 30, 2022 adjusted amounts (non-U.S. GAAP)
$603.3 $103.9 $516.2 $6.80 

During the three and nine months ended September 30, 2022, we recorded a tax benefit of $2.1 million and $12.3 million, respectively, associated with stock-based compensation.
















29
The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures for the three and nine months ended September 30, 2021:

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Three months ended September 30, 2021 GAAP
$181.4 $12.0 $175.6 $2.31 
Unallocated items:
Restructuring and severance related charges (1)
0.3 0.1 0.2 — 
Amortization of acquisition-related intangible assets (3)
0.2 — 0.7 0.01 
Royalty acceleration (4)
— 20.4 (20.4)(0.27)
Cost investment activity (6)
0.9 0.2 0.7 0.01 
Three months ended September 30, 2021 adjusted amounts (non-U.S. GAAP)
$182.8 $32.7 $156.8 $2.06 

($ in millions, except per share data)Operating ProfitIncome tax expenseNet incomeDiluted EPS
Nine months ended September 30, 2021 GAAP
$568.3 $73.0 $514.1 $6.78 
Unallocated items:
Restructuring and severance related charges (1)
2.5 0.6 1.9 0.02 
Pension settlement (2)
— 0.2 0.6 0.01 
Amortization of acquisition-related intangible assets (3)
0.6 0.1 2.1 0.03 
Royalty acceleration (4)
— 20.4 (20.4)(0.27)
Tax law changes (5)
— 1.4 (1.4)(0.02)
Cost investment activity (6)
1.8 (0.1)1.9 0.02 
Nine months ended September 30, 2021 adjusted amounts (non-U.S. GAAP)
$573.2 $95.6 $498.8 $6.57 

During the three and nine months ended September 30, 2021, we recorded a tax benefit of $8.4 million and $26.9 million, respectively, associated with stock-based compensation.

(1)During the nine months ended September 30, 2022, the Company recorded a benefit of $1.6 million in restructuring and severance related costs in connection with its 2020 plan related to revised severance estimates. During the three and nine months ended September 30, 2021, the Company recorded $0.3 million and $2.5 million, respectively, of restructuring and severance related costs.

(2)During the three and nine months ended September 30, 2022, we recorded a gross pension settlement charge of $49.6 million and $50.8 million, respectively, within other nonoperating expense (income), that fully settles the U.S. qualified defined benefit plan (the "U.S. pension plan"). During the nine months ended September 30, 2021, we recorded a pension settlement charge within other nonoperating expense (income), as it was determined that normal-course lump-sum payments for our U.S. pension plan exceeded the threshold for settlement accounting. Please refer to Note 14, Benefit Plans, for further discussion of these items.

30
(3)During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2022, the Company recorded $0.6 million and $1.6 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.5 million and $1.6 million, respectively, of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

(4)During the nine months ended September 30, 2022, the Company increased its expected tax benefit related to the prepayment of future royalties from one of its subsidiaries by $1.3 million. During the three and nine months ended September 30, 2021, the Company prepaid future royalties from one of its subsidiaries, which resulted in a $20.4 million tax benefit.

(5)During the three and nine months ended September 30, 2022, the Company incurred additional tax expense of $3.2 million due to the impact of a tax law change in the state of Pennsylvania enacted during the period. During the nine months ended September 30, 2021, the Company recorded a tax benefit of $1.4 million due to the impact of a United Kingdom tax law change enacted during the period.

(6)During the three months ended September 30, 2021, we recorded a net loss on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded an impairment charge on one of our cost investments, partially offset by the gain on the sale of one of our cost investments.

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.

Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment, for the three months ended September 30, 2022 and 2021:
Three Months Ended
September 30,		Percentage Change
($ in millions)20222021As-ReportedOrganic
Proprietary Products$567.0 $577.0 (1.7)%5.5 %
Contract-Manufactured Products120.0 129.7 (7.5)%(1.2)%
Intersegment sales elimination(0.1)(0.2)— — 
Consolidated net sales$686.9 $706.5 (2.8)%4.3 %

Consolidated net sales decreased by $19.6 million, or 2.8%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $49.8 million.
31
Excluding foreign currency translation effects, consolidated net sales for the three months ended September 30, 2022 increased by $30.2 million, or 4.3%, as compared to the same period in 2021.

Proprietary Products – Proprietary Products net sales decreased by $10.0 million, or 1.7%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $41.7 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2022 increased by $31.7 million, or 5.5%, as compared to the same period in 2021, primarily due to growth in our high-value product offerings, including our Westar® and NovaPure® products, and sales price increases, offset by a decline in COVID-19 related activity for COVID-19 vaccines and antiviral treatments.

Contract-Manufactured Products – Contract-Manufactured Products net sales decreased by $9.7 million, or 7.5%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $8.1 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2022 decreased by $1.6 million, or 1.2%, as compared to the same period in 2021, due to a decline in sales of components for diagnostic devices, offset by sales price increases.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table presents net sales, consolidated and by reportable segment, for the nine months ended September 30, 2022 and 2021:
Nine Months Ended
September 30,		Percentage Change
($ in millions)20222021As-ReportedOrganic
Proprietary Products$1,822.0 $1,708.0 6.7 %12.7 %
Contract-Manufactured Products356.5 393.2 (9.3)%(4.8)%
Intersegment sales elimination(0.3)(0.4)— — 
Consolidated net sales$2,178.2 $2,100.8 3.7 %9.5 %

Consolidated net sales increased by $77.4 million, or 3.7%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $121.3 million. Excluding foreign currency translation effects, consolidated net sales for the nine months ended September 30, 2022 increased by $198.7 million, or 9.5%, as compared to the same period in 2021.

Proprietary Products – Proprietary Products net sales increased by $114.0 million, or 6.7%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $103.3 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2022 increased by $217.3 million, or 12.7%, as compared to the same period in 2021, primarily due to growth in our high-value product offerings, including our NovaPure®, Westar® and Envision® products.

Contract-Manufactured Products – Contract-Manufactured Products net sales decreased by $36.7 million, or 9.3%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $18.0 million. Excluding foreign currency translation effects, net sales for the nine months ended September 30, 2022 decreased by $18.7 million, or 4.8%, as compared to the same period in 2021, due to a decline in sales of components for diagnostic devices, offset by sales price increases.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.
32
Gross Profit

The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Proprietary Products:  
Gross profit$247.3 $267.3 $810.3 $811.5 
Gross profit margin43.6 %46.3 %44.5 %47.5 %
Contract-Manufactured Products:   
Gross profit$20.7 $20.9 $63.8 $63.7 
Gross profit margin17.3 %16.1 %17.9 %16.2 %
Consolidated gross profit$268.0 $288.2 $874.1 $875.2 
Consolidated gross profit margin39.0 %40.8 %40.1 %41.7 %

Consolidated gross profit decreased by $20.2 million, or 7.0%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $17.1 million for the three months ended September 30, 2022, as compared to the same period in 2021. Consolidated gross profit margin decreased by 1.8 margin points for the three months ended September 30, 2022, as compared to the same period in 2021.

Consolidated gross profit decreased by $1.1 million, or 0.1% for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $46.4 million for the nine months ended September 30, 2022, as compared to the same period in 2021. Consolidated gross profit margin decreased by 1.6 margin points for the nine months ended September 30, 2022, as compared to the same period in 2021.

Proprietary Products - Proprietary Products gross profit decreased by $20.0 million, or 7.5%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $15.6 million. Proprietary Products gross profit margin decreased by 2.7 margin points for the three months ended September 30, 2022, as compared to the same periods in 2021, due to product mix, including increased plant spend and production inefficiencies associated with the mix shift. Gross profit margin was also impacted by inflationary pressures on certain aspects of production, which includes raw material, labor, overhead and transportation costs. This was offset by increased sales prices and approximately $20.0 million, net, in one-time fees received due to COVID-19 supply agreements during the three months ended September 30, 2022 as compared to the same period in 2021.

Proprietary Products gross profit decreased by $1.2 million, or 0.1%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $42.9 million. Proprietary Products gross profit margin decreased by 3.0 margin points for the nine months ended September 30, 2022, as compared to the same period in 2021, due to increased plant spend to meet ongoing product demand increases and increased labor and overhead costs, primarily within transportation and compensation, that were driven by inflation. This was offset by increased sales prices in the nine months ended September 30, 2022 as compared to the same period in 2021.






33
Contract-Manufactured Products - Contract-Manufactured Products gross profit decreased by $0.2 million, or 1.0%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $1.5 million. Contract-Manufactured Products gross profit margin increased by 1.2 margin points for the three months ended September 30, 2022, as compared to the same period in 2021, due to increased sales prices and production efficiencies offset by an unfavorable mix of products sold and increased labor and overhead costs, primarily transportation and compensation, that were driven by inflation.

Contract-Manufactured Products gross profit increased by $0.1 million, or 0.2%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $3.5 million. Contract-Manufactured Products gross profit margin increased by 1.7 margin points for the nine months ended September 30, 2022, as compared to the same period in 2021, due to increased sales prices and production efficiencies offset by an unfavorable mix of products sold and increased labor and overhead costs, primarily transportation and compensation, that were driven by inflation.

Research and Development (“R&D”) Costs

The following table presents R&D costs, consolidated and by reportable segment:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Proprietary Products$13.6 $13.1 $42.6 $39.1 
Contract-Manufactured Products— — — — 
Consolidated R&D costs$13.6 $13.1 $42.6 $39.1 

Consolidated R&D costs increased by $0.5 million, or 3.8%, and $3.5 million, or 9.0%, for the three and nine months ended September 30, 2022, respectively, as compared to the same period in 2021, due to additional research performed to identify new product opportunities, offset by lower annual incentive compensation. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumables.

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Proprietary Products$44.3 $58.5 $155.6 $180.0 
Contract-Manufactured Products4.7 3.9 14.4 11.4 
Corporate17.3 29.5 61.2 73.4 
Consolidated SG&A costs$66.3 $91.9 $231.2 $264.8 
SG&A as a % of net sales9.7 %13.0 %10.6 %12.6 %

Consolidated SG&A costs decreased by $25.6 million, or 27.9%, for the three months ended September 30, 2022, as compared to the same period in 2021, due to lower incentive compensation, higher allocation of functional spend to Cost of Goods Sold and a favorable foreign currency translation impact of $3.0 million.

34
Consolidated SG&A costs decreased by $33.6 million, or 12.7%, for the nine months ended September 30, 2022, as compared to the same period in 2021, due to lower incentive compensation, higher allocation of functional spend to Cost of Goods Sold and a favorable foreign currency translation impact of $7.4 million. This was offset by an increase in selling expenses, professional fees and salaries and fringe benefits.

Proprietary Products - Proprietary Products SG&A costs decreased by $14.2 million, or 24.3%, for the three months ended September 30, 2022, as compared to the same period in 2021. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation, higher allocation of functional spend to Cost of Goods Sold and a favorable foreign currency translation impact of $2.6 million.

Proprietary Products SG&A costs decreased by $24.4 million, or 13.6%, for the nine months ended September 30, 2022, as compared to the same period in 2021. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation, higher allocation of functional spend to Cost of Goods Sold and a favorable foreign currency translation impact of $6.4 million. This was offset by an increase in selling expenses, professional fees and salaries and fringe benefits.

Contract-Manufactured Products - Contract-Manufactured Products SG&A costs increased by $0.8 million, or 20.5%, for the three months ended September 30, 2022, as compared to the same period in 2021, and increased by $3.0 million, or 26.3%, for the nine months ended September 30, 2022, as compared to the same period in 2021, due to increased salaries and increased inflation on overhead costs, offset by lower annual incentive compensation

Corporate - Corporate SG&A costs decreased by $12.2 million, or 41.4%, for the three months ended September 30, 2022, as compared to the same period in 2021, primarily due to lower annual incentive compensation and a reduction in mark-to-market expense related to stock-based compensation.

Corporate SG&A costs decreased by $12.2 million, or 16.6%, for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to lower annual incentive compensation and a reduction in mark-to-market expense related to stock-based compensation.

Other (Income) Expense

The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:
(Income) ExpenseThree Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Proprietary Products$0.8 $0.2 $(3.8)$(1.9)
Contract-Manufactured Products1.3 0.2 1.4 0.4 
Corporate and unallocated(0.2)1.4 (1.6)4.5 
Consolidated other (income) expense$1.9 $1.8 $(4.0)$3.0 

Other income and expense items, consisting of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, contingent consideration, fixed asset impairments and miscellaneous income and charges, are generally recorded within segment results.

Consolidated other (income) expense changed by $0.1 million for the three months ended September 30, 2022, as compared to the same period in 2021 and changed by $7.0 million for the nine months ended September 30, 2022, as compared to the same period in 2021, due to the factors described below.



35
Proprietary Products - Proprietary Products other (income) expense changed by $0.6 million for the three months ended September 30, 2022, as compared to the same period in 2021, primarily due to $1.5 million of losses related to oil hedges being recorded during the three months ended September 30, 2022, as compared to $0.5 million of gains related to oil hedges being recorded over the same period in 2021. Additionally, there was increased contingent consideration recorded in the three months ended September 30, 2022, as compared to the same period in 2021. This was offset by increased gains on foreign exchange transactions in the three months ended September 30, 2022, as compared to the same period in 2021.

Proprietary Products other (income) expense changed by $1.9 million for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to increased gains on foreign exchange transactions being recorded during the nine months ended September 30, 2022, as compared to the same period in 2021. This was offset by increased contingent consideration recorded in the nine months ended September 30, 2022, as compared to the same period in 2021.

Contract-Manufactured Products - Contract-Manufactured Products other (income) expense changed by $1.1 million for the three months ended September 30, 2022, as compared to the same period in 2021 due to increased fixed asset impairments in the three months ended September 30, 2022, as compared to the same period in 2021.

Contract-Manufactured Products other (income) expense changed by $1.0 million for the nine months ended September 30, 2022, as compared to the same period in 2021 due to increased fixed asset impairments in the nine months ended September 30, 2022, as compared to the same period in 2021.

Corporate and unallocated items - Corporate and unallocated items changed by $1.6 million for the three months ended September 30, 2022, as compared to the same period in 2021, primarily due to the Company recording a loss on the sale of one of the Company's cost investments of $0.9 million in the three months ended September 30, 2021 that did not recur in 2022 and additional expense related to restructuring and related costs being recorded in the three months ended September 30, 2021 as compared to the same period in 2022.

Corporate and unallocated items changed by $6.1 million for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to the Company recording a benefit of $1.6 million in restructuring and related costs in connection with its 2020 plan related to revised severance estimates in the nine months ended September 30, 2022, while the Company recorded expense of $2.5 million of restructuring and related costs in the same period in 2021. Additionally, a loss of $1.8 million related to cost investment activity was recorded in the nine months ended September 30, 2021 that did not recur in 2022.

Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Proprietary Products$188.6 $195.5 $615.9 $594.3 
Contract-Manufactured Products14.7 16.8 48.0 51.9 
Corporate(16.9)(29.5)(60.6)(73.0)
Adjusted consolidated operating profit$186.4 $182.8 $603.3 $573.2 
Adjusted consolidated operating profit margin27.1 %25.9 %27.7 %27.3 %
Unallocated items(0.2)(1.4)1.0 (4.9)
Consolidated operating profit$186.2 $181.4 $604.3 $568.3 
Consolidated operating profit margin27.1 %25.7 %27.7 %27.1 %

36
Consolidated operating profit increased by $4.8 million, or 2.6%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $14.0 million for the three months ended September 30, 2022, as compared to the same period in 2021.

Consolidated operating profit increased by $36.0 million, or 6.3%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $38.7 million for the nine months ended September 30, 2022, as compared to the same period in 2021.

Proprietary Products - Proprietary Products operating profit decreased by $6.9 million, or 3.5%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $12.8 million, due to the factors described above.

Proprietary Products operating profit increased by $21.6 million, or 3.6%, for the nine months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $35.9 million, due to the factors described above.

Contract-Manufactured Products - Contract-Manufactured Products operating profit decreased by $2.1 million, or 12.5%, for the three months ended September 30, 2022, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $1.2 million, due to the factors described above.

Contract-Manufactured Products operating profit decreased by $3.9 million, or 7.5%, for the nine months ended September 30, 2022, respectively, as compared to the same period in 2021, including an unfavorable foreign currency translation impact of $2.8 million, due to the factors described above.

Corporate - Corporate costs decreased by $12.6 million, or 42.7%, for the three months ended September 30, 2022, as compared to the same period in 2021, due to the factors described above.

Corporate costs decreased by $12.4 million, or 17.0%, for the nine months ended September 30, 2022, respectively, as compared to the same period in 2021, due to the factors described above.

Unallocated items – Other unallocated items during the three months ended September 30, 2022 consisted of $0.2 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020. Other unallocated items during the three months ended September 30, 2021 consisted of $0.3 million in restructuring and related costs, $0.2 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020 and a net loss of $0.9 million on the sale of one of the Company's cost investments.

Other unallocated items during the nine months ended September 30, 2022 consisted of a credit of $1.6 million in restructuring and related costs in connection with the Company's 2020 plan related to revised estimates associated with severance and $0.6 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020. Other unallocated items during the nine months ended September 30, 2021 consisted of $2.5 million in restructuring and related costs, $0.6 million of amortization expense associated with an acquisition of an intangible asset during the second quarter of 2020 and a net loss in our cost investment activity of $1.8 million.











37
Interest Expense, Net

The following table presents interest expense, net, by significant component:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Interest expense$2.8 $2.7 $8.4 $7.6 
Capitalized interest(0.6)(0.9)(2.2)(2.0)
Interest expense, net$2.2 $1.8 $6.2 $5.6 
Interest income$(1.5)$(0.4)$(2.2)$(0.7)

Interest expense, net, increased by $0.4 million, for the three months ended September 30, 2022, as compared to the same period in 2021, and increased by $0.6 million, for the nine months ended September 30, 2022, as compared to the same period in 2021.

Interest income increased by $1.1 million for the three months ended September 30, 2022, as compared to the same period in 2021, and $1.5 million for the nine months ended September 30, 2022, as compared to the same period in 2021 resulting from higher interest rates compared to the prior year.

Other Nonoperating Expense (Income)

Other nonoperating expense (income) changed by $50.4 million for the three months ended September 30, 2022, as compared to the same period in 2021, primarily due to the recording of a $49.6 million pension settlement charge during the three months ended September 30, 2022, which relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan, while no such amounts were recorded in the same period in 2021.

Other nonoperating expense (income) changed by $52.7 million for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to the recording of a $50.8 million pension settlement charge during the nine months ended September 30, 2022, which relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge, as we determined that normal-course lump-sum payments for the U.S. pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

Please refer to Note 14, Benefit Plans, for further discussion of these items.

Income Tax Expense
The provision for income taxes was $20.4 million and $12.0 million for the three months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.0% and 6.6%, respectively. The increase in the effective tax rate is primarily due to the result of the Company's prepayment of future royalties from one of its subsidiaries in three months ended September 30, 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.0 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.0 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.

38
The provision for income taxes was $85.8 million and $73.0 million for the nine months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.6% and 12.9%, respectively. The increase in the effective tax rate is primarily due to the result of the Company's prepayment of future royalties from one of its subsidiaries in nine months ended September 30, 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.3 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.3 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.

Equity in Net Income of Affiliated Companies
Equity in net income of affiliated companies decreased by $1.7 million for the three months ended September 30, 2022, as compared to the same period in 2021, due primarily to the impact of foreign currency translation on the operating results of Daikyo.

Equity in net income of affiliated companies decreased by $2.6 million for the nine months ended September 30, 2022, as compared to the same period in 2021, due primarily to the impact of foreign currency translation on the operating results of Daikyo.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the nine months ended September 30:
($ in millions)20222021
Net cash provided by operating activities$493.2 $423.2 
Net cash used in investing activities$(193.4)$(175.7)
Net cash used in financing activities$(284.1)$(161.9)

Net Cash Provided by Operating Activities – Net cash provided by operating activities increased by $70.0 million for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to decreases in the change in working capital.

Net Cash Used in Investing Activities – Net cash used in investing activities increased by $17.7 million for the nine months ended September 30, 2022, as compared to the same period in 2021, due to an increase in capital expenditures in 2022.

Net Cash Used in Financing Activities – Net cash used in financing activities increased by $122.2 million for the nine months ended September 30, 2022, as compared to the same period in 2021, primarily due to increases in purchases under our share repurchase program in 2022 and additional debt repayments in 2022.

39
Liquidity and Capital Resources

The table below presents selected liquidity and capital measures:
($ in millions)September 30,
2022		December 31,
2021
Cash and cash equivalents$729.0 $762.6 
Accounts receivable, net$485.3 $489.0 
Inventories$413.1 $378.4 
Accounts payable$188.9 $232.2 
Debt$209.4 $253.0 
Equity$2,470.8 $2,335.4 
Working capital$1,276.9 $1,147.9 

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at September 30, 2022 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at September 30, 2022 included $225.4 million of cash held by subsidiaries within the U.S., and $503.6 million of cash held by subsidiaries outside of the U.S. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the share repurchase program at a cost of $202.9 million, or an average price of $360.03 per share.

Working capital – Working capital at September 30, 2022 increased by $129.0 million, or 11.2%, as compared to December 31, 2021, which includes an unfavorable foreign currency translation impact of $64.8 million. Excluding the impact of currency exchange rates, cash and cash equivalents, accounts receivable and inventories increased by $15.7 million, $32.6 million and $67.1 million, respectively, while total current liabilities decreased by $100.5 million. The increase in cash and cash equivalents was due to cash collections from operations, offset by share repurchases, debt repayments and payment of annual incentive compensation during the nine months ended September 30, 2022. The increase in accounts receivable was due to increased sales activity. The increase in inventories that occurred in the period was to ensure we have sufficient inventory on hand to support the needs of our customers. The decrease in total current liabilities was caused by the decline in accrued salaries, wages and benefits and accounts payable.

Debt and credit facilities – The $43.6 million decrease in total debt at September 30, 2022, as compared to December 31, 2021, resulted primarily from debt repayments for our Series A notes.

Our sources of liquidity include our Credit Facility. At September 30, 2022, we had no outstanding borrowings under the Credit Facility. At September 30, 2022, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.4 million, was $497.6 million. We do not expect any significant limitations on our ability to access this source of funds.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2022, we were in compliance with all of our debt covenants.

We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

40
Commitments and Contractual Obligations

A summary of the amounts and estimated timing of future cash payments resulting from commitments and contractual obligations was provided in our 2021 Annual Report. During the three months ended September 30, 2022, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

At September 30, 2022, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2021 Annual Report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2021 Annual Report.

NEW ACCOUNTING STANDARDS

For information on new accounting standards that were adopted during the three months ended September 30, 2022, and the impact, if any, on our financial position or results of operations, see Note 2, New Accounting Standards.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “plan,” “expect,” “believe,” “intend,” “will,” “estimate,” “continue” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:
•sales demand and our ability to meet that demand;
•competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;
•customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;
41
•interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customers’ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;
•the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;
•whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;
•the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Crystal Zenith prefilled syringes;
•average profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;
•maintaining or improving production efficiencies and overhead absorption;
•dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;
•the loss of key personnel or highly-skilled employees;
•the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;
•the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;
•the cost and progress of development, regulatory approval and marketing of new products;
•our ability to obtain and maintain licenses in any jurisdiction in which we do business;
•the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and
•the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.

This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2021 Annual Report as well as Part II, section 1A of this quarterly report.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

42
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2021 Annual Report.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of September 30, 2022, our disclosure controls and procedures are effective.

Changes in Internal Controls
During the quarter ended September 30, 2022, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

None.

ITEM 1A.  RISK FACTORS

We are providing the disclosure below and supplementing the risk factors described in Part I, Item 1A of our 2021 Annual Report with the following risk factor. The additional risk factor identified should be read in conjunction with the risk factors described in the 2021 Annual Report and the information under the "Forward Looking Statements" in the 2021 Annual Report.

We may be unable to increase capacity or efficiency at our own manufacturing facilities, which could adversely affect our business, financial condition, and results of operations.

We must adjust our production capacity as customer demand changes and are focused on increasing capacity at various facilities through our capital strategy. If we are unable to increase capacity levels at the rate we expect, or if unforeseen costs or other challenges associated with increasing that capacity arise, we may not be able to achieve our financial targets.

Additionally, we are committed to supporting a full portfolio of our products for our customers. That commitment, along with shifts of product mix and complexity, may result in more frequent equipment change-overs and potentially increased costs because of the high fixed cost nature of our business, causing lower gross margins due to under-absorption of those fixed costs.


43


ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table shows information with respect to purchases of our common stock made during the three months ended September 30, 2022 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:
PeriodTotal number of shares purchased (1)Average price paid per share (1)Total number of shares purchased as part of publicly announced plans or programs (1)Maximum number of shares that may yet be purchased under the plans or programs (1)
July 1 - 31, 202228,889 $313.02 28,889 144,444 
August 1 - 31, 202228,889 325.87 28,889 115,555 
September 1 - 30, 202228,889 300.78 28,889 86,666 
Total86,667 $313.22 86,667 86,666 

(1)In December 2021, our Board of Directors approved a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market as permitted under Exchange Act Rule 10b-18 or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2022.

ITEM 6.  EXHIBITS

The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

44
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer



October 27, 2022
45
EXHIBIT INDEX
Exhibit NumberDescription
3.1
3.2
4.1
4.2
4.3
4.4 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.1
10.2
10.3
31.1
31.2
32.1*
32.2*
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.


(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

* Furnished, not filed.
F-1
 EX-31.1 2 ex311q32022.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: October 27, 2022

EX-31.2 3 ex312q32022.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer

Date: October 27, 2022

EX-32.1 4 ex321q32022.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: October 27, 2022

 EX-32.2 5 ex322q32022.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President, Chief Financial and Operations Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial and Operations Officer

Date: October 27, 2022


 EX-101.SCH 6 wst-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2112105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2115106 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 2123108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2127109 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2131110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2135111 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2139112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2143113 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2145114 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2149115 - Disclosure - Other (Income) Expense link:presentationLink link:calculationLink link:definitionLink 2155116 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2157117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2158118 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2332307 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2336308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2340309 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2346310 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2350311 - Disclosure - Other (Income) Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2359312 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Revenue - Contracts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2417406 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Leases - Lease Weighted Average (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2426412 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2434416 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2437417 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2438418 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2441419 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2442420 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) link:presentationLink link:calculationLink link:definitionLink 2444421 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2447422 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2448423 - Disclosure - Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2451424 - Disclosure - Other (Income) Expense - Other Expense (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2452425 - Disclosure - Other (Income) Expense - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2453426 - Disclosure - Other (Income) Expense - Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2454427 - Disclosure - Other (Income) Expense - Other Items (Details) link:presentationLink link:calculationLink link:definitionLink 2456428 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2460429 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 wst-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 wst-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 wst-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic Concentration Risk Geographic Concentration Risk [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Operating leases liabilities payments due Lessee, Operating Lease, Liability, to be Paid Pension settlement charge Pension Settlement Charge Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits. Deferred income taxes Deferred Income Tax Assets, Net Long-term debt, gross Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividend payments Payments of Ordinary Dividends, Common Stock Property, plant and equipment Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Benefit from termination of pension plan Effective Income Tax Rate Reconciliation, Termination Of Defined Benefit Plan, Amount Effective Income Tax Rate Reconciliation, Termination Of Defined Benefit Plan, Amount Balance, December 31, 2021 Balance, September 30, 2022 Restructuring Reserve Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Change in deferred income - decrease (increase) Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Capital in excess of par value Additional Paid in Capital Deferred compensation assets Deferred Compensation Plan Assets Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Other, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Changes in assets and liabilities Other Noncash Income (Expense) Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Stock purchase program, cost of shares purchased Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Net income Net income Net Income (Loss) Attributable to Parent Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Other (income) expense Foreign Currency Gain (Loss) [Member] Prior service credit Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Fed Funds Effective Rate Overnight Index Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Interest expense Interest Expense [Member] Net (loss) gain on derivatives, net of tax of $0.0, $(0.4), $(0.8) and $(0.4), respectively Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Total assets at fair value Assets, Fair Value Disclosure Restructuring Plan [Axis] Restructuring Plan [Axis] Leases Lessee, Operating Leases [Text Block] Contract assets, December 31, 2021 Contract assets, September 30, 2022 Contract with Customer, Asset, after Allowance for Credit Loss Hedging Designation [Domain] Hedging Designation [Domain] Additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Line Of Credit Facility Additional Borrowing Capacity Derivative Instrument [Axis] Derivative Instrument [Axis] Remainder of fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Long-term line of credit Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] 2020 Restructuring Plan 2020 Restructuring Plan [Member] 2020 Restructuring Plan [Member] Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Revolving Credit Facility, Due 2024 Revolving Credit Facility, Due 2024 [Member] Revolving Credit Facility, Due 2024 Award Type [Axis] Award Type [Axis] Actuarial gains (losses) Recognized actuarial losses (gains) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities Operating Lease, Liability, Current All Currencies [Domain] All Currencies [Domain] Defined benefit pension and other postretirement plan adjustments, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Generics Generics Customers [Member] Generics Customers [Member] Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Long-term debt Long-term debt, net Long-Term Debt, Excluding Current Maturities Other Defined Benefit Plan, Other Cost (Credit) Total Liabilities Liabilities Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Pension and other postretirement benefits Liability, Defined Benefit Plan, Noncurrent Position [Axis] Position [Axis] Amount receivable from affiliates Due from Affiliates Schedule of Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Change in equity affiliate investment AOCI AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Assets: Assets, Fair Value Disclosure [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] Debt Debt Disclosure [Text Block] Domestic Line of Credit Domestic Line of Credit [Member] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred tax benefit Deferred Income Tax Expense (Benefit) Pension and other postretirement benefits Assets for Plan Benefits, Defined Benefit Plan Year one Lessee, Operating Lease, Liability, to be Paid, Year One Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax PSU payout, minimum (in hundredths) PVS Payout Minimum Percent of an employee's targeted award to be paid out, Minimum. Derivative (gain) loss recognized in income, fair value hedges Gain (Loss) on Fair Value Hedges Recognized in Earnings Applicable Margin Applicable Margin [Member] Applicable Margin Consolidation Items [Domain] Consolidation Items [Domain] Revenue Benchmark Revenue Benchmark [Member] Amount available for issuance of letters of credit Credit Available For The Issuance Of Letters Of Credit Credit Available For The Issuance Of Letters Of Credit Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Development and licensing income [Line Items] Development and licensing income [Line Items] [Line Items] for Development and licensing income [Table] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Net loss on equity affiliate accumulated other comprehensive income, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Contributions by employer Defined Benefit Plan, Plan Assets, Contributions by Employer Performance Share Unit (PSUs) Performance Shares [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Less: current portion of long-term debt Long-Term Debt, Current Maturities Year five Lessee, Operating Lease, Liability, to be Paid, Year Five Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Long-term debt, fair value Long-Term Debt, Fair Value Accounting Policies [Abstract] Accounting Policies [Abstract] Amounts reclassified out from accumulated other comprehensive (loss) income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Derivative, nonmonetary notional amount, volume Derivative, Nonmonetary Notional Amount, Volume Variable lease cost Variable Lease, Cost Segment [Domain] Segments [Domain] Ratio of debt to EBITDA Debt Instrument, Ratio Of Debt To EBITDA Debt Instrument, Ratio Of Debt To EBITDA Amount due and payable to affiliates Due to Affiliate Net Income Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Yen Japan, Yen Interest cost Defined Benefit Plan, Interest Cost Forward Contracts Forward Contracts [Member] Deferred compensation benefits Deferred Compensation Liability, Classified, Noncurrent Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Fair value and net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Award Type [Domain] Award Type [Domain] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Restructuring Plan [Domain] Restructuring Plan [Domain] Derivative Contract Type [Domain] Derivative Contract [Domain] Net Investment Hedges: Net Investment Hedging [Member] Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Dividend yield (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town Benefit Plans Retirement Benefits [Text Block] (Losses) gains on derivatives Gains (losses) on derivatives: Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Europe, Middle East, Africa EMEA [Member] Leases [Abstract] Leases [Abstract] Intersegment sales elimination Intersegment Eliminations [Member] Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Treasury Stock Treasury Stock, Common [Member] Pension benefits Pension Plan [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Stock repurchase program, average price per share (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Credit facility available for swing-line loans Credit Facility Is Available For Swing-Line Loans Credit Facility Is Available For Swing-Line Loans Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Deferred income, noncurrent Contract with Customer, Liability, Noncurrent High-Value Product Delivery Devices Standard Packaging [Member] Standard Packaging [Member] Research and development Research and Development Expense Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Change in contract assets - increase (decrease) Contract With Customer, Asset, Increase (Decrease) Contract With Customer, Asset, Increase (Decrease) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Restructuring and related activities, period of implementation Restructuring and Related Activities, Period of Implementation Restructuring and Related Activities, Period of Implementation Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Net sales Revenues Percentage of net sales Concentration Risk, Percentage Restructuring and related cost, cumulative cost incurred Restructuring and Related Cost, Cost Incurred to Date Interest income Investment Income, Net Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Amortization of acquisition-related intangible assets Amortization of Intangible Assets Basic (in dollars per share) Earnings Per Share, Basic Year three Lessee, Operating Lease, Liability, to be Paid, Year Three Effect on future earnings, amount Effect on Future Earnings, Amount Corporate and Unallocated Corporate, Non-Segment [Member] Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Commodity call options Commodity Option [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total Equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Retained earnings Retained Earnings [Member] Dividends declared Dividends, Common Stock, Cash Total lease cost Lease, Cost Common Stock Common Stock [Member] Other comprehensive loss, net of tax Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Activity related to stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Number of reportable segments Number of Reportable Segments Schedule of Lease, Cost Lease, Cost [Table Text Block] Shares purchased under share repurchase programs Payments for Repurchase of Common Stock Shares available for issuance under the 2016 Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Contingent consideration Business Combination, Contingent Consideration, Liability Repayments of long-term debt Repayments of Other Long-Term Debt Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Document Quarterly Report Document Quarterly Report Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Letter of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Operating lease liabilities Operating Lease, Liability, Noncurrent Defined benefit pension and other postretirement plan adjustments, net of tax of $14.6, $0.2, $15.5, and $0.4, respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Statistical Measurement [Axis] Statistical Measurement [Axis] Share purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Net gain on sale of cost investments Equity Securities, FV-NI, Realized Gain (Loss) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Settlements Settlements Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Applicable margin ratio Debt Instrument, Applicable Margin Ratio Debt Instrument, Applicable Margin Ratio Document Fiscal Year Focus Document Fiscal Year Focus International plans Foreign Plan [Member] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Fixed asset impairments and loss on sale of equipment Gain (Loss) on Sale of Assets and Asset Impairment Charges Interest expense (income) and other nonoperating expense (income), net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative expenses Selling, General and Administrative Expense Accrued salaries, wages and benefits Other Employee-related Liabilities, Current New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability PSU payout, maximum (in hundredths) PVS Payout Maximum Percent of an employee's targeted award to be paid out, Maximum. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Operating profit Operating profit Operating Income (Loss) Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule Of Other Income And Expense, By Component New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Carrying amount, investments not accounted for under the equity method Equity Securities without Readily Determinable Fair Value, Amount Position [Domain] Position [Domain] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Goodwill Goodwill Treasury stock, at cost (in shares) Treasury Stock, Shares Total liabilities at fair value Liabilities, Fair Value Disclosure Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax expense Tax benefit (expense) Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Deferred income taxes Deferred Income Tax Liabilities, Net Year four Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Capital in Excess of Par Value Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Foreign currency translation adjustments, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Benefit from prepayment of future royalties Effective Income Tax Rate Reconciliation, Royalty Acceleration, Amount Effective Income Tax Rate Reconciliation, Royalty Acceleration, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Base Rate Base Rate [Member] Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.2 million, respectively Common Stock, Value, Issued Sales to affiliates Sales to Equity Method Investees Sales to Equity Method Investees Other items Other Operating Income (Expense), Net Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Asia Pacific Asia Pacific [Member] Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Pension and other postretirement benefits Liability, Defined Benefit Plan, Current Operating Segments Operating Segments [Member] Term Loan, due December 31, 2024 (4.53%) Term Loan Due 2024 [Member] Term Loan Due 2024 Other (income) expense Other Income Short-term lease cost Short-Term Lease, Cost Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Product Concentration Risk Product Concentration Risk [Member] Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Foreign Exchange Forward Foreign Exchange Forward [Member] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Carrying amount, equity-method investments Equity Method Investments Deferred income, current Contract with Customer, Liability, Current Foreign exchange transaction (gains) losses Foreign Currency Transaction Gain (Loss), before Tax Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedges: Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag High-Value Product Components High-Value Components [Member] High-Value Components [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Fair Value Hedges Fair Value Hedging [Member] Operating lease cost Operating Lease, Cost Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pharma Pharma Customers [Member] Pharma Customers [Member] Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other noncurrent assets Other Assets, Noncurrent Cash payments Payments for Restructuring Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance and benefits Employee Severance [Member] Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Development and licensing income [Table] Development and licensing income [Table] Development and licensing income [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property, plant and equipment, net Property, Plant and Equipment, Net Currency [Axis] Currency [Axis] Operating cash flows from operating leases Operating Lease, Payments Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] SGD Singapore, Dollars Domestic Plan [Member] Domestic Plan [Member] Treasury stock, at cost (1.3 million and 1.1 million shares, respectively) Treasury Stock, Value Stock volatility (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other (Income) Expense Other Income and Other Expense Disclosure [Text Block] Total debt Long-Term Debt Series A notes, due July 5, 2022 (3.67%) Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Other nonoperating expense (income) Other Nonoperating Income (Expense) Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares authorized (in shares) Common Stock, Shares Authorized Derivative instruments not designated as hedging instruments, gain (loss), net Derivative instruments not designated as hedging instruments, (loss) gain, net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Net sales Net Sales [Member] Net sales member Short Short [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Preceding period for increase in facility Debt Instrument, Increase In Facility, Preceding Period Debt Instrument, Increase In Facility, Preceding Period Line of Credit Facility [Table] Line of Credit Facility [Table] Revolving credit facility, Due 2024 Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 [Member] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Long Long [Member] Title of each class Title of 12(b) Security Commodity call options Other Assets, Fair Value Disclosure Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Deferred compensation liabilities Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent SmartDose SmartDose [Member] SmartDose [Member] Stock options, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Debt Instrument [Line Items] Debt Instrument [Line Items] Activity related to stock -based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Line Items] Class of Stock [Line Items] Debt issuance costs Payments of Debt Issuance Costs Total lease liabilities Operating Lease, Liability Segment Information Segment Reporting Disclosure [Text Block] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Foreign currency translation adjustments, net of tax of $1.1, $0.1, $3.8 and $1.8, respectively Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Contract-Manufactured Products Delivery Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Stock options, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Inventories Total inventories Inventory, Net Accounts payable Accounts Payable, Current Restructuring and related charges Restructuring Charges Standard Packaging Delivery Devices [Member] Delivery Devices [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Other (income) expense (Note 15) Total other (income) expense Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Foreign Line of Credit Foreign Line of Credit [Member] Entity Filer Category Entity Filer Category Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic U.S. plans UNITED STATES Liabilities: Liabilities, Fair Value Disclosure [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 17) Commitments and Contingencies Security Exchange Name Security Exchange Name Derivative, notional amount Derivative, Notional Amount Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Issued Cost investment activity Cost Investment Impairment Cost Investment Impairment Schedule of Long-term Debt Obligations, Net of Current Maturities Schedule of Debt [Table Text Block] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Service cost Defined Benefit Plan, Service Cost Contingent consideration payments in excess of acquisition-date liability Payment for Contingent Consideration Liability, Operating Activities Notes payable and other current debt Long-term debt, current Debt, Current Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Work in process Inventory, Work in Process, Net of Reserves Revenue Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Restructuring and related charges (Credits) Charges Restructuring and Related Cost, Incurred Cost Risk-free interest rate (in hundredths) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Shares repurchased for employee tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement Total Liabilities and Equity Liabilities and Equity Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Derivative (gain) loss on hedged item, fair value hedges Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Level 2 Fair Value, Inputs, Level 2 [Member] Schedule of Segment Information Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Diluted (in dollars per share) Earnings Per Share, Diluted Consolidation Items [Axis] Consolidation Items [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Other charges Other Restructuring [Member] Year two Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Impairment charge from cost investments Equity Securities, FV-NI, Unrealized Gain (Loss) Americas Americas [Member] Amortization Amortization Options Held Options Held [Member] Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Deferred income, December 31, 2021 Deferred income, September 30, 2022 Deferred income Contract with Customer, Liability Number of fiscal quarters following acquisition Debt Instrument, Number Of Fiscal Quarters Following Acquisition Debt Instrument, Number Of Fiscal Quarters Following Acquisition Product and Service [Axis] Product and Service [Axis] Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Derivative, forward point components, (gain) loss, recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Line of credit Facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Interest expense Interest expense Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Credit Facility [Axis] Credit Facility [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventories Inventory Disclosure [Text Block] USD United States of America, Dollars Equity: Equity [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Cross-currency swap Currency Swap [Member] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Number of instances ratio of debt to EBITDA exceeded Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Entity Central Index Key Entity Central Index Key Purchases and royalty payments made to affiliates Purchases and Royalty Payments from Equity Method Investees Purchases and Royalty Payments from Equity Method Investees Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Stock repurchase program, shares authorized (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Proprietary Products Packaging Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. City Area Code City Area Code Corporate general costs General and Administrative Expense ASSETS Assets [Abstract] Other non-cash items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net (loss) gain on derivatives, tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock options, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Biologics Biologics Customers [Member] Biologics Customers [Member] Other long-term liabilities Other Liabilities, Noncurrent Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Capital expenditures Payments to Acquire Property, Plant, and Equipment Forward treasury locks Treasury Lock [Member] Derivative contract term Derivative, Term of Contract Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Ratio of debt to EBITDA after acquisition Debt Instrument, Ratio Of Debt To EBITDA After Acquisition Debt Instrument, Ratio Of Debt To EBITDA After Acquisition Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of goods and services sold Cost of Sales [Member] Other retirement benefits Other Postretirement Benefits Plan [Member] Customer [Domain] Customer [Domain] EX-101.PRE 10 wst-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Oct. 17, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 1-8036  
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 23-1210010  
Entity Address, Address Line One 530 Herman O. West Drive  
Entity Address, City or Town Exton  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19341-0645  
City Area Code 610  
Local Phone Number 594-2900  
Title of each class Common Stock, par value $0.25 per share  
Trading Symbol WST  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   74,032,987
Entity Central Index Key 0000105770  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net sales $ 686.9 $ 706.5 $ 2,178.2 $ 2,100.8
Cost of goods and services sold 418.9 418.3 1,304.1 1,225.6
Gross profit 268.0 288.2 874.1 875.2
Research and development 13.6 13.1 42.6 39.1
Selling, general and administrative expenses 66.3 91.9 231.2 264.8
Other (income) expense (Note 15) 1.9 1.8 (4.0) 3.0
Operating profit 186.2 181.4 604.3 568.3
Interest expense 2.2 1.8 6.2 5.6
Interest income (1.5) (0.4) (2.2) (0.7)
Other nonoperating expense (income) 49.3 (1.1) 49.1 (3.6)
Income before income taxes 136.2 181.1 551.2 567.0
Income tax expense 20.4 12.0 85.8 73.0
Equity in net income of affiliated companies (4.8) (6.5) (17.5) (20.1)
Net income $ 120.6 $ 175.6 $ 482.9 $ 514.1
Net income per share:        
Basic (in dollars per share) $ 1.62 $ 2.37 $ 6.49 $ 6.95
Diluted (in dollars per share) $ 1.59 $ 2.31 $ 6.36 $ 6.78
Weighted average shares outstanding:        
Basic (in shares) 74.4 74.1 74.4 74.0
Diluted (in shares) 75.7 76.0 75.9 75.8
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income $ 120.6 $ 175.6 $ 482.9 $ 514.1
Other comprehensive loss, net of tax:        
Foreign currency translation adjustments, net of tax of $1.1, $0.1, $3.8 and $1.8, respectively (76.0) (24.2) (162.5) (46.9)
Defined benefit pension and other postretirement plan adjustments, net of tax of $14.6, $0.2, $15.5, and $0.4, respectively 13.6 0.4 16.4 1.1
Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively (0.1) 0.0 (0.2) 0.0
Net (loss) gain on derivatives, net of tax of $0.0, $(0.4), $(0.8) and $(0.4), respectively (0.1) 1.3 (2.6) 0.7
Other comprehensive loss, net of tax (62.6) (22.5) (148.9) (45.1)
Comprehensive income $ 58.0 $ 153.1 $ 334.0 $ 469.0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Foreign currency translation adjustments, tax $ 1.1 $ 0.1 $ 3.8 $ 1.8
Defined benefit pension and other postretirement plan adjustments, tax 14.6 0.2 15.5 0.4
Net loss on equity affiliate accumulated other comprehensive income, tax 0.0 0.0 0.0 0.0
Net (loss) gain on derivatives, tax $ 0.0 $ (0.4) $ (0.8) $ (0.4)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 729.0 $ 762.6
Accounts receivable, net 485.3 489.0
Inventories 413.1 378.4
Other current assets 106.2 112.0
Total current assets 1,733.6 1,742.0
Property, plant and equipment 2,232.9 2,215.0
Less: accumulated depreciation and amortization 1,163.9 1,157.5
Property, plant and equipment, net 1,069.0 1,057.5
Operating lease right-of-use assets 86.6 69.3
Investments in affiliated companies 188.6 207.7
Goodwill 104.0 109.9
Intangible assets, net 18.1 23.0
Deferred income taxes 63.0 48.5
Pension and other postretirement benefits 1.2 16.7
Other noncurrent assets 52.7 39.2
Total Assets 3,316.8 3,313.8
Current liabilities:    
Notes payable and other current debt 2.2 44.2
Accounts payable 188.9 232.2
Pension and other postretirement benefits 2.3 2.4
Accrued salaries, wages and benefits 66.7 116.3
Income taxes payable 29.9 26.3
Operating lease liabilities 13.3 9.3
Other current liabilities 153.4 163.4
Total current liabilities 456.7 594.1
Long-term debt 207.2 208.8
Deferred income taxes 16.6 4.9
Pension and other postretirement benefits 35.2 40.5
Operating lease liabilities 77.2 63.0
Deferred compensation benefits 19.2 28.9
Other long-term liabilities 33.9 38.2
Total Liabilities 846.0 978.4
Commitments and contingencies (Note 17)
Equity:    
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding 0.0 0.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million, respectively; shares outstanding: 74.0 million and 74.2 million, respectively 18.8 18.8
Capital in excess of par value 230.6 249.0
Retained earnings 2,913.1 2,456.7
Accumulated other comprehensive loss (308.5) (159.6)
Treasury stock, at cost (1.3 million and 1.1 million shares, respectively) (383.2) (229.5)
Total Equity 2,470.8 2,335.4
Total Liabilities and Equity $ 3,316.8 $ 3,313.8
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 3,000,000 3,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.25 $ 0.25
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 75,300,000 75,300,000
Common stock, shares outstanding (in shares) 74,000,000 74,200,000
Treasury stock, at cost (in shares) 1,300,000 1,100,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net income $ 482.9 $ 514.1
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 86.8 84.6
Amortization 2.7 3.3
Stock-based compensation 17.0 27.5
Pension settlement charge 50.8 0.7
Contingent consideration payments in excess of acquisition-date liability (1.4) (1.0)
Other non-cash items, net (16.3) (17.5)
Changes in assets and liabilities (129.3) (188.5)
Net cash provided by operating activities 493.2 423.2
Cash flows from investing activities:    
Capital expenditures (189.7) (176.9)
Other, net (3.7) 1.2
Net cash used in investing activities (193.4) (175.7)
Cash flows from financing activities:    
Repayments of long-term debt (43.7) (1.1)
Debt issuance costs (1.3) 0.0
Dividend payments (40.0) (37.8)
Proceeds from stock-based compensation awards 17.1 23.1
Employee stock purchase plan contributions 6.1 5.7
Shares purchased under share repurchase programs (202.9) (137.1)
Shares repurchased for employee tax withholdings (19.4) (14.7)
Net cash used in financing activities (284.1) (161.9)
Effect of exchange rates on cash (49.3) (13.1)
Net (decrease) increase in cash and cash equivalents (33.6) 72.5
Cash, including cash equivalents at beginning of period 762.6 615.5
Cash, including cash equivalents at end of period $ 729.0 $ 688.0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
New Accounting Standards
 9 Months Ended
Sep. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements.

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We adopted this guidance during the quarter and its adoption did not have a material impact on our financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Biologics
41 %
40 %
42 %
40 %
Generics
 18 %
18 %
18 %
17 %
Pharma
24 %
24 %
24 %
24 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
High-Value Product Components
54 %
55 %
56 %
54 %
High-Value Product Delivery Devices
6 %
5 %
5 %
4 %
Standard Packaging
23 %
22 %
23 %
23 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Americas
53 %
45 %
48 %
45 %
Europe, Middle East, Africa
38 %
45 %
43 %
45 %
Asia Pacific
9 %
10 %
9 %
10 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2021$14.6 
Contract assets, September 30, 2022
18.3 
Change in contract assets - increase (decrease)$3.7 
Deferred income, December 31, 2021$(61.3)
Deferred income, September 30, 2022
(52.0)
Change in deferred income - decrease (increase)$9.3 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2022, $23.6 million of revenue was recognized that was included in deferred income at the beginning of the year.
The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2022, there was $3.2 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $2.3 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Income Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2022202120222021
Net income$120.6 $175.6 $482.9 $514.1 
Weighted average common shares outstanding74.4 74.1 74.4 74.0 
Dilutive effect of equity awards, based on the treasury stock method
1.3 1.9 1.5 1.8 
Weighted average shares assuming dilution75.7 76.0 75.9 75.8 

During the three months ended September 30, 2022 and 2021, there were 0.2 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.0 million antidilutive shares outstanding during the nine months ended September 30, 2022 and 2021, respectively.

In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2022.

During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the program at a cost of $202.9 million, or an average price of $360.03 per share.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2022		December 31,
2021
Raw materials$179.0 $153.8 
Work in process79.0 63.5 
Finished goods155.1 161.1 
 $413.1 $378.4 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating lease cost$3.7 $3.3 $10.4 $9.5 
Short-term lease cost0.3 0.4 1.1 0.9 
Variable lease cost2.3 1.1 4.7 3.3 
Total lease cost$6.3 $4.8 $16.2 $13.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.7 $2.9 $10.0 $9.2 
Right-of-use assets obtained in exchange for new operating lease liabilities$14.0 $— $29.5 $0.8 

As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term for operating leases was 8.9 and 10.7 years, respectively.

As of September 30, 2022 and December 31, 2021, the weighted average discount rate was 3.27% and 3.58%, respectively.
Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20222021
2022 (remaining period as of)$4.2 $11.5 
202315.9 10.7 
202414.9 10.0 
202512.8 8.2 
202611.6 7.3 
Thereafter45.0 38.7 
104.4 86.4 
Less: imputed lease interest(13.9)(14.1)
Total lease liabilities$90.5 $72.3 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Affiliated Companies
 9 Months Ended
Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]  
Affiliated Companies Affiliated Companies
At September 30, 2022 and December 31, 2021, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $177.2 million and $201.2 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $11.4 million and $6.5 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

Our purchases from, and royalty payments made to, affiliates totaled $33.6 million and $131.2 million for the three and nine months ended September 30, 2022, respectively, as compared to $34.0 million and $119.6 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the payable balance due to affiliates was $20.8 million and $25.5 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.6 million and $10.2 million, respectively, for the three and nine months ended September 30, 2022, as compared to $2.8 million and $8.8 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the receivable balance due from affiliates was $1.8 million and $2.3 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2021 Annual Report for additional details.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2022, with the exception of the Series A notes which is as of December 31, 2021.
($ in millions)September 30,
2022		December 31,
2021
Term Loan, due December 31, 2024 (4.53%)
$83.8 $85.5 
Series A notes, due July 5, 2022 (3.67%)
— 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
209.8 253.5 
Less: unamortized debt issuance costs0.4 0.5 
Total debt209.4 253.0 
Less: current portion of long-term debt2.2 44.2 
Long-term debt, net$207.2 $208.8 


Credit Facility

In March 2022, we amended and extended the existing credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve month period in the aggregate through an increase in the revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions.

At September 30, 2022, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2022, we were in compliance with all of our debt covenants.
Term Loan

At September 30, 2022, we had $83.8 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $81.6 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Please refer to Note 10, Debt, to the consolidated financial statements in our 2021 Annual Report for additional details regarding our debt agreements.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of September 30, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD13.5 — 11.8 
Yen5,686.2 23.8 20.6 
SGD68.7 33.7 15.6 

In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2022, the notional amount of the cross-currency swap is ¥9.2 billion ($83.8 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2022, we purchased several series of call options for a total of 823,536 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases.
As of September 30, 2022, we had outstanding contracts to purchase 259,559 barrels of crude oil from September 2022 to June 2024, at a weighted-average strike price of $109.84 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2022 and December 31, 2021.

The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Fair Value Hedges:
Hedged item (intercompany loan)
$(14.1)$(5.9)$(35.4)$(11.0)Other (income) expense
Derivative designated as hedging instrument
14.1 5.9 35.4 11.0 Other (income) expense
Amount excluded from effectiveness testing
2.2 0.9 4.4 2.1 Other (income) expense
Total$2.2 $0.9 $4.4 $2.1 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 and 2021 were $1.1 million, $2.8 million, and $0.6 million, $1.9 million, respectively.
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$(0.4)$(0.2)$0.5 $0.1 Other (income) expense
Total$(0.4)$(0.2)$0.5 $0.1 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.7 $0.1 $(0.5)$0.1 Net sales
Foreign currency hedge contracts(1.5)1.4 1.0 (0.3)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.8)$1.5 $0.6 $(0.1) 
Net Investment Hedges:     
Cross-currency swap$4.3 $0.6 $— $— Other (income) expense
Total$4.3 $0.6 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$0.3 $(0.6)$(0.7)$0.9 Other (income) expense
Total$0.3 $(0.6)$(0.7)$0.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$1.1 $(0.5)$(1.1)$0.9 Net sales
Foreign currency hedge contracts(4.9)(1.4)2.5 1.2 Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(3.8)$(1.9)$1.6 $2.3  
Net Investment Hedges:     
Cross-currency swap$13.2 $6.0 $— $— Other (income) expense
Total$13.2 $6.0 $— $—  
The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales$(0.5)$0.1 $(1.1)$0.9 
Cost of goods and services sold1.0 (0.3)2.5 1.2 
Interest expense0.1 0.1 0.2 0.2 
Other (income) expense0.5 0.1 (0.7)0.9 

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Commodity call options$(1.5)$0.5 $1.6 $1.6 Other (income) expense
Total$(1.5)$0.5 $1.6 $1.6 

For the three and nine months ended September 30, 2022 and 2021, there was no material ineffectiveness related to our hedges.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.3 $12.3 $— $— 
Foreign currency contracts22.6 — 22.6 — 
Cross-currency swap20.5 — 20.5 — 
Commodity call options1.3 — 1.3 — 
 $56.7 $12.3 $44.4 $— 
Liabilities:    
Contingent consideration$4.9 $— $— $4.9 
Deferred compensation liabilities12.6 12.6 — — 
Foreign currency contracts8.8 — 8.8 — 
 $26.3 $12.6 $8.8 $4.9 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$15.5 $15.5 $— $— 
Foreign currency contracts14.8 — 14.8 — 
Cross-currency swap4.4 — 4.4 — 
Commodity call options1.7 1.7 
 $36.4 $15.5 $20.9 $— 
Liabilities:    
Contingent consideration$3.7 $— $— $3.7 
Deferred compensation liabilities16.1 16.1 — — 
Foreign currency contracts3.4 — 3.4 — 
 $23.2 $16.1 $3.4 $3.7 

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other (income) expense in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.
Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2022, the estimated fair value of long-term debt was $202.2 million compared to a carrying amount of $207.2 million. At December 31, 2021, the estimated fair value of long-term debt was $217.9 million and the carrying amount was $208.8 million.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income 0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive (loss) income before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive (loss) income3.2 — 0.5 — 3.7 
Other comprehensive (loss) income, net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2022202120222021
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(0.1)$1.2 $(1.1)Net sales
Foreign currency contracts(1.2)0.4 (2.9)(1.9)Cost of goods and services sold
Foreign currency contracts(0.7)(0.9)1.1 (2.1)Other (income) expense
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(1.5)(0.7)(0.9)(5.4)
Tax benefit (expense)0.4 0.7 — 2.2 
Net of tax$(1.1)$— $(0.9)$(3.2)
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$— $0.1 $— $0.2 (a)
Actuarial gains (losses)1.1 0.1 1.1 (0.1)(a)
Settlements(27.6)— (28.8)(0.7)(a)
Other— — (0.4)— 
Total before tax(26.5)0.2 (28.1)(0.6)
Tax benefit (expense)14.2 (0.1)14.6 0.1 
Net of tax$(12.3)$0.1 $(13.5)$(0.5)
Total reclassifications for the period, net of tax$(13.4)$0.1 $(14.4)$(3.7)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive income, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2022, there were 1,692,482 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2022, we granted 116,820 stock options at a weighted average exercise price of $366.15 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $96.63 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.8%; expected life of 5.6 years based on prior experience; stock volatility of 25.1% based on historical data; and a dividend yield of 0.2%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2022, we granted 31,597 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $364.54 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2022, we granted 4,987 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $354.65 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.
Stock-based compensation expense was $6.0 million and $17.0 million for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, stock-based compensation expense was $11.4 million and $27.5 million, respectively.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Benefit Plans
 9 Months Ended
Sep. 30, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Benefit Plans Benefit Plans
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$0.3 $0.1 $— $— $0.3 $0.1 
Interest cost0.5 1.6 0.1 — 0.6 1.6 
Expected return on assets(0.8)(2.9)— — (0.8)(2.9)
Amortization of prior service credit— — — (0.1)— (0.1)
Recognized actuarial losses (gains)0.3 0.5 (0.4)(0.3)(0.1)0.2 
Settlements49.6 — — — 49.6 — 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$49.6 $(0.9)$(0.3)$(0.4)$49.3 $(1.3)
International plans0.3 0.2 — — 0.3 0.2 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$1.0 $0.9 $— $— $1.0 $0.9 
Interest cost3.7 4.5 0.1 0.1 3.8 4.6 
Expected return on assets(5.4)(9.0)— — (5.4)(9.0)
Amortization of prior service credit— 0.1 — (0.3)— (0.2)
Recognized actuarial losses (gains)1.0 1.5 (1.1)(1.2)(0.1)0.3 
Settlements50.8 0.7 — — 50.8 0.7 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$50.3 $(2.4)$(1.0)$(1.4)$49.3 $(3.8)
International plans0.8 1.1 — — 0.8 1.1 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating expense (income), which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for the U.S. pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Other (Income) Expense Other (Income) Expense
Other (income) expense consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Restructuring and related charges$— $0.4 $(1.6)$2.5 
Fixed asset impairments and loss on sale of equipment1.4 0.2 1.5 0.6 
Contingent consideration1.5 0.1 2.6 0.9 
Foreign exchange transaction (gains) losses(2.2)0.4 (4.6)(2.5)
Other items1.2 0.7 (1.9)1.5 
Total other (income) expense$1.9 $1.8 $(4.0)$3.0 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $5 million to $6 million, with annualized savings in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $5.2 million in restructuring and related charges associated with this plan.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2021$2.8 $0.5 $3.3 
(Credits) Charges(1.4)(0.2)(1.6)
Cash payments(0.6)(0.2)(0.8)
Balance, September 30, 2022$0.8 $0.1 $0.9 

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Other Items

During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2021, we recorded a gain of $0.5 million and $1.6 million, respectively, related to oil hedges. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our hedging activity.
During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a net loss in our cost investment activity of $1.8 million, inclusive of an impairment charge of $2.2 million for one of the Company's cost investments.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $20.4 million and $12.0 million for the three months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.0% and 6.6%, respectively. The provision for income taxes was $85.8 million and $73.0 million for the nine months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.6% and 12.9%, respectively.

The increase in effective tax rate for the three months ended September 30, 2022 and 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.0 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans,. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.0 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.
The increase in effective tax rate for the nine months ended September 30, 2022 and 2021 is the result of the Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.3 million recorded related to the termination of the U.S. pension plan recorded in 2022, as mentioned in Note 14, Benefit Plans,. The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.3 million benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2021 Annual Report.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information Segment InformationOur business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.
The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.

The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales:    
Proprietary Products$567.0 $577.0 $1,822.0 $1,708.0 
Contract-Manufactured Products120.0 129.7 356.5 393.2 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.4)
Consolidated net sales$686.9 $706.5 $2,178.2 $2,100.8 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating profit (loss):
Proprietary Products$188.6 $195.5 $615.9 $594.3 
Contract-Manufactured Products14.7 16.8 48.0 51.9 
Total business segment operating profit$203.3 $212.3 $663.9 $646.2 
Corporate and Unallocated
Stock-based compensation expense$(6.0)$(11.4)$(17.0)$(27.5)
Corporate general costs (1)(10.9)(18.1)(43.6)(45.5)
Unallocated Items:
Restructuring and related charges— (0.3)1.6 (2.5)
Amortization of acquisition-related intangible assets (2)(0.2)(0.2)(0.6)(0.6)
Cost investment activity— (0.9)— (1.8)
Total Corporate and Unallocated(17.1)(30.9)(59.6)(77.9)
Total consolidated operating profit$186.2 $181.4 $604.3 $568.3 
Interest expense (income) and other nonoperating expense (income), net50.0 0.3 53.1 1.3 
Income before income taxes$136.2 $181.1 $551.2 $567.0 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.

Please refer to Note 15, Other (Income) Expense, for further discussion of these items.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements.

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We adopted this guidance during the quarter and its adoption did not have a material impact on our financial statements.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Biologics
41 %
40 %
42 %
40 %
Generics
 18 %
18 %
18 %
17 %
Pharma
24 %
24 %
24 %
24 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
High-Value Product Components
54 %
55 %
56 %
54 %
High-Value Product Delivery Devices
6 %
5 %
5 %
4 %
Standard Packaging
23 %
22 %
23 %
23 %
Contract-Manufactured Products
17 %
18 %
16 %
19 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Americas
53 %
45 %
48 %
45 %
Europe, Middle East, Africa
38 %
45 %
43 %
45 %
Asia Pacific
9 %
10 %
9 %
10 %
100 %
100 %
100 %
100 %
Schedule of Change in Contract with Customer, Asset and Liability The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2021$14.6 
Contract assets, September 30, 2022
18.3 
Change in contract assets - increase (decrease)$3.7 
Deferred income, December 31, 2021$(61.3)
Deferred income, September 30, 2022
(52.0)
Change in deferred income - decrease (increase)$9.3 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Income Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic to Diluted Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2022202120222021
Net income$120.6 $175.6 $482.9 $514.1 
Weighted average common shares outstanding74.4 74.1 74.4 74.0 
Dilutive effect of equity awards, based on the treasury stock method
1.3 1.9 1.5 1.8 
Weighted average shares assuming dilution75.7 76.0 75.9 75.8 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:
($ in millions)September 30,
2022		December 31,
2021
Raw materials$179.0 $153.8 
Work in process79.0 63.5 
Finished goods155.1 161.1 
 $413.1 $378.4 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Lease, Cost
The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating lease cost$3.7 $3.3 $10.4 $9.5 
Short-term lease cost0.3 0.4 1.1 0.9 
Variable lease cost2.3 1.1 4.7 3.3 
Total lease cost$6.3 $4.8 $16.2 $13.7 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.7 $2.9 $10.0 $9.2 
Right-of-use assets obtained in exchange for new operating lease liabilities$14.0 $— $29.5 $0.8 
Schedule of Lessee, Operating Lease, Liability, Maturity Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20222021
2022 (remaining period as of)$4.2 $11.5 
202315.9 10.7 
202414.9 10.0 
202512.8 8.2 
202611.6 7.3 
Thereafter45.0 38.7 
104.4 86.4 
Less: imputed lease interest(13.9)(14.1)
Total lease liabilities$90.5 $72.3 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Obligations, Net of Current Maturities
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2022, with the exception of the Series A notes which is as of December 31, 2021.
($ in millions)September 30,
2022		December 31,
2021
Term Loan, due December 31, 2024 (4.53%)
$83.8 $85.5 
Series A notes, due July 5, 2022 (3.67%)
— 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
209.8 253.5 
Less: unamortized debt issuance costs0.4 0.5 
Total debt209.4 253.0 
Less: current portion of long-term debt2.2 44.2 
Long-term debt, net$207.2 $208.8 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Contracts As of September 30, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEuro
USD13.5 — 11.8 
Yen5,686.2 23.8 20.6 
SGD68.7 33.7 15.6 
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Gain (Loss) Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Fair Value Hedges:
Hedged item (intercompany loan)
$(14.1)$(5.9)$(35.4)$(11.0)Other (income) expense
Derivative designated as hedging instrument
14.1 5.9 35.4 11.0 Other (income) expense
Amount excluded from effectiveness testing
2.2 0.9 4.4 2.1 Other (income) expense
Total$2.2 $0.9 $4.4 $2.1 
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$(0.4)$(0.2)$0.5 $0.1 Other (income) expense
Total$(0.4)$(0.2)$0.5 $0.1 
Cash Flow Hedges:     
Foreign currency hedge contracts$0.7 $0.1 $(0.5)$0.1 Net sales
Foreign currency hedge contracts(1.5)1.4 1.0 (0.3)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.8)$1.5 $0.6 $(0.1) 
Net Investment Hedges:     
Cross-currency swap$4.3 $0.6 $— $— Other (income) expense
Total$4.3 $0.6 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021 
Fair Value Hedges
Foreign currency hedge contracts$0.3 $(0.6)$(0.7)$0.9 Other (income) expense
Total$0.3 $(0.6)$(0.7)$0.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$1.1 $(0.5)$(1.1)$0.9 Net sales
Foreign currency hedge contracts(4.9)(1.4)2.5 1.2 Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(3.8)$(1.9)$1.6 $2.3  
Net Investment Hedges:     
Cross-currency swap$13.2 $6.0 $— $— Other (income) expense
Total$13.2 $6.0 $— $—  
The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales$(0.5)$0.1 $(1.1)$0.9 
Cost of goods and services sold1.0 (0.3)2.5 1.2 
Interest expense0.1 0.1 0.2 0.2 
Other (income) expense0.5 0.1 (0.7)0.9 

The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of (Loss) Gain Recognized in Income for theAmount of Gain (Loss) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2022202120222021
Commodity call options$(1.5)$0.5 $1.6 $1.6 Other (income) expense
Total$(1.5)$0.5 $1.6 $1.6 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2022		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$12.3 $12.3 $— $— 
Foreign currency contracts22.6 — 22.6 — 
Cross-currency swap20.5 — 20.5 — 
Commodity call options1.3 — 1.3 — 
 $56.7 $12.3 $44.4 $— 
Liabilities:    
Contingent consideration$4.9 $— $— $4.9 
Deferred compensation liabilities12.6 12.6 — — 
Foreign currency contracts8.8 — 8.8 — 
 $26.3 $12.6 $8.8 $4.9 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2021		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$15.5 $15.5 $— $— 
Foreign currency contracts14.8 — 14.8 — 
Cross-currency swap4.4 — 4.4 — 
Commodity call options1.7 1.7 
 $36.4 $15.5 $20.9 $— 
Liabilities:    
Contingent consideration$3.7 $— $— $3.7 
Deferred compensation liabilities16.1 16.1 — — 
Foreign currency contracts3.4 — 3.4 — 
 $23.2 $16.1 $3.4 $3.7 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications(3.5)(0.2)2.9 (162.5)(163.3)
Amounts reclassified out from accumulated other comprehensive (loss) income 0.9 — 13.5 — 14.4 
Other comprehensive (loss) income, net of tax(2.6)(0.2)16.4 (162.5)(148.9)
Balance, September 30, 2022$(3.8)$1.3 $(15.4)$(290.6)$(308.5)

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:
($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2020$(1.9)$0.6 $(40.5)$(68.8)$(110.6)
Other comprehensive (loss) income before reclassifications(2.5)— 0.6 (46.9)(48.8)
Amounts reclassified out from accumulated other comprehensive (loss) income3.2 — 0.5 — 3.7 
Other comprehensive (loss) income, net of tax0.7 — 1.1 (46.9)(45.1)
Balance, September 30, 2021$(1.2)$0.6 $(39.4)$(115.7)$(155.7)
Schedule of Reclassification out of Accumulated Other Comprehensive Loss
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:
($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2022202120222021
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(0.1)$1.2 $(1.1)Net sales
Foreign currency contracts(1.2)0.4 (2.9)(1.9)Cost of goods and services sold
Foreign currency contracts(0.7)(0.9)1.1 (2.1)Other (income) expense
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax(1.5)(0.7)(0.9)(5.4)
Tax benefit (expense)0.4 0.7 — 2.2 
Net of tax$(1.1)$— $(0.9)$(3.2)
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$— $0.1 $— $0.2 (a)
Actuarial gains (losses)1.1 0.1 1.1 (0.1)(a)
Settlements(27.6)— (28.8)(0.7)(a)
Other— — (0.4)— 
Total before tax(26.5)0.2 (28.1)(0.6)
Tax benefit (expense)14.2 (0.1)14.6 0.1 
Net of tax$(12.3)$0.1 $(13.5)$(0.5)
Total reclassifications for the period, net of tax$(13.4)$0.1 $(14.4)$(3.7)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Stockholders Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net income— — — — — 173.8 — 173.8 
Activity related to stock-based compensation— — (29.1)(0.3)29.2 — — 0.1 
Shares purchased under share repurchase program— — — 0.4 (147.1)— — (147.1)
Dividends declared ($0.18 per share)
— — — — — (13.2)— (13.2)
Other comprehensive loss, net of tax— — — — — — (22.8)(22.8)
Balance, March 31, 202275.3 $18.8 $219.9 1.2 $(347.4)$2,617.3 $(182.4)$2,326.2 
Net income— — — — — 188.5 — 188.5 
Activity related to stock-based compensation— — 5.4 — 9.7 — — 15.1 
Shares purchased under share repurchase program— — — 0.1 (28.6)— — (28.6)
Dividends declared ($0.18 per share)
— — — — — (13.3)— (13.3)
Other comprehensive income, net of tax— — — — — — (63.5)(63.5)
Balance, June 30, 202275.3 $18.8 $225.3 1.3 $(366.3)$2,792.5 $(245.9)$2,424.4 
Net income— — — — — 120.6 — 120.6 
Activity related to stock-based compensation— — 5.3 (0.1)10.3 — — 15.6 
Shares purchased under share repurchase program— — — 0.1 (27.2)— — (27.2)
Other comprehensive loss, net of tax— — — — — — (62.6)(62.6)
Balance, September 30, 202275.3 $18.8 $230.6 1.3 $(383.2)$2,913.1 $(308.5)$2,470.8 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:
Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 202075.3 $18.8 $267.3 1.3 $(167.7)$1,846.7 $(110.6)$1,854.5 
Net income— — — — — 151.2 — 151.2 
Activity related to stock-based compensation— — (20.6)(0.3)23.1 — — 2.5 
Shares purchased under share repurchase program— — — 0.5 (137.1)— — (137.1)
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive loss, net of tax— — — — — — (29.6)(29.6)
Balance, March 31, 202175.3 $18.8 $246.7 1.5 $(281.7)$1,985.4 $(140.2)$1,829.0 
Net income— — — — — 187.3 — 187.3 
Activity related to stock-based compensation— — 1.3 (0.2)20.5 — — 21.8 
Dividends declared ($0.17 per share)
— — — — — (12.5)— (12.5)
Other comprehensive income, net of tax— — — — — — 7.0 7.0 
Balance, June 30, 202175.3 $18.8 $248.0 1.3 $(261.2)$2,160.2 $(133.2)$2,032.6 
Net income— — — — — 175.6 — 175.6 
Activity related to stock-based compensation— — 3.2 (0.1)13.4 — — 16.6 
Other comprehensive loss, net of tax— — — — — — (22.5)(22.5)
Balance, September 30, 202175.3 $18.8 $251.2 1.2 $(247.8)$2,335.8 $(155.7)$2,202.3 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The components of net periodic benefit cost for the three months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$0.3 $0.1 $— $— $0.3 $0.1 
Interest cost0.5 1.6 0.1 — 0.6 1.6 
Expected return on assets(0.8)(2.9)— — (0.8)(2.9)
Amortization of prior service credit— — — (0.1)— (0.1)
Recognized actuarial losses (gains)0.3 0.5 (0.4)(0.3)(0.1)0.2 
Settlements49.6 — — — 49.6 — 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$49.6 $(0.9)$(0.3)$(0.4)$49.3 $(1.3)
International plans0.3 0.2 — — 0.3 0.2 
Net periodic benefit cost$49.9 $(0.7)$(0.3)$(0.4)$49.6 $(1.1)

The components of net periodic benefit cost for the nine months ended September 30 were as follows:
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
Service cost$1.0 $0.9 $— $— $1.0 $0.9 
Interest cost3.7 4.5 0.1 0.1 3.8 4.6 
Expected return on assets(5.4)(9.0)— — (5.4)(9.0)
Amortization of prior service credit— 0.1 — (0.3)— (0.2)
Recognized actuarial losses (gains)1.0 1.5 (1.1)(1.2)(0.1)0.3 
Settlements50.8 0.7 — — 50.8 0.7 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)
 Pension benefitsOther retirement benefitsTotal
($ in millions)202220212022202120222021
U.S. plans$50.3 $(2.4)$(1.0)$(1.4)$49.3 $(3.8)
International plans0.8 1.1 — — 0.8 1.1 
Net periodic benefit cost$51.1 $(1.3)$(1.0)$(1.4)$50.1 $(2.7)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense (Tables)
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Schedule of Other Expense (Income)
Other (income) expense consists of:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Restructuring and related charges$— $0.4 $(1.6)$2.5 
Fixed asset impairments and loss on sale of equipment1.4 0.2 1.5 0.6 
Contingent consideration1.5 0.1 2.6 0.9 
Foreign exchange transaction (gains) losses(2.2)0.4 (4.6)(2.5)
Other items1.2 0.7 (1.9)1.5 
Total other (income) expense$1.9 $1.8 $(4.0)$3.0 
Schedule of Restructuring Reserve
The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Other chargesTotal
Balance, December 31, 2021$2.8 $0.5 $3.3 
(Credits) Charges(1.4)(0.2)(1.6)
Cash payments(0.6)(0.2)(0.8)
Balance, September 30, 2022$0.8 $0.1 $0.9 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table presents information about our reportable segments, reconciled to consolidated totals:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Net sales:    
Proprietary Products$567.0 $577.0 $1,822.0 $1,708.0 
Contract-Manufactured Products120.0 129.7 356.5 393.2 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.4)
Consolidated net sales$686.9 $706.5 $2,178.2 $2,100.8 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table provides summarized financial information for our segments:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Operating profit (loss):
Proprietary Products$188.6 $195.5 $615.9 $594.3 
Contract-Manufactured Products14.7 16.8 48.0 51.9 
Total business segment operating profit$203.3 $212.3 $663.9 $646.2 
Corporate and Unallocated
Stock-based compensation expense$(6.0)$(11.4)$(17.0)$(27.5)
Corporate general costs (1)(10.9)(18.1)(43.6)(45.5)
Unallocated Items:
Restructuring and related charges— (0.3)1.6 (2.5)
Amortization of acquisition-related intangible assets (2)(0.2)(0.2)(0.6)(0.6)
Cost investment activity— (0.9)— (1.8)
Total Corporate and Unallocated(17.1)(30.9)(59.6)(77.9)
Total consolidated operating profit$186.2 $181.4 $604.3 $568.3 
Interest expense (income) and other nonoperating expense (income), net50.0 0.3 53.1 1.3 
Income before income taxes$136.2 $181.1 $551.2 $567.0 
(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(2) During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Revenue Recognition (Details) - Revenue Benchmark
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Customer Concentration Risk | Biologics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 41.00% 40.00% 42.00% 40.00%
Customer Concentration Risk | Generics        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 18.00% 18.00% 18.00% 17.00%
Customer Concentration Risk | Pharma        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 24.00% 24.00% 24.00% 24.00%
Customer Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 17.00% 18.00% 16.00% 19.00%
Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Product Concentration Risk | High-Value Product Components        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 54.00% 55.00% 56.00% 54.00%
Product Concentration Risk | High-Value Product Delivery Devices        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 6.00% 5.00% 5.00% 4.00%
Product Concentration Risk | Standard Packaging        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 23.00% 22.00% 23.00% 23.00%
Product Concentration Risk | Contract-Manufactured Products        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 17.00% 18.00% 16.00% 19.00%
Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Geographic Concentration Risk | Americas        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 53.00% 45.00% 48.00% 45.00%
Geographic Concentration Risk | Europe, Middle East, Africa        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 38.00% 45.00% 43.00% 45.00%
Geographic Concentration Risk | Asia Pacific        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 9.00% 10.00% 9.00% 10.00%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Contracts and Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Contract With Customer, Asset [Roll Forward]  
Contract assets, December 31, 2021 $ 14.6
Contract assets, September 30, 2022 18.3
Change in contract assets - increase (decrease) 3.7
Contract With Customer, Liability [Roll Forward]  
Deferred income, December 31, 2021 (61.3)
Deferred income, September 30, 2022 (52.0)
Change in deferred income - decrease (increase) $ 9.3
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Contracts and Liabilities, Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Jun. 30, 2013
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in the deferred income balance $ 23.6    
Deferred income 52.0 $ 61.3 $ 20.0
SmartDose      
Disaggregation of Revenue [Line Items]      
Deferred income 3.2    
Deferred income, current 0.9    
Deferred income, noncurrent $ 2.3    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Earnings Per Share [Abstract]                  
Net income $ 120.6 $ 188.5 $ 173.8 $ 175.6 $ 187.3 $ 151.2 $ 482.9 $ 514.1  
Weighted average common shares outstanding (in shares) 74,400,000     74,100,000     74,400,000 74,000,000.0  
Dilutive effect of equity awards, based on the treasury stock method (in shares) 1,300,000     1,900,000     1,500,000 1,800,000  
Weighted average shares assuming dilution (in shares) 75,700,000     76,000,000.0     75,900,000 75,800,000  
Antidilutive options excluded from computation of diluted net income per share (in shares) 200,000     0     100,000 0  
Stock repurchase program, shares authorized (in shares)                 650,000
Share purchased under share repurchase program (in shares) 86,667           563,334    
Stock purchase program, cost of shares purchased $ 27.2 $ 28.6 $ 147.1     $ 137.1 $ 202.9    
Stock repurchase program, average price per share (in dollars per share) $ 313.22           $ 360.03    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 179.0 $ 153.8
Work in process 79.0 63.5
Finished goods 155.1 161.1
Total inventories $ 413.1 $ 378.4
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Lease Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Leases [Abstract]        
Operating lease cost $ 3.7 $ 3.3 $ 10.4 $ 9.5
Short-term lease cost 0.3 0.4 1.1 0.9
Variable lease cost 2.3 1.1 4.7 3.3
Total lease cost $ 6.3 $ 4.8 $ 16.2 $ 13.7
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases $ 3.7 $ 2.9 $ 10.0 $ 9.2
Right-of-use assets obtained in exchange for new operating lease liabilities $ 14.0 $ 0.0 $ 29.5 $ 0.8
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Lease Weighted Average (Details)
Sep. 30, 2022
Dec. 31, 2021
Leases [Abstract]    
Weighted average remaining lease term 8 years 10 months 24 days 10 years 8 months 12 days
Weighted average discount rate 3.27% 3.58%
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Leases [Abstract]    
Remainder of fiscal year $ 4.2  
Year one 15.9 $ 11.5
Year two 14.9 10.7
Year three 12.8 10.0
Year four 11.6 8.2
Thereafter 45.0  
Year five   7.3
Thereafter   38.7
Operating leases liabilities payments due 104.4 86.4
Less: imputed lease interest (13.9) (14.1)
Total lease liabilities $ 90.5 $ 72.3
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Affiliated Companies (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]          
Carrying amount, equity-method investments $ 177.2   $ 177.2   $ 201.2
Carrying amount, investments not accounted for under the equity method 11.4   11.4   6.5
Purchases and royalty payments made to affiliates 33.6 $ 34.0 131.2 $ 119.6  
Amount due and payable to affiliates 20.8   20.8   25.5
Sales to affiliates 2.6 $ 2.8 10.2 $ 8.8  
Amount receivable from affiliates $ 1.8   $ 1.8   $ 2.3
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Long-term debt, gross $ 209.8 $ 253.5
Less: unamortized debt issuance costs 0.4 0.5
Total debt 209.4 253.0
Less: current portion of long-term debt 2.2 44.2
Long-term debt, net $ 207.2 208.8
Term Loan, due December 31, 2024 (4.53%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 4.53%  
Long-term debt, gross $ 83.8 85.5
Long-term debt, net $ 81.6  
Series A notes, due July 5, 2022 (3.67%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.67%  
Long-term debt, gross $ 0.0 42.0
Series B notes, due July 5, 2024 (3.82%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.82%  
Long-term debt, gross $ 53.0 53.0
Series C notes, due July 5, 2027 (4.02%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 4.02%  
Long-term debt, gross $ 73.0 $ 73.0
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - Narrative (Details)
$ in Millions
 1 Months Ended
Mar. 31, 2022
USD ($)
fiscal_quarter
instance
Sep. 30, 2022
USD ($)
Feb. 28, 2022
USD ($)
Dec. 31, 2021
USD ($)
Line of Credit Facility [Line Items]        
Long-term debt, gross   $ 209.8   $ 253.5
Long-term debt, current   2.2   44.2
Long-term debt   207.2   208.8
Revolving Credit Facility, Due 2024        
Line of Credit Facility [Line Items]        
Line of credit facility, current borrowing capacity $ 500.0   $ 300.0  
Amount available for issuance of letters of credit 50.0      
Additional borrowing capacity $ 929.0      
Preceding period for increase in facility 12 months      
Ratio of debt to EBITDA 3.5      
Number of instances ratio of debt to EBITDA exceeded | instance 3      
Number of fiscal quarters following acquisition | fiscal_quarter 4      
Ratio of debt to EBITDA after acquisition 4.0      
Revolving Credit Facility, Due 2024 | Applicable Margin        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 0.10%      
Revolving Credit Facility, Due 2024 | Fed Funds Effective Rate Overnight Index Swap Rate        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 0.50%      
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate        
Line of Credit Facility [Line Items]        
Basis spread on variable rate 1.00%      
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum        
Line of Credit Facility [Line Items]        
Applicable margin ratio 0.00875      
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum        
Line of Credit Facility [Line Items]        
Applicable margin ratio 0.01375      
Revolving Credit Facility, Due 2024 | Base Rate | Minimum        
Line of Credit Facility [Line Items]        
Applicable margin ratio 0      
Revolving Credit Facility, Due 2024 | Base Rate | Maximum        
Line of Credit Facility [Line Items]        
Applicable margin ratio 0.00375      
Revolving Credit Facility, Due 2024 | Domestic Line of Credit        
Line of Credit Facility [Line Items]        
Credit facility available for swing-line loans $ 50.0      
Revolving Credit Facility, Due 2024 | Foreign Line of Credit        
Line of Credit Facility [Line Items]        
Credit facility available for swing-line loans $ 40.0      
Revolving credit facility, Due 2024        
Line of Credit Facility [Line Items]        
Line of credit facility, current borrowing capacity   500.0    
Line of credit Facility, unused commitment level   497.6    
Revolving credit facility, Due 2024 | Letter of Credit        
Line of Credit Facility [Line Items]        
Long-term line of credit   2.4    
Term Loan, due December 31, 2024 (4.53%)        
Line of Credit Facility [Line Items]        
Long-term debt, gross   83.8   $ 85.5
Long-term debt, current   2.2    
Long-term debt   $ 81.6    
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)
€ in Millions, ¥ in Millions, $ in Millions, $ in Millions
 9 Months Ended 59 Months Ended
Sep. 30, 2022
SGD ($)
$ / bbl
bbl
Sep. 30, 2022
SGD ($)
$ / bbl
bbl
Sep. 30, 2022
USD ($)
$ / bbl
Sep. 30, 2022
EUR (€)
$ / bbl
Sep. 30, 2022
JPY (¥)
$ / bbl
Dec. 31, 2019
USD ($)
Foreign Exchange Forward            
Derivative [Line Items]            
Derivative contract term 18 months          
Options Held            
Derivative [Line Items]            
Derivative, nonmonetary notional amount, volume | bbl 259,559 823,536        
Derivative, average price risk option strike price | $ / bbl 109.84 109.84 109.84 109.84 109.84  
SGD | Forward Contracts            
Derivative [Line Items]            
Derivative, notional amount $ 601.5 $ 601.5        
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount $ 68.7 $ 68.7        
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount     $ 33.7 € 15.6    
USD | Forward Contracts            
Derivative [Line Items]            
Derivative, notional amount     13.4      
USD | Foreign Exchange Forward | Long | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount     13.5      
USD | Foreign Exchange Forward | Short | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount     0.0 11.8    
USD | Cross Currency Interest Rate Contract            
Derivative [Line Items]            
Derivative, notional amount     83.8      
USD | Cross Currency Interest Rate Contract | Net Investment Hedges:            
Derivative [Line Items]            
Derivative, notional amount           $ 90.0
Yen | Foreign Exchange Forward | Long | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount | ¥         ¥ 5,686.2  
Yen | Foreign Exchange Forward | Short | Designated as Hedging Instrument            
Derivative [Line Items]            
Derivative, notional amount     $ 23.8 € 20.6    
Yen | Cross Currency Interest Rate Contract            
Derivative [Line Items]            
Derivative, notional amount | ¥         ¥ 9,200.0  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss recognized in income, fair value hedges $ 2.2 $ 0.9 $ 4.4 $ 2.1
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net (1.5) 0.5 1.6 1.6
Fair Value Hedges        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, forward point components, (gain) loss, recognized in earnings 1.1 0.6 2.8 1.9
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.4) (0.2) 0.3 (0.6)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.5 0.1 (0.7) 0.9
Fair Value Hedges | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.4) (0.2) 0.3 (0.6)
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.5 0.1 (0.7) 0.9
Cash Flow Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (0.8) 1.5 (3.8) (1.9)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.6 (0.1) 1.6 2.3
Cash Flow Hedges: | Forward treasury locks        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.0 0.0 0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 0.1 0.2 0.2
Net Investment Hedges:        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 4.3 0.6 13.2 6.0
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Net Investment Hedges: | Cross-currency swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 4.3 0.6 13.2 6.0
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0   0.0 0.0
Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss on hedged item, fair value hedges (14.1) (5.9) (35.4) (11.0)
Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges 14.1 5.9 35.4 11.0
Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges 2.2 0.9 4.4 2.1
Gain (loss) on derivative instruments, net, pretax 0.5 0.1 (0.7) 0.9
Other (income) expense | Commodity call options | Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net (1.5) 0.5 1.6 1.6
Net sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax (0.5) 0.1 (1.1) 0.9
Net sales | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.7 0.1 1.1 (0.5)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income (0.5) 0.1 (1.1) 0.9
Cost of goods and services sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 1.0 (0.3) 2.5 1.2
Cost of goods and services sold | Cash Flow Hedges: | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (1.5) 1.4 (4.9) (1.4)
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 1.0 (0.3) 2.5 1.2
Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax $ 0.1 $ 0.1 $ 0.2 $ 0.2
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Assets:    
Deferred compensation assets $ 12.3 $ 15.5
Commodity call options 1.3 1.7
Total assets at fair value 56.7 36.4
Liabilities:    
Contingent consideration 4.9 3.7
Deferred compensation liabilities 12.6 16.1
Total liabilities at fair value 26.3 23.2
Foreign currency contracts    
Assets:    
Foreign currency contracts 22.6 14.8
Liabilities:    
Foreign currency contracts 8.8 3.4
Cross-currency swap    
Assets:    
Foreign currency contracts 20.5 4.4
Level 1    
Assets:    
Deferred compensation assets 12.3 15.5
Commodity call options 0.0
Total assets at fair value 12.3 15.5
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 12.6 16.1
Total liabilities at fair value 12.6 16.1
Level 1 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0 0.0
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 1 | Cross-currency swap    
Assets:    
Foreign currency contracts 0.0 0.0
Level 2    
Assets:    
Deferred compensation assets 0.0 0.0
Commodity call options 1.3 1.7
Total assets at fair value 44.4 20.9
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 8.8 3.4
Level 2 | Foreign currency contracts    
Assets:    
Foreign currency contracts 22.6 14.8
Liabilities:    
Foreign currency contracts 8.8 3.4
Level 2 | Cross-currency swap    
Assets:    
Foreign currency contracts 20.5 4.4
Level 3    
Assets:    
Deferred compensation assets 0.0 0.0
Commodity call options 0.0
Total assets at fair value 0.0 0.0
Liabilities:    
Contingent consideration 4.9 3.7
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 4.9 3.7
Level 3 | Foreign currency contracts    
Assets:    
Foreign currency contracts 0.0 0.0
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 3 | Cross-currency swap    
Assets:    
Foreign currency contracts $ 0.0 $ 0.0
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurement - Other Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Fair Value Disclosures [Abstract]    
Long-term debt, fair value $ 202.2 $ 217.9
Long-term debt $ 207.2 $ 208.8
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance $ 2,424.4 $ 2,326.2 $ 2,335.4 $ 2,032.6 $ 1,829.0 $ 1,854.5 $ 2,335.4 $ 1,854.5
Other comprehensive (loss) income before reclassifications             (163.3) (48.8)
Amounts reclassified out from accumulated other comprehensive (loss) income             14.4 3.7
Other comprehensive loss, net of tax (62.6) (63.5) (22.8) (22.5) 7.0 (29.6) (148.9) (45.1)
Ending balance 2,470.8 2,424.4 2,326.2 2,202.3 2,032.6 1,829.0 2,470.8 2,202.3
Accumulated other comprehensive loss                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance (245.9) (182.4) (159.6) (133.2) (140.2) (110.6) (159.6) (110.6)
Other comprehensive loss, net of tax (62.6) (63.5) (22.8) (22.5) 7.0 (29.6)    
Ending balance (308.5) $ (245.9) (182.4) (155.7) $ (133.2) (140.2) (308.5) (155.7)
(Losses) gains on derivatives                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (1.2)     (1.9) (1.2) (1.9)
Other comprehensive (loss) income before reclassifications             (3.5) (2.5)
Amounts reclassified out from accumulated other comprehensive (loss) income             0.9 3.2
Other comprehensive loss, net of tax             (2.6) 0.7
Ending balance (3.8)     (1.2)     (3.8) (1.2)
Change in equity affiliate investment AOCI                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     1.5     0.6 1.5 0.6
Other comprehensive (loss) income before reclassifications             (0.2) 0.0
Amounts reclassified out from accumulated other comprehensive (loss) income             0.0 0.0
Other comprehensive loss, net of tax             (0.2) 0.0
Ending balance 1.3     0.6     1.3 0.6
Defined benefit pension and other postretirement plans                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     (31.8)     (40.5) (31.8) (40.5)
Other comprehensive (loss) income before reclassifications             2.9 0.6
Amounts reclassified out from accumulated other comprehensive (loss) income             13.5 0.5
Other comprehensive loss, net of tax             16.4 1.1
Ending balance (15.4)     (39.4)     (15.4) (39.4)
Foreign currency translation                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Beginning balance     $ (128.1)     $ (68.8) (128.1) (68.8)
Other comprehensive (loss) income before reclassifications             (162.5) (46.9)
Amounts reclassified out from accumulated other comprehensive (loss) income             0.0 0.0
Other comprehensive loss, net of tax             (162.5) (46.9)
Ending balance $ (290.6)     $ (115.7)     $ (290.6) $ (115.7)
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Cost of goods and services sold $ (418.9)     $ (418.3)     $ (1,304.1) $ (1,225.6)
Interest expense (2.2)     (1.8)     (6.2) (5.6)
Prior service credit 0.0     0.1     0.0 0.2
Actuarial gains (losses) 0.1     (0.2)     0.1 (0.3)
Settlements (49.6)     0.0     (50.8) (0.7)
Income before income taxes 136.2     181.1     551.2 567.0
Tax benefit (expense) (20.4)     (12.0)     (85.8) (73.0)
Net income 120.6 $ 188.5 $ 173.8 175.6 $ 187.3 $ 151.2 482.9 514.1
Reclassification out of Accumulated Other Comprehensive Loss                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net income (13.4)     0.1     (14.4) (3.7)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Income before income taxes (1.5)     (0.7)     (0.9) (5.4)
Tax benefit (expense) 0.4     0.7     0.0 2.2
Net income (1.1)     0.0     (0.9) (3.2)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net sales 0.5     (0.1)     1.2 (1.1)
Cost of goods and services sold (1.2)     0.4     (2.9) (1.9)
Other (income) expense (0.7)     (0.9)     1.1 (2.1)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Interest expense (0.1)     (0.1)     (0.3) (0.3)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans:                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Prior service credit 0.0     0.1     0.0 0.2
Actuarial gains (losses) 1.1     0.1     1.1 (0.1)
Settlements (27.6)     0.0     (28.8) (0.7)
Other 0.0     0.0     (0.4) 0.0
Income before income taxes (26.5)     0.2     (28.1) (0.6)
Tax benefit (expense) 14.2     (0.1)     14.6 0.1
Net income $ (12.3)     $ 0.1     $ (13.5) $ (0.5)
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholder's Equity - Change in Shareholders' Equity (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares)     75,300,000       75,300,000  
Beginning balance $ 2,424.4 $ 2,326.2 $ 2,335.4 $ 2,032.6 $ 1,829.0 $ 1,854.5 $ 2,335.4 $ 1,854.5
Net income 120.6 188.5 173.8 175.6 187.3 151.2 $ 482.9 514.1
Activity related to stock-based compensation $ 15.6 15.1 0.1 16.6 21.8 2.5    
Share purchased under share repurchase program (in shares) 86,667           563,334  
Shares purchased under share repurchase program $ (27.2) (28.6) (147.1)     (137.1) $ (202.9)  
Dividends declared   (13.3) (13.2)   (12.5) (12.5)    
Other comprehensive loss, net of tax $ (62.6) (63.5) (22.8) (22.5) 7.0 (29.6) $ (148.9) (45.1)
Ending balance (in shares) 75,300,000           75,300,000  
Ending balance $ 2,470.8 $ 2,424.4 $ 2,326.2 $ 2,202.3 $ 2,032.6 $ 1,829.0 $ 2,470.8 $ 2,202.3
Common Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Beginning balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Ending balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Ending balance $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Capital in Excess of Par Value                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance 225.3 219.9 249.0 248.0 246.7 267.3 249.0 267.3
Activity related to stock-based compensation 5.3 5.4 (29.1) 3.2 1.3 (20.6)    
Ending balance 230.6 225.3 219.9 251.2 248.0 246.7 230.6 251.2
Treasury Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ (366.3) $ (347.4) $ (229.5) $ (261.2) $ (281.7) $ (167.7) $ (229.5) $ (167.7)
Beginning balance (in shares) 1,300,000 1,200,000 1,100,000 1,300,000 1,500,000 1,300,000 1,100,000 1,300,000
Activity related to stock-based compensation $ 10.3 $ 9.7 $ 29.2 $ 13.4 $ 20.5 $ 23.1    
Activity related to stock -based compensation (in shares) (100,000)   (300,000) (100,000) (200,000) (300,000)    
Share purchased under share repurchase program (in shares) 100,000 100,000 400,000     500,000    
Shares purchased under share repurchase program $ (27.2) $ (28.6) $ (147.1)     $ (137.1)    
Ending balance $ (383.2) $ (366.3) $ (347.4) $ (247.8) $ (261.2) $ (281.7) $ (383.2) $ (247.8)
Ending balance (in shares) 1,300,000 1,300,000 1,200,000 1,200,000 1,300,000 1,500,000 1,300,000 1,200,000
Retained earnings                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance $ 2,792.5 $ 2,617.3 $ 2,456.7 $ 2,160.2 $ 1,985.4 $ 1,846.7 $ 2,456.7 $ 1,846.7
Net income 120.6 188.5 173.8 175.6 187.3 151.2    
Dividends declared   (13.3) (13.2)   (12.5) (12.5)    
Ending balance 2,913.1 2,792.5 2,617.3 2,335.8 2,160.2 1,985.4 2,913.1 2,335.8
Accumulated other comprehensive loss                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beginning balance (245.9) (182.4) (159.6) (133.2) (140.2) (110.6) (159.6) (110.6)
Other comprehensive loss, net of tax (62.6) (63.5) (22.8) (22.5) 7.0 (29.6)    
Ending balance $ (308.5) $ (245.9) $ (182.4) $ (155.7) $ (133.2) $ (140.2) $ (308.5) $ (155.7)
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholder's Equity - Supplemental Equity Information (Details) - $ / shares
 3 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Equity [Abstract]        
Dividends declared per share (in dollars per share) $ 0.18 $ 0.18 $ 0.17 $ 0.17
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares available for issuance under the 2016 Plan (in shares) 1,692,482   1,692,482  
Stock options, granted (in shares)     116,820  
Stock options, weighted average exercise price (in dollars per share)     $ 366.15  
Stock options, weighted average grant date fair value (in dollars per share)     $ 96.63  
Risk-free interest rate (in hundredths)     1.80%  
Expected life (in years)     5 years 7 months 6 days  
Stock volatility (in hundredths)     25.10%  
Dividend yield (in hundredths)     0.20%  
Stock-based compensation expense $ 6.0 $ 11.4 $ 17.0 $ 27.5
Performance Share Unit (PSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     31,597  
Grant date fair value (in dollars per share)     $ 364.54  
PSU payout, minimum (in hundredths) 0.00%   0.00%  
PSU payout, maximum (in hundredths) 200.00%   200.00%  
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     4,987  
Grant date fair value (in dollars per share)     $ 354.65  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost $ 0.3 $ 0.1 $ 1.0 $ 0.9
Interest cost 0.6 1.6 3.8 4.6
Expected return on assets (0.8) (2.9) (5.4) (9.0)
Amortization of prior service credit 0.0 (0.1) 0.0 (0.2)
Recognized actuarial losses (gains) (0.1) 0.2 (0.1) 0.3
Settlements 49.6 0.0 50.8 0.7
Net periodic benefit cost 49.6 (1.1) 50.1 (2.7)
U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 49.3 (1.3) 49.3 (3.8)
International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.3 0.2 0.8 1.1
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.3 0.1 1.0 0.9
Interest cost 0.5 1.6 3.7 4.5
Expected return on assets (0.8) (2.9) (5.4) (9.0)
Amortization of prior service credit 0.0 0.0 0.0 0.1
Recognized actuarial losses (gains) 0.3 0.5 1.0 1.5
Settlements 49.6 0.0 50.8 0.7
Net periodic benefit cost 49.9 (0.7) 51.1 (1.3)
Pension benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 49.6 (0.9) 50.3 (2.4)
Pension benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.3 0.2 0.8 1.1
Other retirement benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.0 0.0 0.0 0.0
Interest cost 0.1 0.0 0.1 0.1
Expected return on assets 0.0 0.0 0.0 0.0
Amortization of prior service credit 0.0 (0.1) 0.0 (0.3)
Recognized actuarial losses (gains) (0.4) (0.3) (1.1) (1.2)
Settlements 0.0 0.0 0.0 0.0
Net periodic benefit cost (0.3) (0.4) (1.0) (1.4)
Other retirement benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.3) (0.4) (1.0) (1.4)
Other retirement benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 49.6 $ 0.0 $ 50.8 $ 0.7
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Contributions by employer 6.5      
Settlements $ 49.6 $ 0.0 $ 50.8 $ 0.7
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense - Other Expense (Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Other Income and Expenses [Abstract]        
Restructuring and related charges $ 0.0 $ 0.4 $ (1.6) $ 2.5
Fixed asset impairments and loss on sale of equipment 1.4 0.2 1.5 0.6
Contingent consideration 1.5 0.1 2.6 0.9
Foreign exchange transaction (gains) losses (2.2) 0.4 (4.6) (2.5)
Other items 1.2 0.7 (1.9) 1.5
Total other (income) expense $ 1.9 $ 1.8 $ (4.0) $ 3.0
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense - Narrative (Details) - 2020 Restructuring Plan
$ in Millions
 1 Months Ended
Jul. 31, 2020
USD ($)
Restructuring Cost and Reserve [Line Items]  
Restructuring and related activities, period of implementation 24 months
Restructuring and related cost, cumulative cost incurred $ 5.2
Minimum  
Restructuring Cost and Reserve [Line Items]  
Restructuring and related cost, expected cost 5.0
Effect on future earnings, amount 0.9
Maximum  
Restructuring Cost and Reserve [Line Items]  
Restructuring and related cost, expected cost 6.0
Effect on future earnings, amount $ 1.6
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense - Restructuring and Related Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Restructuring Reserve [Roll Forward]        
(Credits) Charges $ 0.0 $ 0.4 $ (1.6) $ 2.5
2020 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2021     3.3  
(Credits) Charges     (1.6)  
Cash payments     (0.8)  
Balance, September 30, 2022 0.9   0.9  
Severance and benefits | 2020 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2021     2.8  
(Credits) Charges     (1.4)  
Cash payments     (0.6)  
Balance, September 30, 2022 0.8   0.8  
Other charges | 2020 Restructuring Plan        
Restructuring Reserve [Roll Forward]        
Balance, December 31, 2021     0.5  
(Credits) Charges     (0.2)  
Cash payments     (0.2)  
Balance, September 30, 2022 $ 0.1   $ 0.1  
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense - Other Items (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Development and licensing income [Line Items]        
Net gain on sale of cost investments   $ 0.9   $ 1.8
Impairment charge from cost investments       2.2
Not Designated as Hedging Instrument        
Development and licensing income [Line Items]        
Derivative instruments not designated as hedging instruments, (loss) gain, net $ (1.5) 0.5 $ 1.6 1.6
Commodity call options | Not Designated as Hedging Instrument | Other (income) expense        
Development and licensing income [Line Items]        
Derivative instruments not designated as hedging instruments, (loss) gain, net $ (1.5) $ 0.5 $ 1.6 $ 1.6
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 20.4 $ 12.0 $ 85.8 $ 73.0
Effective income tax rate 15.00% 6.60% 15.60% 12.90%
Benefit from prepayment of future royalties   $ 20.4   $ 20.4
Benefit from termination of pension plan $ 20.0   $ 20.3  
Deferred tax benefit $ 8.0   $ 8.0  
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales $ 686.9 $ 706.5 $ 2,178.2 $ 2,100.8
Operating profit 186.2 181.4 604.3 568.3
Stock-based compensation expense     (17.0) (27.5)
Interest expense (income) and other nonoperating expense (income), net 50.0 0.3 53.1 1.3
Income before income taxes 136.2 181.1 551.2 567.0
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit 203.3 212.3 663.9 646.2
Intersegment sales elimination        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales (0.1) (0.2) (0.3) (0.4)
Corporate and Unallocated        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Operating profit (17.1) (30.9) (59.6) (77.9)
Stock-based compensation expense (6.0) (11.4) (17.0) (27.5)
Corporate general costs (10.9) (18.1) (43.6) (45.5)
Restructuring and related charges 0.0 (0.3) 1.6 (2.5)
Amortization of acquisition-related intangible assets (0.2) (0.2) (0.6) (0.6)
Cost investment activity 0.0 (0.9) 0.0 (1.8)
Proprietary Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 567.0 577.0 1,822.0 1,708.0
Operating profit 188.6 195.5 615.9 594.3
Contract-Manufactured Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 120.0 129.7 356.5 393.2
Operating profit $ 14.7 $ 16.8 $ 48.0 $ 51.9
XML 78 wst-20220930_htm.xml IDEA: XBRL DOCUMENT 0000105770 2022-01-01 2022-09-30 0000105770 2022-10-17 0000105770 2022-07-01 2022-09-30 0000105770 2021-07-01 2021-09-30 0000105770 2021-01-01 2021-09-30 0000105770 2022-09-30 0000105770 2021-12-31 0000105770 2020-12-31 0000105770 2021-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000105770 2013-06-30 0000105770 wst:SmartDoseMember 2022-09-30 0000105770 wst:TermLoanDue2024Member 2022-09-30 0000105770 wst:TermLoanDue2024Member 2021-12-31 0000105770 wst:SeniorNotesDue2022Member 2022-09-30 0000105770 wst:SeniorNotesDue2022Member 2021-12-31 0000105770 wst:SeniorBNotesDue2024Member 2022-09-30 0000105770 wst:SeniorBNotesDue2024Member 2021-12-31 0000105770 wst:SeniorCNotesDue2027Member 2022-09-30 0000105770 wst:SeniorCNotesDue2027Member 2021-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-02-28 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 us-gaap:DomesticLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 us-gaap:ForeignLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member wst:ApplicableMarginMember 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member us-gaap:FederalFundsEffectiveSwapRateMember 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-03-01 2022-03-31 0000105770 srt:MinimumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:BaseRateMember 2022-03-01 2022-03-31 0000105770 srt:MaximumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:BaseRateMember 2022-03-01 2022-03-31 0000105770 srt:MinimumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-03-01 2022-03-31 0000105770 srt:MaximumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-03-01 2022-03-31 0000105770 wst:Revolvingcreditfacilitydue2024Member 2022-09-30 0000105770 us-gaap:LetterOfCreditMember wst:Revolvingcreditfacilitydue2024Member 2022-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember 2022-09-30 0000105770 currency:USD us-gaap:ForwardContractsMember 2022-09-30 0000105770 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember 2022-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember 2022-09-30 0000105770 us-gaap:OptionMember 2017-11-01 2022-09-30 0000105770 us-gaap:OptionMember 2022-01-01 2022-09-30 0000105770 us-gaap:OptionMember 2022-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:FairValueHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:FairValueHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:FairValueHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:FairValueHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:CashFlowHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2022-07-01 2022-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:CashFlowHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:CashFlowHedgingMember 2021-01-01 2021-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2022-01-01 2022-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2021-01-01 2021-09-30 0000105770 wst:NetSalesMember 2022-07-01 2022-09-30 0000105770 wst:NetSalesMember 2021-07-01 2021-09-30 0000105770 wst:NetSalesMember 2022-01-01 2022-09-30 0000105770 wst:NetSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000105770 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000105770 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000105770 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000105770 us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000105770 us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0000105770 us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0000105770 us-gaap:InterestExpenseMember 2021-01-01 2021-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2021-07-01 2021-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:NondesignatedMember 2022-07-01 2022-09-30 0000105770 us-gaap:NondesignatedMember 2021-07-01 2021-09-30 0000105770 us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0000105770 us-gaap:NondesignatedMember 2021-01-01 2021-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2022-09-30 0000105770 us-gaap:FairValueInputsLevel2Member 2022-09-30 0000105770 us-gaap:FairValueInputsLevel3Member 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0000105770 us-gaap:CurrencySwapMember 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2021-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000105770 us-gaap:CurrencySwapMember 2021-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000105770 us-gaap:CurrencySwapMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000105770 us-gaap:CommonStockMember 2021-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000105770 2022-01-01 2022-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000105770 us-gaap:CommonStockMember 2022-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-03-31 0000105770 us-gaap:RetainedEarningsMember 2022-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000105770 2022-03-31 0000105770 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000105770 2022-04-01 2022-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000105770 us-gaap:CommonStockMember 2022-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-06-30 0000105770 us-gaap:RetainedEarningsMember 2022-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000105770 2022-06-30 0000105770 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000105770 us-gaap:CommonStockMember 2022-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2022-09-30 0000105770 us-gaap:RetainedEarningsMember 2022-09-30 0000105770 us-gaap:CommonStockMember 2020-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2020-12-31 0000105770 us-gaap:RetainedEarningsMember 2020-12-31 0000105770 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000105770 2021-01-01 2021-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000105770 us-gaap:CommonStockMember 2021-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000105770 us-gaap:TreasuryStockCommonMember 2021-03-31 0000105770 us-gaap:RetainedEarningsMember 2021-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000105770 2021-03-31 0000105770 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000105770 2021-04-01 2021-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2021-04-01 2021-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000105770 us-gaap:CommonStockMember 2021-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000105770 us-gaap:TreasuryStockCommonMember 2021-06-30 0000105770 us-gaap:RetainedEarningsMember 2021-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000105770 2021-06-30 0000105770 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2021-07-01 2021-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000105770 us-gaap:CommonStockMember 2021-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000105770 us-gaap:TreasuryStockCommonMember 2021-09-30 0000105770 us-gaap:RetainedEarningsMember 2021-09-30 0000105770 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000105770 us-gaap:PerformanceSharesMember 2022-09-30 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 country:US 2022-07-01 2022-09-30 0000105770 country:US 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember 2022-07-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember 2021-07-01 2021-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 country:US 2022-01-01 2022-09-30 0000105770 country:US 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000105770 us-gaap:ForeignPlanMember 2022-01-01 2022-09-30 0000105770 us-gaap:ForeignPlanMember 2021-01-01 2021-09-30 0000105770 wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 wst:A2020RestructuringPlanMember 2020-07-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2021-12-31 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2021-12-31 0000105770 wst:A2020RestructuringPlanMember 2021-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2022-01-01 2022-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2022-01-01 2022-09-30 0000105770 wst:A2020RestructuringPlanMember 2022-01-01 2022-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2022-09-30 0000105770 us-gaap:OtherRestructuringMember wst:A2020RestructuringPlanMember 2022-09-30 0000105770 wst:A2020RestructuringPlanMember 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2022-01-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2022-01-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2021-01-01 2021-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2022-07-01 2022-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2021-07-01 2021-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000105770 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000105770 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure wst:instance wst:fiscal_quarter iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:segment 0000105770 --12-31 2022 Q3 false 10-Q true 2022-09-30 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-0645 610 594-2900 Common Stock, par value $0.25 per share WST NYSE Yes Yes Large Accelerated Filer false false false 74032987 686900000 706500000 2178200000 2100800000 418900000 418300000 1304100000 1225600000 268000000.0 288200000 874100000 875200000 13600000 13100000 42600000 39100000 66300000 91900000 231200000 264800000 -1900000 -1800000 4000000.0 -3000000.0 186200000 181400000 604300000 568300000 2200000 1800000 6200000 5600000 1500000 400000 2200000 700000 -49300000 1100000 -49100000 3600000 136200000 181100000 551200000 567000000.0 20400000 12000000.0 85800000 73000000.0 4800000 6500000 17500000 20100000 120600000 175600000 482900000 514100000 1.62 2.37 6.49 6.95 1.59 2.31 6.36 6.78 74400000 74100000 74400000 74000000.0 75700000 76000000.0 75900000 75800000 120600000 175600000 482900000 514100000 1100000 100000 3800000 1800000 -76000000.0 -24200000 -162500000 -46900000 14600000 200000 15500000 400000 -13600000 -400000 -16400000 -1100000 0.0 0.0 0.0 0.0 -100000 0 -200000 0 0.0 -400000 -800000 -400000 -100000 1300000 -2600000 700000 -62600000 -22500000 -148900000 -45100000 58000000.0 153100000 334000000.0 469000000.0 729000000.0 762600000 485300000 489000000.0 413100000 378400000 106200000 112000000.0 1733600000 1742000000 2232900000 2215000000 1163900000 1157500000 1069000000 1057500000 86600000 69300000 188600000 207700000 104000000.0 109900000 18100000 23000000.0 63000000.0 48500000 1200000 16700000 52700000 39200000 3316800000 3313800000 2200000 44200000 188900000 232200000 2300000 2400000 66700000 116300000 29900000 26300000 13300000 9300000 153400000 163400000 456700000 594100000 207200000 208800000 16600000 4900000 35200000 40500000 77200000 63000000.0 19200000 28900000 33900000 38200000 846000000.0 978400000 3000000 3000000 0 0 0 0 0 0 0.25 0.25 200000000 200000000 75300000 75300000 74000000 74200000 18800000 18800000 230600000 249000000.0 2913100000 2456700000 -308500000 -159600000 1300000 1100000 383200000 229500000 2470800000 2335400000 3316800000 3313800000 482900000 514100000 86800000 84600000 2700000 3300000 17000000.0 27500000 50800000 700000 1400000 1000000.0 16300000 17500000 129300000 188500000 493200000 423200000 189700000 176900000 3700000 -1200000 -193400000 -175700000 43700000 1100000 1300000 0 40000000.0 37800000 17100000 23100000 6100000 5700000 202900000 137100000 19400000 14700000 -284100000 -161900000 -49300000 -13100000 -33600000 72500000 762600000 615500000 729000000.0 688000000.0 Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2022, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West has been actively monitoring the coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continue to operate as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We adopted this guidance during the quarter and its adoption did not have a material impact on our financial statements.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to improve the transparency of financial disclosures for government assistance received by business entities. The amendment requires disclosures for transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This guidance is effective for fiscal years beginning after December 15, 2021. We adopted this guidance as of January 1, 2022, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We adopted this guidance during the quarter and its adoption did not have a material impact on our financial statements.</span></div> RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. <div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2022</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2022</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the nine months ended September 30, 2022, $23.6 million of revenue was recognized that was included in deferred income at the beginning of the year. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. As of September 30, 2022, there was $3.2 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $2.3 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span> <div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td></tr></table></div> 0.41 0.40 0.42 0.40 0.18 0.18 0.18 0.17 0.24 0.24 0.24 0.24 0.17 0.18 0.16 0.19 1 1 1 1 0.54 0.55 0.56 0.54 0.06 0.05 0.05 0.04 0.23 0.22 0.23 0.23 0.17 0.18 0.16 0.19 1 1 1 1 0.53 0.45 0.48 0.45 0.38 0.45 0.43 0.45 0.09 0.10 0.09 0.10 1 1 1 1 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, September 30, 2022</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, September 30, 2022</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 14600000 18300000 3700000 61300000 52000000.0 9300000 23600000 20000000 3200000 900000 2300000 Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, there were 0.2 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.0 million antidilutive shares outstanding during the nine months ended September 30, 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced a share repurchase program for calendar-year 2022 authorizing the repurchase of up to 650,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we purchased 86,667 shares of our common stock under the program at a cost of $27.2 million, or an average price of $313.22 per share. During the nine months ended September 30, 2022, we purchased 563,334 shares of our common stock under the program at a cost of $202.9 million, or an average price of $360.03 per share.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 120600000 175600000 482900000 514100000 74400000 74100000 74400000 74000000.0 1300000 1900000 1500000 1800000 75700000 76000000.0 75900000 75800000 200000 0 100000 0 650000 86667 27200000 313.22 563334 202900000 360.03 Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 179000000.0 153800000 79000000.0 63500000 155100000 161100000 413100000 378400000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term for operating leases was 8.9 and 10.7 years, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the weighted average discount rate was 3.27% and 3.58%, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3700000 3300000 10400000 9500000 300000 400000 1100000 900000 2300000 1100000 4700000 3300000 6300000 4800000 16200000 13700000 3700000 2900000 10000000.0 9200000 14000000.0 0 29500000 800000 P8Y10M24D P10Y8M12D 0.0327 0.0358 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 4200000 11500000 15900000 10700000 14900000 10000000.0 12800000 8200000 11600000 7300000 45000000.0 38700000 104400000 86400000 13900000 14100000 90500000 72300000 Affiliated Companies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $177.2 million and $201.2 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $11.4 million and $6.5 million, respectively. We record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases from, and royalty payments made to, affiliates totaled $33.6 million and $131.2 million for the three and nine months ended September 30, 2022, respectively, as compared to $34.0 million and $119.6 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the payable balance due to affiliates was $20.8 million and $25.5 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. ("Daikyo") that allows us to purchase and re-sell Daikyo products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to affiliates were $2.6 million and $10.2 million, respectively, for the three and nine months ended September 30, 2022, as compared to $2.8 million and $8.8 million, respectively, for the same periods in 2021. As of September 30, 2022 and December 31, 2021, the receivable balance due from affiliates was $1.8 million and $2.3 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 7, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Companies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div> 177200000 201200000 11400000 6500000 33600000 131200000 34000000 119600000 20800000 25500000 2600000 10200000 2800000 8800000 1800000 2300000 Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2022, with the exception of the Series A notes which is as of December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (4.53%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we amended and extended the existing credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve month period in the aggregate through an increase in the revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the borrowing capacity available under our $500.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.4 million, was $497.6 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2022, we were in compliance with all of our debt covenants.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, we had $83.8 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $81.6 million was classified as long-term. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details regarding our debt agreements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2022, with the exception of the Series A notes which is as of December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (4.53%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0453 83800000 85500000 0.0367 0 42000000.0 0.0382 53000000.0 53000000.0 0.0402 73000000.0 73000000.0 209800000 253500000 400000 500000 209400000 253000000.0 2200000 44200000 207200000 208800000 300000000 500000000 500000000 50000000 40000000 50000000 929000000 P12M 0.0010 0.0050 0.0100 0 0.00375 0.00875 0.01375 3.5 3 4 4.0 500000000 2400000 497600000 83800000 2200000 81600000 Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency interco</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpany loans. As of September 30, 2022, the notional amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,686.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. As of September 30, 2022, the notional amount of the cross-currency swap is ¥9.2 billion ($83.8 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (“Yen”) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed principal payments of USD in return for paying fixed principal payments of Yen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From November 2017 through September 2022, we purchased several series of call options for a total of 823,536 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had outstanding contracts to purchase 259,559 barrels of crude oil from September 2022 to June 2024, at a weighted-average strike price of $109.84 per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of September 30, 2022 and December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2022 and 2021 were $1.1 million, $2.8 million, and $0.6 million, $1.9 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Loss) Gain Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022 and 2021, there was no material ineffectiveness related to our hedges.</span></div> 601500000 13400000 P18M As of September 30, 2022, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,686.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 13500000 0 11800000 5686200000 23800000 20600000 68700000 33700000 15600000 90000000 9200000000 83800000 823536 259559 109.84 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:42pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Loss) Gain Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income for the </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> 14100000 5900000 35400000 11000000.0 -14100000 -5900000 -35400000 -11000000.0 -2200000 -900000 -4400000 -2100000 -2200000 -900000 -4400000 -2100000 -1100000 -2800000 -600000 -1900000 -400000 -200000 -500000 -100000 -400000 -200000 -500000 -100000 700000 100000 500000 -100000 -1500000 1400000 -1000000.0 300000 0 0 -100000 -100000 -800000 1500000 -600000 100000 4300000 600000 0 0 4300000 600000 0 0 300000 -600000 700000 -900000 300000 -600000 700000 -900000 1100000 -500000 1100000 -900000 -4900000 -1400000 -2500000 -1200000 0 0 -200000 -200000 -3800000 -1900000 -1600000 -2300000 13200000 6000000.0 0 0 13200000 6000000.0 0 0 -500000 100000 -1100000 900000 1000000.0 -300000 2500000 1200000 100000 100000 200000 200000 500000 100000 -700000 900000 -1500000 500000 1600000 1600000 -1500000 500000 1600000 1600000 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform (the “SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other (income) expense in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2022, the estimated fair value of long-term debt was $202.2 million compared to a carrying amount of $207.2 million. At December 31, 2021, the estimated fair value of long-term debt was $217.9 million and the carrying amount was $208.8 million.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12300000 12300000 0 0 22600000 0 22600000 0 20500000 0 20500000 0 1300000 0 1300000 0 56700000 12300000 44400000 0 4900000 0 0 4900000 12600000 12600000 0 0 8800000 0 8800000 0 26300000 12600000 8800000 4900000 15500000 15500000 0 0 14800000 0 14800000 0 4400000 0 4400000 0 1700000 1700000 36400000 15500000 20900000 0 3700000 0 0 3700000 16100000 16100000 0 0 3400000 0 3400000 0 23200000 16100000 3400000 3700000 202200000 207200000 217900000 208800000 Accumulated Other Comprehensive Loss<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.269%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -1200000 1500000 -31800000 -128100000 -159600000 -3500000 -200000 2900000 -162500000 -163300000 -900000 0 -13500000 0 -14400000 -2600000 -200000 16400000 -162500000 -148900000 -3800000 1300000 -15400000 -290600000 -308500000 -1900000 600000 -40500000 -68800000 -110600000 -2500000 0 600000 -46900000 -48800000 -3200000 0 -500000 0 -3700000 700000 0 1100000 -46900000 -45100000 -1200000 600000 -39400000 -115700000 -155700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.269%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> 500000 -100000 1200000 -1100000 1200000 -400000 2900000 1900000 -700000 -900000 1100000 -2100000 100000 100000 300000 300000 -1500000 -700000 -900000 -5400000 -400000 -700000 0 -2200000 -1100000 0 -900000 -3200000 0 -100000 0 -200000 1100000 100000 1100000 -100000 -27600000 0 -28800000 -700000 0 0 400000 0 -26500000 200000 -28100000 -600000 -14200000 100000 -14600000 -100000 -12300000 100000 -13500000 -500000 -13400000 100000 -14400000 -3700000 Shareholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.431%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"/><td style="width:32.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.431%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.421%"><tr><td style="width:1.0%"/><td style="width:32.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.884%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.473%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,829.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.17 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.6 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 75300000 18800000 249000000.0 1100000 -229500000 2456700000 -159600000 2335400000 173800000 173800000 -29100000 -300000 29200000 100000 400000 147100000 147100000 0.18 13200000 13200000 -22800000 -22800000 75300000 18800000 219900000 1200000 -347400000 2617300000 -182400000 2326200000 188500000 188500000 5400000 9700000 15100000 100000 28600000 28600000 0.18 13300000 13300000 -63500000 -63500000 75300000 18800000 225300000 1300000 -366300000 2792500000 -245900000 2424400000 120600000 120600000 5300000 -100000 10300000 15600000 100000 27200000 27200000 -62600000 -62600000 75300000 18800000 230600000 1300000 -383200000 2913100000 -308500000 2470800000 75300000 18800000 267300000 1300000 -167700000 1846700000 -110600000 1854500000 151200000 151200000 -20600000 -300000 23100000 2500000 500000 137100000 137100000 0.17 12500000 12500000 -29600000 -29600000 75300000 18800000 246700000 1500000 -281700000 1985400000 -140200000 1829000000 187300000 187300000 1300000 -200000 20500000 21800000 0.17 12500000 12500000 7000000.0 7000000.0 75300000 18800000 248000000.0 1300000 -261200000 2160200000 -133200000 2032600000 175600000 175600000 3200000 -100000 13400000 16600000 -22500000 -22500000 75300000 18800000 251200000 1200000 -247800000 2335800000 -155700000 2202300000 Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2022, there were 1,692,482 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted 116,820 stock options at a weighted average exercise price of $366.15 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $96.63 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.8%; expected life of 5.6 years based on prior experience; stock volatility of 25.1% based on historical data; and a dividend yield of 0.2%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted 31,597 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $364.54 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted 4,987 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $354.65 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div>Stock-based compensation expense was $6.0 million and $17.0 million for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, stock-based compensation expense was $11.4 million and $27.5 million, respectively. 1692482 116820 366.15 96.63 0.018 P5Y7M6D 0.251 0.002 31597 364.54 0 2 4987 354.65 6000000 17000000.0 11400000 27500000 Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). Prior to the third quarter of 2022, a Notice of Intent to Terminate was sent to all interested parties and a favorable determination letter was received from the Internal Revenue Service. During the three months ended September 30, 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $6.5 million was then made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations. During the three and nine months ended September 30, 2022, we recorded $49.6 million and $50.8 million in pension settlement charges, respectively, within other nonoperating expense (income), which for the nine months ended September 30, 2022 relieved the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. During the nine months ended September 30, 2021, we recorded a $0.7 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for the U.S. pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 300000 100000 0 0 300000 100000 500000 1600000 100000 0 600000 1600000 800000 2900000 0 0 800000 2900000 0 0 0 -100000 0 -100000 -300000 -500000 400000 300000 100000 -200000 -49600000 0 0 0 -49600000 0 49900000 -700000 -300000 -400000 49600000 -1100000 49600000 -900000 -300000 -400000 49300000 -1300000 300000 200000 0 0 300000 200000 49900000 -700000 -300000 -400000 49600000 -1100000 1000000.0 900000 0 0 1000000.0 900000 3700000 4500000 100000 100000 3800000 4600000 5400000 9000000.0 0 0 5400000 9000000.0 0 100000 0 -300000 0 -200000 -1000000.0 -1500000 1100000 1200000 100000 -300000 -50800000 -700000 0 0 -50800000 -700000 51100000 -1300000 -1000000.0 -1400000 50100000 -2700000 50300000 -2400000 -1000000.0 -1400000 49300000 -3800000 800000 1100000 0 0 800000 1100000 51100000 -1300000 -1000000.0 -1400000 50100000 -2700000 6500000 -49600000 -50800000 -700000 Other (Income) Expense <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairments and loss on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction (gains) losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (income) expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $5 million to $6 million, with annualized savings in the range of $0.9 million to $1.6 million. Since its approval, we recorded a net pre-tax amount equal to $5.2 million in restructuring and related charges associated with this plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Items</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we recorded a loss of $1.5 million and a gain of $1.6 million, respectively, related to oil hedges. During the three and nine months ended September 30, 2021, we recorded a gain of $0.5 million and $1.6 million, respectively, related to oil hedges. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our hedging activity.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we recorded a net loss of $0.9 million on the sale of one of the Company's cost investments. During the nine months ended September 30, 2021, we recorded a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss in our cost investment activity of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, inclusive of </span>an impairment charge of $2.2 million for one of the Company's cost investments. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairments and loss on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction (gains) losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (income) expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 400000 -1600000 2500000 -1400000 -200000 -1500000 -600000 1500000 100000 2600000 900000 2200000 -400000 4600000 2500000 -1200000 -700000 1900000 -1500000 -1900000 -1800000 4000000.0 -3000000.0 P24M 5000000 6000000 900000 1600000 5200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2800000 500000 3300000 -1400000 -200000 -1600000 600000 200000 800000 800000 100000 900000 -1500000 1600000 500000 1600000 900000 1800000 -2200000 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $20.4 million and $12.0 million for the three months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.0% and 6.6%, respectively. The provision for income taxes was $85.8 million and $73.0 million for the nine months ended September 30, 2022 and 2021, respectively, and the effective tax rate was 15.6% and 12.9%, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in effective tax rate for the three months ended September 30, 2022 and 2021 is the result of the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit</span><span style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $20.0 million recorded related to the termination of the U.S. pension plan recorded in 2022, a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s mentioned in Note 14, </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_73" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the </span><span style="background-color:#ffffff;color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> benefit is a deferred tax benefit of $8.0 million. This is due to the reversal of stranded tax effects in AOCI for the historic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in effective tax rate for the nine months ended September 30, 2022 and 2021 is the result of the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's prepayment of future royalties from one of its subsidiaries in 2021, which resulted in a $20.4 million tax benefit that was not repeated in 2022, as well as a larger tax benefit related to stock-based compensation in 2021 when compared to 2022, offset by the tax benefit of $20.3 million recorded related to the termination of the U.S. pension plan recorded in 2022, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s mentioned in Note 14, </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_73" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> benefit is a deferred tax benefit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This is due to the reversal of stranded tax effects in AOCI for the historic accrual of deferred tax on pension AOCI at historic federal and state income tax rates while the related deferred tax asset was adjusted to the latest enacted income tax rates through net income.</span> 20400000 12000000 0.150 0.066 85800000 73000000.0 0.156 0.129 -20400000 -20000000 -20000000 -8000000 -20400000 -20300000 -20300000 -8000000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the commitments and contingencies included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000162828022003342/wst-20211231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> Segment InformationOur business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income) and other nonoperating expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1850ed8091a3476d86031d538676d07e_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other (Income) Expense</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of these items.</span></div> 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost investment activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income) and other nonoperating expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three and nine months ended September 30, 2022, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three and nine months ended September 30, 2021, the Company recorded $0.2 million and $0.6 million, respectively, of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div> 567000000.0 577000000.0 1822000000 1708000000 120000000.0 129700000 356500000 393200000 -100000 -200000 -300000 -400000 686900000 706500000 2178200000 2100800000 188600000 195500000 615900000 594300000 14700000 16800000 48000000.0 51900000 203300000 212300000 663900000 646200000 6000000.0 11400000 17000000.0 27500000 10900000 18100000 43600000 45500000 0 300000 -1600000 2500000 200000 200000 600000 600000 0 900000 0 1800000 -17100000 -30900000 -59600000 -77900000 186200000 181400000 604300000 568300000 -50000000.0 -300000 -53100000 -1300000 136200000 181100000 551200000 567000000.0 200000 600000 200000 600000 EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 80 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 368 302 1 false 80 0 false 12 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.westpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103102 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 2104103 - Disclosure - Revenue Sheet http://www.westpharma.com/role/Revenue Revenue Notes 10 false false R11.htm 2109104 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 11 false false R12.htm 2112105 - Disclosure - Inventories Sheet http://www.westpharma.com/role/Inventories Inventories Notes 12 false false R13.htm 2115106 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 13 false false R14.htm 2121107 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 14 false false R15.htm 2123108 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 15 false false R16.htm 2127109 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 16 false false R17.htm 2131110 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 2135111 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 18 false false R19.htm 2139112 - Disclosure - Shareholders' Equity Sheet http://www.westpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 2143113 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 2145114 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 21 false false R22.htm 2149115 - Disclosure - Other (Income) Expense Sheet http://www.westpharma.com/role/OtherIncomeExpense Other (Income) Expense Notes 22 false false R23.htm 2155116 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2157117 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 2158118 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 25 false false R26.htm 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 26 false false R27.htm 2305301 - Disclosure - Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueTables Revenue (Tables) Tables http://www.westpharma.com/role/Revenue 27 false false R28.htm 2310302 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 28 false false R29.htm 2313303 - Disclosure - Inventories (Tables) Sheet http://www.westpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.westpharma.com/role/Inventories 29 false false R30.htm 2316304 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 30 false false R31.htm 2324305 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 31 false false R32.htm 2328306 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 32 false false R33.htm 2332307 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 33 false false R34.htm 2336308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 34 false false R35.htm 2340309 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.westpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.westpharma.com/role/ShareholdersEquity 35 false false R36.htm 2346310 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 36 false false R37.htm 2350311 - Disclosure - Other (Income) Expense (Tables) Sheet http://www.westpharma.com/role/OtherIncomeExpenseTables Other (Income) Expense (Tables) Tables http://www.westpharma.com/role/OtherIncomeExpense 37 false false R38.htm 2359312 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 38 false false R39.htm 2406401 - Disclosure - Revenue - Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue - Revenue Recognition (Details) Details 39 false false R40.htm 2407402 - Disclosure - Revenue - Contracts and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails Revenue - Contracts and Liabilities (Details) Details 40 false false R41.htm 2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails Revenue - Contracts and Liabilities, Narrative (Details) Details 41 false false R42.htm 2411404 - Disclosure - Net Income Per Share (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Details http://www.westpharma.com/role/NetIncomePerShareTables 42 false false R43.htm 2414405 - Disclosure - Inventories (Details) Sheet http://www.westpharma.com/role/InventoriesDetails Inventories (Details) Details http://www.westpharma.com/role/InventoriesTables 43 false false R44.htm 2417406 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 44 false false R45.htm 2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails Leases - Lease Cash Flow and Supplemental Information (Details) Details 45 false false R46.htm 2419408 - Disclosure - Leases - Lease Weighted Average (Details) Sheet http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails Leases - Lease Weighted Average (Details) Details 46 false false R47.htm 2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 47 false false R48.htm 2422410 - Disclosure - Affiliated Companies (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesDetails Affiliated Companies (Details) Details http://www.westpharma.com/role/AffiliatedCompanies 48 false false R49.htm 2425411 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.westpharma.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 49 false false R50.htm 2426412 - Disclosure - Debt - Narrative (Details) Sheet http://www.westpharma.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 50 false false R51.htm 2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details) Details 51 false false R52.htm 2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Details 52 false false R53.htm 2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Details 53 false false R54.htm 2434416 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails Fair Value Measurement - Other Financial Instruments (Details) Details 54 false false R55.htm 2437417 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Details 55 false false R56.htm 2438418 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Details 56 false false R57.htm 2441419 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) Sheet http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails Shareholder's Equity - Change in Shareholders' Equity (Details) Details 57 false false R58.htm 2442420 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) Sheet http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails Shareholder's Equity - Supplemental Equity Information (Details) Details 58 false false R59.htm 2444421 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.westpharma.com/role/StockBasedCompensation 59 false false R60.htm 2447422 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Sheet http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Details 60 false false R61.htm 2448423 - Disclosure - Benefit Plans - Narrative (Details) Sheet http://www.westpharma.com/role/BenefitPlansNarrativeDetails Benefit Plans - Narrative (Details) Details 61 false false R62.htm 2451424 - Disclosure - Other (Income) Expense - Other Expense (Income) (Details) Sheet http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails Other (Income) Expense - Other Expense (Income) (Details) Details http://www.westpharma.com/role/OtherIncomeExpenseTables 62 false false R63.htm 2452425 - Disclosure - Other (Income) Expense - Narrative (Details) Sheet http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails Other (Income) Expense - Narrative (Details) Details http://www.westpharma.com/role/OtherIncomeExpenseTables 63 false false R64.htm 2453426 - Disclosure - Other (Income) Expense - Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails Other (Income) Expense - Restructuring and Related Charges (Details) Details http://www.westpharma.com/role/OtherIncomeExpenseTables 64 false false R65.htm 2454427 - Disclosure - Other (Income) Expense - Other Items (Details) Sheet http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails Other (Income) Expense - Other Items (Details) Details http://www.westpharma.com/role/OtherIncomeExpenseTables 65 false false R66.htm 2456428 - Disclosure - Income Taxes (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.westpharma.com/role/IncomeTaxes 66 false false R67.htm 2460429 - Disclosure - Segment Information (Details) Sheet http://www.westpharma.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.westpharma.com/role/SegmentInformationTables 67 false false All Reports Book All Reports wst-20220930.htm ex311q32022.htm ex312q32022.htm ex321q32022.htm ex322q32022.htm wst-20220930.xsd wst-20220930_cal.xml wst-20220930_def.xml wst-20220930_lab.xml wst-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wst-20220930.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 368, "dts": { "calculationLink": { "local": [ "wst-20220930_cal.xml" ] }, "definitionLink": { "local": [ "wst-20220930_def.xml" ] }, "inline": { "local": [ "wst-20220930.htm" ] }, "labelLink": { "local": [ "wst-20220930_lab.xml" ] }, "presentationLink": { "local": [ "wst-20220930_pre.xml" ] }, "schema": { "local": [ "wst-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 501, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 22, "keyStandard": 280, "memberCustom": 20, "memberStandard": 60, "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.westpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Revenue", "role": "http://www.westpharma.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Net Income Per Share", "role": "http://www.westpharma.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112105 - Disclosure - Inventories", "role": "http://www.westpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115106 - Disclosure - Leases", "role": "http://www.westpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Affiliated Companies", "role": "http://www.westpharma.com/role/AffiliatedCompanies", "shortName": "Affiliated Companies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123108 - Disclosure - Debt", "role": "http://www.westpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127109 - Disclosure - Derivative Financial Instruments", "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131110 - Disclosure - Fair Value Measurements", "role": "http://www.westpharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135111 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139112 - Disclosure - Shareholders' Equity", "role": "http://www.westpharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143113 - Disclosure - Stock-Based Compensation", "role": "http://www.westpharma.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145114 - Disclosure - Benefit Plans", "role": "http://www.westpharma.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149115 - Disclosure - Other (Income) Expense", "role": "http://www.westpharma.com/role/OtherIncomeExpense", "shortName": "Other (Income) Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - Income Taxes", "role": "http://www.westpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157117 - Disclosure - Commitments and Contingencies", "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158118 - Disclosure - Segment Information", "role": "http://www.westpharma.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Revenue (Tables)", "role": "http://www.westpharma.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Inventories (Tables)", "role": "http://www.westpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - Leases (Tables)", "role": "http://www.westpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Debt (Tables)", "role": "http://www.westpharma.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332307 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336308 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340309 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.westpharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346310 - Disclosure - Benefit Plans (Tables)", "role": "http://www.westpharma.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350311 - Disclosure - Other (Income) Expense (Tables)", "role": "http://www.westpharma.com/role/OtherIncomeExpenseTables", "shortName": "Other (Income) Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2359312 - Disclosure - Segment Information (Tables)", "role": "http://www.westpharma.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i76ba4917f5bc454fadbb83d7da23e512_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Revenue - Revenue Recognition (Details)", "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "shortName": "Revenue - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i76ba4917f5bc454fadbb83d7da23e512_D20220701-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i97a3cb1b965a4889b3ac5827d8d45594_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Revenue - Contracts and Liabilities (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "shortName": "Revenue - Contracts and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i97a3cb1b965a4889b3ac5827d8d45594_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "shortName": "Revenue - Contracts and Liabilities, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Net Income Per Share (Details)", "role": "http://www.westpharma.com/role/NetIncomePerShareDetails", "shortName": "Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Inventories (Details)", "role": "http://www.westpharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417406 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Leases - Lease Weighted Average (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "shortName": "Leases - Lease Weighted Average (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Affiliated Companies (Details)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "shortName": "Affiliated Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i97a3cb1b965a4889b3ac5827d8d45594_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - Debt - Long-term Debt (Details)", "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails", "shortName": "Debt - Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426412 - Disclosure - Debt - Narrative (Details)", "role": "http://www.westpharma.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "idbab2b8815a94c67b0908a0ca00152fa_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i244e22c0c0124291821d71b4d0415415_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429413 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk and Commodity Price Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i244e22c0c0124291821d71b4d0415415_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430414 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433415 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434416 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails", "shortName": "Fair Value Measurement - Other Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i40e7717167004952ae80c80bb28cd309_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437417 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438418 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifeb0f67922234b57809219c06002a0f4_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i97a3cb1b965a4889b3ac5827d8d45594_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441419 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "shortName": "Shareholder's Equity - Change in Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i0912d0a2b5d1427eac18596b7479fe4d_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442420 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails", "shortName": "Shareholder's Equity - Supplemental Equity Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i0912d0a2b5d1427eac18596b7479fe4d_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444421 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ia6920f3cf3ec4468997131e42538a18a_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447422 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails", "shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448423 - Disclosure - Benefit Plans - Narrative (Details)", "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "shortName": "Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i19980603ce3f44faa094dc3b6f7b21d2_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451424 - Disclosure - Other (Income) Expense - Other Expense (Income) (Details)", "role": "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails", "shortName": "Other (Income) Expense - Other Expense (Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ib80bea4b755740f789dfc928894eab13_D20200701-20200731", "decimals": null, "first": true, "lang": "en-US", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452425 - Disclosure - Other (Income) Expense - Narrative (Details)", "role": "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "shortName": "Other (Income) Expense - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ib80bea4b755740f789dfc928894eab13_D20200701-20200731", "decimals": null, "first": true, "lang": "en-US", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453426 - Disclosure - Other (Income) Expense - Restructuring and Related Charges (Details)", "role": "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails", "shortName": "Other (Income) Expense - Restructuring and Related Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "idc395c91451f4939b9ac7ddb26a62a46_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i3bdee4d52d084cebbf52ed7e9c8af604_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454427 - Disclosure - Other (Income) Expense - Other Items (Details)", "role": "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails", "shortName": "Other (Income) Expense - Other Items (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i3bdee4d52d084cebbf52ed7e9c8af604_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456428 - Disclosure - Income Taxes (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "ifda4cc172ef0464a9f1139cc0299f3fc_D20220701-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460429 - Disclosure - Segment Information (Details)", "role": "http://www.westpharma.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - New Accounting Standards", "role": "http://www.westpharma.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20220930.htm", "contextRef": "i4c6190efe3b0472e944f6e2b87739801_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 80, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. plans" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Japan, Yen", "terseLabel": "Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Singapore, Dollars", "terseLabel": "SGD" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r115", "r166", "r178", "r179", "r180", "r181", "r182", "r184", "r188", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r262", "r264", "r266", "r267" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r115", "r166", "r178", "r179", "r180", "r181", "r182", "r184", "r188", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r262", "r264", "r266", "r267" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r195", "r347", "r353", "r688" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r248", "r249", "r250", "r251", "r272", "r309", "r446", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r685", "r689", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r248", "r249", "r250", "r251", "r272", "r309", "r446", "r451", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r685", "r689", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r195", "r347", "r353", "r688" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r191", "r249", "r250", "r347", "r351", "r643", "r684", "r686" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r191", "r249", "r250", "r347", "r351", "r643", "r684", "r686" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r233", "r248", "r249", "r250", "r251", "r272", "r309", "r387", "r446", "r451", "r479", "r480", "r481", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r685", "r689", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r233", "r248", "r249", "r250", "r251", "r272", "r309", "r387", "r446", "r451", "r479", "r480", "r481", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r685", "r689", "r712", "r713" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r192", "r193", "r347", "r352", "r687", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r192", "r193", "r347", "r352", "r687", "r700", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "verboseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r197", "r198" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r16", "r650", "r667" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r57", "r63", "r71", "r72", "r73", "r527" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans:" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r229" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r63", "r71", "r72", "r73", "r74", "r526" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "(Losses) gains on derivatives", "verboseLabel": "Gains (losses) on derivatives:" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r54", "r55", "r56", "r63", "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Change in equity affiliate investment AOCI" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r25", "r60", "r62", "r63", "r669", "r694", "r697" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r71", "r72", "r594", "r595", "r596", "r597", "r598", "r600" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r63", "r71", "r72", "r73", "r117", "r118", "r119", "r527", "r624", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r51", "r63", "r71", "r72", "r73", "r527", "r595", "r596", "r597", "r598", "r600" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r117", "r118", "r119", "r489", "r490", "r491", "r572" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r102", "r226" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r102", "r224", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of acquisition-related intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r111", "r174", "r180", "r186", "r205", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r524", "r528", "r585", "r629", "r631", "r649", "r666" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r37", "r111", "r205", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r524", "r528", "r585", "r629", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r579" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r101", "r521" ], "calculation": { "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": 3.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r518", "r519", "r520" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r9", "r104" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r104", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, including cash equivalents at end of period", "periodStartLabel": "Cash, including cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r99", "r593" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges:" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r566" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 2.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r566" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 1.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Derivative (gain) loss on hedged item, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r654", "r673" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r245", "r246", "r247", "r252", "r702" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option contract in which the underlying asset is a commodity.", "label": "Commodity Option [Member]", "terseLabel": "Commodity call options" } } }, "localname": "CommodityOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r117", "r118", "r572" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3\u00a0million and 75.3 million, respectively; shares outstanding: 74.0\u00a0million and 74.2 million, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r80", "r658", "r679" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r79", "r89", "r657", "r678" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r159", "r160", "r195", "r583", "r584", "r701" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r159", "r160", "r195", "r583", "r584", "r698", "r701" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r159", "r160", "r195", "r583", "r584", "r698", "r701" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r159", "r160", "r195", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of net sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r159", "r160", "r195", "r583", "r584", "r701" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r334", "r336", "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract assets, September\u00a030, 2022", "periodStartLabel": "Contract assets, December 31, 2021" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r334", "r335", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "negatedPeriodEndLabel": "Deferred income, September\u00a030, 2022", "negatedPeriodStartLabel": "Deferred income, December 31, 2021", "terseLabel": "Deferred income" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Change in deferred income - decrease (increase)" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r334", "r335", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred income, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r334", "r335", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred income, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in the deferred income balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate and Unallocated" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r83", "r643" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedTerseLabel": "Cost of goods and services sold", "verboseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r388", "r556" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r156", "r195" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Long-term debt, current", "verboseLabel": "Notes payable and other current debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r107", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r293", "r294", "r296", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r18", "r297", "r651", "r664" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44", "r270" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r110", "r115", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r295", "r299", "r300", "r301", "r302", "r324", "r327", "r328", "r329", "r602", "r603", "r605", "r606", "r663" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "verboseLabel": "Deferred compensation benefits" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r14" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r495", "r496" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r102", "r112", "r502", "r510", "r511", "r512" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "negatedTerseLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r495", "r496" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r371" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Recognized actuarial losses (gains)", "terseLabel": "Actuarial gains (losses)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r364", "r404", "r431", "r436", "r437" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "negatedTerseLabel": "Prior service credit", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r362", "r363", "r386", "r436", "r648", "r665" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r380", "r388", "r390", "r434", "r436", "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Contributions by employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r364", "r402", "r429", "r436", "r437" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r364", "r369", "r401", "r428", "r436", "r437" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r399", "r426", "r436", "r437" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanOtherCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of defined benefit plan cost (credit), classified as other.", "label": "Defined Benefit Plan, Other Cost (Credit)", "negatedTerseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r365", "r406", "r433" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Settlements", "negatedTerseLabel": "Settlements", "terseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r367", "r400", "r427", "r436", "r437" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r420", "r421", "r424", "r425", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r102", "r227" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average strike price on the group of price risk option contracts such as put options or call options.", "label": "Derivative, Average Price Risk Option Strike Price", "terseLabel": "Derivative, average price risk option strike price" } } }, "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r547", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "negatedTerseLabel": "Derivative, forward point components, (gain) loss, recognized in earnings" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r50", "r540", "r542", "r550", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r569", "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r538", "r540", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r538", "r540", "r550", "r558", "r559", "r562", "r568" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r548", "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net", "verboseLabel": "Derivative instruments not designated as hedging instruments, (loss) gain, net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nominal volume used to calculate payments on a derivative instrument.", "label": "Derivative, Nonmonetary Notional Amount, Volume", "terseLabel": "Derivative, nonmonetary notional amount, volume" } } }, "localname": "DerivativeNonmonetaryNotionalAmountVolume", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "volumeItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r532", "r534" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r531", "r533", "r534", "r538", "r539", "r543", "r550", "r560", "r561", "r568", "r569" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative contract term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r347", "r351", "r352", "r353", "r354", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r456", "r457", "r484", "r485", "r486", "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, inside the reporting entity's home country.", "label": "Domestic Line of Credit [Member]", "terseLabel": "Domestic Line of Credit" } } }, "localname": "DomesticLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r441", "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan [Member]" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r626", "r627", "r675" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Amount receivable from affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrentAndNoncurrent": { "auth_ref": [ "r626", "r628", "r653", "r674", "r699" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due to Affiliate", "terseLabel": "Amount due and payable to affiliates" } } }, "localname": "DueToAffiliateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East, Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r81", "r126", "r127", "r128", "r129", "r130", "r137", "r139", "r144", "r145", "r146", "r150", "r151", "r573", "r574", "r659", "r680" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r81", "r126", "r127", "r128", "r129", "r130", "r139", "r144", "r145", "r146", "r150", "r151", "r573", "r574", "r659", "r680" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r147", "r148", "r149", "r152" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r593" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOnFutureEarningsAmount": { "auth_ref": [ "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on earnings.", "label": "Effect on Future Earnings, Amount", "terseLabel": "Effect on future earnings, amount" } } }, "localname": "EffectOnFutureEarningsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r71", "r72", "r73", "r117", "r118", "r119", "r123", "r131", "r133", "r153", "r207", "r323", "r330", "r489", "r490", "r491", "r503", "r504", "r572", "r594", "r595", "r596", "r597", "r598", "r600", "r624", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r10", "r175", "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying amount, equity-method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Affiliated Companies" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r203", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net gain on sale of cost investments" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r203", "r681" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Impairment charge from cost investments" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Carrying amount, investments not accounted for under the equity method" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r579", "r580", "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r299", "r300", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r436", "r580", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r388", "r390", "r395", "r436", "r580", "r632" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r284", "r299", "r300", "r388", "r390", "r395", "r436", "r580", "r633" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r284", "r299", "r300", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r436", "r580", "r634" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r284", "r299", "r300", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r436", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Other (income) expense" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r589", "r590", "r591", "r592" ], "calculation": { "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": 2.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange transaction (gains) losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r50", "r388", "r555" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country.", "label": "Foreign Line of Credit [Member]", "terseLabel": "Foreign Line of Credit" } } }, "localname": "ForeignLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r441", "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International plans" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "auth_ref": [ "r547", "r567" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 3.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "negatedTerseLabel": "Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges" } } }, "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (loss) on derivative instruments, net, pretax" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r544" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "negatedTotalLabel": "Derivative (gain) loss recognized in income, fair value hedges" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r102" ], "calculation": { "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": 4.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedTerseLabel": "Fixed asset impairments and loss on sale of equipment" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedTerseLabel": "Corporate general costs" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r158", "r701" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r13", "r212", "r213", "r220", "r222", "r631", "r647" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r82", "r111", "r174", "r179", "r182", "r185", "r188", "r205", "r254", "r255", "r256", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r585" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r538", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r174", "r179", "r182", "r185", "r188" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r77", "r102", "r171", "r204", "r655", "r676" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net income of affiliated companies" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r231", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r499", "r500", "r501", "r508", "r513", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r132", "r133", "r172", "r497", "r509", "r514", "r682" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Tax benefit (expense)", "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r101" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other non-cash items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r140", "r141", "r142", "r146", "r455" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r223", "r225" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r168", "r601", "r604", "r660" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r166", "r178", "r179", "r180", "r181", "r182", "r184", "r188" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment sales elimination" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r29", "r210" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r35", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.westpharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r31", "r210" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r30", "r210" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r85", "r87" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedTerseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r15" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in affiliated companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r619", "r621" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating leases liabilities payments due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year one" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of fiscal year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r620" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed lease interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r111", "r181", "r205", "r254", "r255", "r256", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r525", "r528", "r529", "r585", "r629", "r630" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r111", "r205", "r585", "r631", "r652", "r671" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r43", "r111", "r205", "r254", "r255", "r256", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r525", "r528", "r529", "r585", "r629", "r630", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r579" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r18", "r651", "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit Facility, unused commitment level" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r39", "r110" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r283", "r298", "r299", "r300", "r651", "r668" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Less: current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "verboseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r253" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r100", "r103" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r65", "r68", "r73", "r78", "r103", "r111", "r122", "r126", "r127", "r128", "r129", "r132", "r133", "r143", "r174", "r179", "r182", "r185", "r188", "r205", "r254", "r255", "r256", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r574", "r585", "r656", "r677" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedges:" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r120", "r121", "r124", "r125", "r134", "r135", "r136", "r200", "r201", "r208", "r209", "r505", "r506", "r507", "r571", "r575", "r576", "r577", "r586", "r587", "r588", "r607", "r608", "r623", "r625", "r644", "r645", "r646", "r693", "r694", "r695", "r696", "r697" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.westpharma.com/role/SegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Interest expense (income) and other nonoperating expense (income), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r63", "r74" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r174", "r179", "r182", "r185", "r188" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.westpharma.com/role/SegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating profit", "totalLabel": "Operating profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r612", "r621" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r610" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r610" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r610" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r611", "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r609" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r618", "r621" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r617", "r621" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r178", "r179", "r180", "r181", "r182", "r188" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Options Held" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r36", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Commodity call options" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r58", "r60", "r522", "r526" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $14.6, $0.2, $15.5, and $0.4, respectively" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "auth_ref": [ "r522", "r523", "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "terseLabel": "Defined benefit pension and other postretirement plan adjustments, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r522", "r523", "r526" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, net of tax of $1.1, $0.1, $3.8 and $1.8, respectively" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "auth_ref": [ "r522", "r523", "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r54", "r55", "r60" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, $0.0 and $0.0, respectively" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r54", "r55", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "terseLabel": "Net loss on equity affiliate accumulated other comprehensive income, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r52", "r60", "r541", "r545", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "auth_ref": [ "r53", "r60", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "terseLabel": "Net (loss) gain on derivatives, tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r53", "r546" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Net (loss) gain on derivatives, net of tax of $0.0, $(0.4), $(0.8) and $(0.4), respectively" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r66", "r69", "r522", "r523", "r526" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss, net of tax", "totalLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liabilities" } } }, "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Employee-related Liabilities, Current", "terseLabel": "Accrued salaries, wages and benefits" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other (income) expense" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r359", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "Other (Income) Expense" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r42", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Changes in assets and liabilities" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other nonoperating expense (income)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": 5.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other items" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r361", "r362", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r414", "r417", "r421", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r442", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other retirement benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r235", "r236", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other charges" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Contingent consideration payments in excess of acquisition-date liability" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r90", "r92" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares purchased under share repurchase programs" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r98", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r96" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividend payments" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Shares repurchased for employee tax withholdings" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r387", "r389", "r395", "r413", "r415", "r416", "r417", "r418", "r419", "r436", "r438", "r439", "r440", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r16", "r362", "r363", "r386", "r436" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "verboseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r19", "r362", "r363", "r386", "r436" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r360", "r362", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r414", "r417", "r421", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension benefits" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Unit (PSUs)" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r307" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r93", "r488" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Employee stock purchase plan contributions" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r93", "r488" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock-based compensation awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r228" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r230", "r631", "r662", "r672" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r63", "r74" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified out from accumulated other comprehensive (loss) income" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r179", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r179", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Segment Information" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r95" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r494", "r642", "r714" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r235", "r238", "r242", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Restructuring and related cost, cumulative cost incurred" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r235", "r238", "r242", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r235", "r238", "r242", "r244" ], "calculation": { "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": 1.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "(Credits) Charges", "verboseLabel": "Restructuring and related charges" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r102", "r234", "r239", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedTerseLabel": "Restructuring and related charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r235", "r236", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r236", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance, September 30, 2022", "periodStartLabel": "Balance, December 31, 2021" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r330", "r631", "r670", "r693", "r697" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r117", "r118", "r119", "r123", "r131", "r133", "r207", "r489", "r490", "r491", "r503", "r504", "r572", "r690", "r692" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r417", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r441", "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r417", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r441", "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r360", "r361", "r362", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r414", "r417", "r421", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r360", "r361", "r362", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r414", "r417", "r421", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r165", "r166", "r178", "r183", "r184", "r191", "r192", "r195", "r346", "r347", "r643" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r350", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r76", "r111", "r165", "r166", "r178", "r183", "r184", "r191", "r192", "r195", "r205", "r254", "r255", "r256", "r259", "r260", "r261", "r263", "r265", "r267", "r268", "r585", "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r616", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r159", "r195" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r63", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r540", "r550", "r559" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r531", "r533", "r534", "r538", "r539", "r543", "r550", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Foreign Currency Contracts" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r32", "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r235", "r236", "r237", "r238", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r236", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r453", "r454", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r20", "r21", "r22", "r108", "r154", "r155", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r316", "r321", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r161", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r195", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r238", "r244", "r684" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r161", "r163", "r164", "r174", "r177", "r182", "r186", "r187", "r188", "r189", "r191", "r194", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r101" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "negatedTerseLabel": "Stock-based compensation expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Stock volatility (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (in hundredths)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Stock options, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskandCommodityPriceRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r613", "r621" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r161", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r195", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r232", "r238", "r244", "r684" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r71", "r72", "r73", "r117", "r118", "r119", "r123", "r131", "r133", "r153", "r207", "r323", "r330", "r489", "r490", "r491", "r503", "r504", "r572", "r594", "r595", "r596", "r597", "r598", "r600", "r624", "r690", "r691", "r692" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r323", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock -based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r330", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Stock repurchase program, shares authorized (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r111", "r199", "r205", "r585", "r631" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r109", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r330", "r333", "r570" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Forward treasury locks" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Stock repurchase program, average price per share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r48", "r331" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r22", "r323", "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Share purchased under share repurchase program (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r48", "r331", "r332" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost (1.3\u00a0million and 1.1 million shares, respectively)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r323", "r330", "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Shares purchased under share repurchase program", "terseLabel": "Stock purchase program, cost of shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r235", "r236", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Less: unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r614", "r621" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r138", "r146" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r137", "r146" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "wst_A2020RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Restructuring Plan [Member]", "label": "2020 Restructuring Plan [Member]", "terseLabel": "2020 Restructuring Plan" } } }, "localname": "A2020RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails", "http://www.westpharma.com/role/OtherIncomeExpenseRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_ApplicableMarginMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Applicable Margin", "label": "Applicable Margin [Member]", "terseLabel": "Applicable Margin" } } }, "localname": "ApplicableMarginMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_BiologicsCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biologics Customers [Member]", "label": "Biologics Customers [Member]", "terseLabel": "Biologics" } } }, "localname": "BiologicsCustomersMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "wst_ContractManufacturedCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract-Manufactured Customers [Member]", "label": "Contract-Manufactured Customers [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedCustomersMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractManufacturedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Manufactured Products [Member]", "label": "Contract Manufactured Products [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedProductsMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractWithCustomerAssetIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Increase (Decrease)", "label": "Contract With Customer, Asset, Increase (Decrease)", "terseLabel": "Change in contract assets - increase (decrease)" } } }, "localname": "ContractWithCustomerAssetIncreaseDecrease", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract With Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_ContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability [Roll Forward]", "label": "Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilityRollForward", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_CostInvestmentImpairment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cost Investment Impairment", "label": "Cost Investment Impairment", "negatedTerseLabel": "Cost investment activity" } } }, "localname": "CostInvestmentImpairment", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "wst_CreditAvailableForTheIssuanceOfLettersOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Credit Available For The Issuance Of Letters Of Credit", "label": "Credit Available For The Issuance Of Letters Of Credit", "terseLabel": "Amount available for issuance of letters of credit" } } }, "localname": "CreditAvailableForTheIssuanceOfLettersOfCredit", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wst_CreditFacilityIsAvailableForSwingLineLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Credit Facility Is Available For Swing-Line Loans", "label": "Credit Facility Is Available For Swing-Line Loans", "terseLabel": "Credit facility available for swing-line loans" } } }, "localname": "CreditFacilityIsAvailableForSwingLineLoans", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wst_DebtInstrumentApplicableMarginRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Applicable Margin Ratio", "label": "Debt Instrument, Applicable Margin Ratio", "terseLabel": "Applicable margin ratio" } } }, "localname": "DebtInstrumentApplicableMarginRatio", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "wst_DebtInstrumentIncreaseInFacilityPrecedingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Increase In Facility, Preceding Period", "label": "Debt Instrument, Increase In Facility, Preceding Period", "terseLabel": "Preceding period for increase in facility" } } }, "localname": "DebtInstrumentIncreaseInFacilityPrecedingPeriod", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "wst_DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition", "label": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition", "terseLabel": "Number of fiscal quarters following acquisition" } } }, "localname": "DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "wst_DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded", "label": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded", "terseLabel": "Number of instances ratio of debt to EBITDA exceeded" } } }, "localname": "DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "wst_DebtInstrumentRatioOfDebtToEBITDA": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Ratio Of Debt To EBITDA", "label": "Debt Instrument, Ratio Of Debt To EBITDA", "terseLabel": "Ratio of debt to EBITDA" } } }, "localname": "DebtInstrumentRatioOfDebtToEBITDA", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "wst_DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition", "label": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition", "terseLabel": "Ratio of debt to EBITDA after acquisition" } } }, "localname": "DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "wst_DeliveryDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delivery Devices [Member]", "label": "Delivery Devices [Member]", "terseLabel": "Standard Packaging" } } }, "localname": "DeliveryDevicesMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_DeliverySystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Delivery Systems [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "DeliverySystemsMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_DevelopmentandlicensingincomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Development and licensing income [Table]", "label": "Development and licensing income [Line Items]", "terseLabel": "Development and licensing income [Line Items]" } } }, "localname": "DevelopmentandlicensingincomeLineItems", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "stringItemType" }, "wst_DevelopmentandlicensingincomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development and licensing income [Table]", "label": "Development and licensing income [Table]", "terseLabel": "Development and licensing income [Table]" } } }, "localname": "DevelopmentandlicensingincomeTable", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseOtherItemsDetails" ], "xbrltype": "stringItemType" }, "wst_EffectiveIncomeTaxRateReconciliationRoyaltyAccelerationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Royalty Acceleration, Amount", "label": "Effective Income Tax Rate Reconciliation, Royalty Acceleration, Amount", "negatedTerseLabel": "Benefit from prepayment of future royalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRoyaltyAccelerationAmount", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "wst_EffectiveIncomeTaxRateReconciliationTerminationOfDefinedBenefitPlanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Termination Of Defined Benefit Plan, Amount", "label": "Effective Income Tax Rate Reconciliation, Termination Of Defined Benefit Plan, Amount", "negatedTerseLabel": "Benefit from termination of pension plan" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTerminationOfDefinedBenefitPlanAmount", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "wst_GenericsCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generics Customers [Member]", "label": "Generics Customers [Member]", "terseLabel": "Generics" } } }, "localname": "GenericsCustomersMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_HighValueComponentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High-Value Components [Member]", "label": "High-Value Components [Member]", "terseLabel": "High-Value Product Components" } } }, "localname": "HighValueComponentsMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility Additional Borrowing Capacity", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wst_NetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net sales member", "label": "Net Sales [Member]", "terseLabel": "Net sales" } } }, "localname": "NetSalesMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "wst_OtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Income (Expense)", "negatedTerseLabel": "Other (income) expense (Note 15)", "negatedTotalLabel": "Total other (income) expense" } } }, "localname": "OtherIncomeExpense", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/OtherIncomeExpenseOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "wst_PackagingSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Packaging Systems [Member]", "terseLabel": "Proprietary Products" } } }, "localname": "PackagingSystemsMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_PensionSettlementCharge": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits.", "label": "Pension Settlement Charge", "terseLabel": "Pension settlement charge" } } }, "localname": "PensionSettlementCharge", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "wst_PharmaCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharma Customers [Member]", "label": "Pharma Customers [Member]", "terseLabel": "Pharma" } } }, "localname": "PharmaCustomersMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases and Royalty Payments from Equity Method Investees", "label": "Purchases and Royalty Payments from Equity Method Investees", "terseLabel": "Purchases and royalty payments made to affiliates" } } }, "localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_PvsPayoutMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Maximum.", "label": "PVS Payout Maximum", "verboseLabel": "PSU payout, maximum (in hundredths)" } } }, "localname": "PvsPayoutMaximum", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_PvsPayoutMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Minimum.", "label": "PVS Payout Minimum", "verboseLabel": "PSU payout, minimum (in hundredths)" } } }, "localname": "PvsPayoutMinimum", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring and Related Activities, Period of Implementation", "label": "Restructuring and Related Activities, Period of Implementation", "terseLabel": "Restructuring and related activities, period of implementation" } } }, "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseNarrativeDetails" ], "xbrltype": "durationItemType" }, "wst_RevolvingCreditFacilityDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility, Due 2024", "label": "Revolving Credit Facility, Due 2024 [Member]", "terseLabel": "Revolving Credit Facility, Due 2024" } } }, "localname": "RevolvingCreditFacilityDue2024Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_Revolvingcreditfacilitydue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving credit facility, due 2024 [Member]", "label": "Revolving credit facility, due 2024 [Member]", "terseLabel": "Revolving credit facility, Due 2024" } } }, "localname": "Revolvingcreditfacilitydue2024Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_SalesToEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales to Equity Method Investees", "label": "Sales to Equity Method Investees", "terseLabel": "Sales to affiliates" } } }, "localname": "SalesToEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Income And Expense, By Component", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "terseLabel": "Schedule of Other Expense (Income)" } } }, "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/OtherIncomeExpenseTables" ], "xbrltype": "textBlockItemType" }, "wst_SeniorBNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior B Notes Due 2024 [Member]", "label": "Senior B Notes Due 2024 [Member]", "terseLabel": "Series B notes, due July 5, 2024 (3.82%)" } } }, "localname": "SeniorBNotesDue2024Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorCNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior C Notes Due 2027 [Member]", "label": "Senior C Notes Due 2027 [Member]", "terseLabel": "Series C notes, due July 5, 2027 (4.02%)" } } }, "localname": "SeniorCNotesDue2027Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior A Notes Due 2022 [Member]", "label": "Senior A Notes Due 2022 [Member]", "terseLabel": "Series A notes, due July 5, 2022 (3.67%)" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SmartDoseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SmartDose [Member]", "label": "SmartDose [Member]", "terseLabel": "SmartDose" } } }, "localname": "SmartDoseMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_StandardPackagingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Packaging [Member]", "label": "Standard Packaging [Member]", "terseLabel": "High-Value Product Delivery Devices" } } }, "localname": "StandardPackagingMember", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_TermLoanDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Due 2024", "label": "Term Loan Due 2024 [Member]", "terseLabel": "Term Loan, due December 31, 2024 (4.53%)" } } }, "localname": "TermLoanDue2024Member", "nsuri": "http://www.westpharma.com/20220930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r578": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r622": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r715": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r716": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r717": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r718": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r719": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r720": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" } }, "version": "2.1" } ZIP 85 0000105770-22-000054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-22-000054-xbrl.zip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�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

C39..#)KGKPB%66 ()2 P)2,QI2@ M30M8;*ZY&QH&G',\4HR# $1_K66<%(D 6O M)D."R1@@YI@ E?%!6A^\/:[:]FD:=@/)@+.3C<4\#-"0Y.9A\GJ:\6W0T: \Y<'B_,OL^K+D.E5^-% M"I/_C6%^55J>=/!"B +.HJ#8B; =G99@=$J:E4A/GNT\L7],FG]V]>OSC[_/+%I\_T\>W+=Y\_ MO7_U^MWS]V]?_O7=V5]?O*8?W>9HMTO<^R[1ZJ[W4:P=>27\8@'G(7P;U0+^ MK[BJH:O(N<9@=DFH)!PXS>J-'XI%0J$M!1-F[Z(P*3_FQ9>PB"NHK->Y?/]P MLEQ?F17R"E$/-R=5C/^)WG%[@*WKAGL^FJT?^?;S\\OQBL:3EYB]_I,E% MC;S.%@ND_^7/X<>HOAR6Z0S2,4/<1P7D;"M(!HT1OEZ*"XVY/X#,?BZHMT3. ME?4ZE:YZW-VN6'P^6RS?E[_,9GEQ-LV?LMJUK@J!RP8FV,+NFB6L-F8_E^KL-WB9-#97NX<9DMPZ0) M+#Z2](F +X3O%V1*)[-O52HO?WS#Z0)'.FN*"'F$X KYE4G5FU;)0G+TWQ!5 MEOJQ[BF'[6J/$-3/M?EN]Z]6\A_ 3O4))Y-ZL(53G(<)L726OXZGJVO!M3SB MBBOF>3$42(*K=?7*H (O9:VUDR(7&U-YM#3]$%3M1ED_]_&[A%<'&ND19Q2( MC=XOO^#\4E17U&-*BK.L0(9@:_,S>DN8Y2!49LH[3_'OG>WL7D2W__WOVEWJ=X7COA?6YF9MY_PPK?Z?DE,V]FM;R"K*'BL28K*B?9:G#( M#1C!90RU2YYH'7]M(:.?*_I=&I!C93T %V=5H(>+ZTW5")&E20RXJCT&A//@ M.0K [(QU00N>6&.HW"&AG^OY7<+D&!D/P'%Y/?U.Q%=I7 KG'2Y'VI>0E"!G M"QVA/%1'GMPQ^DQ$RZSTSCUV"'D83.Z1T<]E_6ZA933'TPMB:[T-SZ:+9UAF<[S\O<_A!R[>CJ>S^54=.KU9Y.3??LK+ M_[J@'[_%Y9=9OGGY%J,D- ^J. HNZTM'.S=$Q378%%7)QK%B6[M,)V2OIY8% MW5K.88)C$#[>FN7UF_^, MZ:C2M>2Q5" IX#!;;*2'#,DZL:2,Y2H2>OI!., MWR.EIQX)W>/Q.*$/(C>^VRNA8D:MC( 4!8G*3O;L32V2EILD!@])_:GJA> $@((3,1,4 ZA8! M/;5OZ!(\APMX !O9RS"?TI:^^(#S5:7WM400C932)\BN@AVCK4V*B \OT(ML M?'ST@O=I>39V$Q3B/G,=CH%5@C:4N.A4-M[P]8 MLDA>N:!CZUAT*R']%J"TT?(3T-E?X -(@-UEXL5XL52U+EDB=S'CG&S)J7?ZI*3(.<0H0\ .W_'.K\(\QF9L7"^[J+TOMR[ MJ+1F[\5XD2:SQ07%J63 %]>2Y)I3=. ,<,T$J&(41*LU"%-L5)9SK5NG(]I0 MWE,GG"ZWPQY4.HC-^+VV\X%P&%QT45JOD/! M_6ZV?6#H0!COK\XAHW4MT/L712GLD>ERKV*1]A6OP4O-@#GT+#H*D^QC5V4: MXO4A$OO=Y(>+V"8J_86O;#Q___;#QY?_3K_S^F\O3W!_X]'U3G698W>F&]WL MN/8AWI=+I^)LFFMG@CE^P>EB_'U]L' -])!$*J58*%D9 A_S$"L6,;*D5"D^ M-3] VI/$MKDZ7X(W*&3=%ACQ*S@XJ3WH[ RBMI$WKP@X(%?7E77L$AV/I_#V MD?L XJ'5F?06R51>B+'WY7/X<7G9DKX_Q[# %WCY[[7LDO&(S&6P*&*=GJ2K M[ 1$D0MY]=$6UOHNU?%4][MYGQ*>)];P@#']:C8GCV5ZV78@_5R-@ZN]\$CG MT[SZ:G*)@/R?%Y?'-M?RJ0T5Z0?+Y7P<+Y8A3O#S[,-*U2-&[@M%IQE4JAV8 M7:87?O6E\ %%R9G;UH;VI SV:\A/C=X=7Y[^H33@]^P%EO$4\_J$_<.$I+&? M'#1&24HI8%:!@JAS&;$$D-(IZW7.,K4^9^R*EW[WF8&^/2<%R"!*Y1Y3Q-GW M,)Y4]LBH? H37/=Y'N,6H8RD\ )-(?>2U?$OJO9;,Y9!,8QS4^-U\UA?F=;. MUCZT]WN54?E^0>+^OK[:56^^X\H'GDTOJZUOZZ 023?2J#>< MJS"<*%'4*AHE4=.&J1RX6LM%C,B0?8X>'VOXVOIM.)JA?J^,#O@5.2U4!O[> M[+)#%AF*MDR#*%B'&Z< D79-2"S%))7.C_'T>H-#'@++.@-S5M*+ZABX%!!$<#ZD&+27CTT%.JQ-R(/D].NTG#)/U$HG MS> UK).;RQ?M"R['*4Q.?8QS>_$AG.D\(HZ>#G@DTXK7]D@J1U';41?PH3A( M07)5/)(%;NT+GOB 9Y]DU-WTTU,!M=>.940(00103 ;PVIO:F*]H5V?+N5.% ME<=S\VL=/>V#VV/2DQTB8L#^\I94TQ.,9RFBE]Y!D8H1X]E 3'7 HHCD7#DA M=6I=1=J,^%_K5*L+Y'>K[P$#_?%$4G7B3)0A,0H*@C8D[F1KC26:.G4^*\Y] MB>F4(>&CQ/Y:;G<70&ZKSX$#=Y_TSDUFIPHA9S1:9 2CRR1^NY MB=:(UOU1.F&DW\S?4 !_&AS\8K6%S\[>G+U[_O+3O[]\^?E3\TK"!Y[>98RY M"T/M@\A7XVF8IG&8?)@MQJL7ZSIK0KB)5BBP/A.DN1803>3TI49C"N-2M[8A MN]!UK,&M7827-Y6^V3)I6>80577HO97@2QV@X$I2(F9ZI5N7:=VF8#!A61LD MW+5K1XA[ +OS)?7KB2S73$2;$FJRI4S6^3RI6E6=(RCG@_=87&F^NVXEI%_H M'*/9K2 Y1LP#P,KSL*@M8.L_M=O!=_),ZSG;\GF8SW^.I^=_"Y,+'%GCCGH?+JVG%.CB)F6L@P=1&PZ6 TX)#SII"=B:X$:TS-(_1TV_2I3V@FLE^ M #BJ'5BF]"L_:^,^92ADX89 O[KF+J6B&"%H8-9DK26S7+4^6=Q0'L?A=(^8W,/^3X5_28"VJ/D M2#D/P(;<)CZ'0FY>29"TS* T;:3.J@C"\.!P#6E20M:M5_*% '8U=,[0Q29V5 MQM98>9RB(;@J3>*HAH(?@H5)Z>+KQ:16F[] (B*-5SJASR>XOE-R]K4>8?WW MZOL/,C_R,B$F'T!ZK"*-DKPS*4#&(CB]B]J&YCF>1K0/P3MJ$^+WHH;@9'5K!_<5^@ VT^OI M#6_J^<['VEOB??GK E?B&J%(U@FB/JCL:P+#0TB>G$:AD!E7&#>M^]<\2M 0 M_+ F$&HG]@$8H8V.JZ^G9Z6,)V1]1SF]4[-8C%+J^_2^_(?L_%T M^3?Z]0M2X$AE2^)2&FK77V*6@EC'@P'OB.=(__'-K=11!/<[\JT4_<8*"H,9PNUJ[W]D_#9%SD# ' M (+7).[I^3A.+NULO>1Q/?[UFB>++ MG+>B"Q%,M;_")DT,8-.?>:*53ZQY8 MN]#5[T2@IF:GL1(& *P7ZV6O^]U?LS92):OL& >M:XZVU!QM;?.J2$J)V43> M8NO3W(>IZ7=64$,0-1+X,*!SIW;VDI57LWG]8OW]Q;O9-*W3=4*Y@L62=TCO M""A>/$2+""Z6B$)*Q60'B-J/R)X'";5%6H?Z&0 -\X*-IB0 GW6A@%G@@QP MHE@VU-X/2K+BF J&N.GN6&9?(/T*52C'RWD 8+FD?^24-E()74'-Y_->KMSSC)SF14E[27( Z:(WXQ I3ERUR9CF3\M9^L>7V82D MOK@^'("HG<*4K$I=40=*XAHN=@K$0NLS4\M*XQ>9B:?DO=NM'^PQ [1A4# M -4+C-=55J&@\WR8 M> =1K'15DO%=\,"Y4RL:1%%R-*G4&QTD>+)9@;)2L5J?.*Z^?]O?E')?C^6KCWW);=LWFADQ'.?%DDZ/ 0%+L M2!YBK&= 6)!SZQ@3NO4^O#V:*K[K2?H")(G5N8@;-^*TY=?OTUF/Q$_XJJP MXKYX1SPF^I^O:39#'[@OX+6AZ!6#"*EX*4HGU_:?I*S?6H..@-B!4@9@*\GB MSR\V,KDWC B1Z[5J!)2!/ :-#*+-$JSC ;VQ2.%W^YUV.S']5AYTM]DV$/T M,'2[G.)*6C^ON3%.\50D!"U#Y2:!C_0A12>1)><8MKX5]3A%_=80=&6>VBEA M")"JQG:+=96RI%QG0(G:F$=930RE>L7+9D;2\=+&UG[9 Z3T6T[0Y1YWI-@' M@)XM' 0*48*P$BCR5>0#)D,<:(3HHH[.!XRF]?,,5*P&"C,39ZX(+P'$3U(Y3Q&C#+EYDGTK90,)M7084[S M>!4,P.[3VYL5222O%28(B%'('>>80,&=(SEH6B\JZ^7;8A/#!9!:Z MP^OI%3P 5#\0O6PPA,HG1$6>A,)ZS5(S"F"8!"V,XCH5%T/K0O4GB1I,6J([ M-+95S "0=K4=U"YK]*:M6WQ=1[4=QP\O[;[7E.LF@3!45HBH-2R8)7VH(0TCM/ MKZ"*GY*.I?-_)+, BVC>-9Z,J9: M$MZY#1"-L4$*IW-LG3K;0D:_98+':/5>$X7C1#P E%03.9MNT&]S,*%>]=$Z MN%I^X<$%)\'YS(D#M-RVMBQW:>@W4]\0'T<)=P#@.,MY5=,?)A_".+^>/@_? MQN0HC4Q(B> <(9E:"L9,I) P*V"1T&U902%:.\ /D-)OYKTA5%J(>@"(^8C+ M4%.K+\-\2K[6XE9/HS).X^4(G6*)$^B]J*=1#!E)B25P.2038\X6>6/P/$U5 MOQGQACAJK(!!)'0V>-AEW.4H(E/!:0N,%5//.SWX0DZ^Y-;$$) SW;S3XGXD M]IOR;FFV.E3- ,S9YSHQY&+^F'0(2=9)F4HSJ&^#E2P/M#Q%]"9(KG%;.?FR'E?@@ZDHE[6ZR$&&IS4V0>@A82 MDA6N**-=\:VK[.Y3T6^2N2%2CA3P %*#3^4L1BIKSZ6N)3H\@_*J0$")@-'4 MEFE9,FS=K^ IFGIN77#J;//Q>OG%AAAOGZC4RO M%XL+XB1*U,P'LO]<*U#:"_!>(&14-KM0+.T*)P#6)36_0*^.UJ Z0 T#!=3[ MB^5B&::UL=\(?8J2AT(N@$N@'''BLE'D?I+7Z70*H?GXH"=(&LRTV]-!ZU"% M# !?&\BTTQ;U46- MP!-D#6;(;#%*03M)+&2B2E?164<3Y*EHD1I[6P^0DZ_ MN=!38NLH10P14^MM7DBMK"J6Y"');W2U@[(0JUC<9LVL],TOY#Q 2K]YT=-C MZ0 %#!%'FWNZ24Q+0U&'$K$V$PP"' H-Q&)!@47)TOJ&PF/T])L_/3VB#E7% M &!UZRSADIL1YL0XN@ :A0=E,-";(2W$J%,N(F4=6W=-V$)&OR6[G8/H6,$W MP\YIT 6^>)-,U,7*UCUT'J/G6#M5A^+2,S_, M9]_')+EG/_^ZJ/=JK^^(G:7E^/OE<<3UG$3)HT>I(2CE0#'GP)-I!L1 MM@$ M563K37%_*@>3/#T.07>M6\?J&L#&21S>E&J,5&0^<=20L';SUF2YR?9'L-9R M'Y3PNGET>(N ?F'4M;;O@^M T0\ -V?Y/R_6PY<^SSYBFI%KL9KY?-*NTD^.;@ZTE339*AUJPUEGG><#53, 6-T(\]5L MOCG^=922X5BL .N%!15-K8-*"@0/+H8<@I2M+]0_2$S/XZ&'!K@V2AL ^E;! M_+.PN-TO8"211U#6*'!:17#.6&5JME&VKMO83DG/LY^'AKL&ZNH1 M='\LEE=M>S[A;U&DSV"$$756\O<%:*3?*;W^YYLD6(HR!='0V+(+58 M=>H7Y!6G!-$'Z3%;@^VOR1Y#<,\CI8>"W],K?SCW#TC6-0N/+_#R7Y)NO8]S MS>#Z/F%MU>=#]*YDI.U TW; 70;G!0/B3 J>T&3?.IVZ.W4]3Z8>&I0[4NNQ MN&W7IZEV!")Y7LKWY8_JM."()70VJP0NY$R;3:K-IVHUOV4<62X8<^OQQ0\2 MT_/ ZZ$!LHW2AF,W=\^4C:(I(67&H5@O:6-0'IRL5TY06%>DTB&VCGIVIZ[? M2.CT6?,NE#: .V(/D?N6_V5D?'H M4^U2K]+E)%D&3J0(+ F28:RW2YI?NMB9ND&>*C;#R?8 J+72!N$U7O%69Y?/ M9PDQ+UZ1O%=^R19YCACCS*I"+@[Y'^OF]TE9\#:&.IDXT"<=H7)'$@=Y5-@U M-+M0WR#PN;L\1[RHK*)4X&J_,,6+!I*>!^.RYR1?A\V;^.U.W2 =RJY0V9'2 MANM0K@M!MPI2,Q94RC7C51()$B-$E1GXH+&$@#Z6UA-;]J=R,#??3N)0ME+7 M !S*C_AMO06\+Y?MH3>&UHRL#%[1:P1Y-4;$QGH%64?(TB/3QB?I6^_6CQ(T M2+>Q&1KN]0YKI9I![,0?KIFI]->K,B0U?#Y;+!>CVNHW*+-QK8$DQ M4)@<2;1DT-*AB.01>]:Z[/9IJOJMFNAI1V^DI.'YD1]QU5#W\^QS^/'W\?)+ M[49(8B1^'RCPC-&C=HA0I^& ,N3).!$96-*ER1Q]X:T3B8?2VF\Y14]([52A MP\'O[M(=.64M5W664Q*R3LG0M"_8N.JKZ=$FKF1K'W5WZOJ]KG]BC':DM &D MOE^6@FGYOKS\03O$]!P_$MK?3RNS]?_U"/1[F%R^GB3'<:)WH?Z /)K;W]CX M37)[)A?UU7TQ7GR;+<+D+_/9Q3?Z"_HZK6I-+S"ORU#(X:_OL_KB6V MJ85+S8Q4R%K'VD.+US;-P5CPT7A0*B:62>&F^86XTW(XF$YI;5^L <-D +O8 M4=(9,9NRJXKC3O T81^G@Q*Q\V'ABF^=/%UZ]A_G-6/HW/I^,R3K6X,J79Q>K2 MV8?99+R:LWN+PYT:@AVU7*/.8.U8;M0B[/XR-_%OR"C)&H+B=4:TB!F",!RL M5,ZX('D0K2N6'J;FZ#OWCTGV,PGSV:2F. V/4:9L(91OI0B)Z$$ M.L^;3Q?:B;*>FX^T0_<._[AA\U/M!QKF^1!+]L"#&MFH M7HK70ZVU)SB" MUX%#D4[8HD+2NGUGM:/)/CXK?# )&R]6P&B%X&#J,;FR]!8'*3.($HMG@MG< M?*!'"[K[+A\\+6;OIY9/K/DAF]2/^!VG%WB #;WZRT9&8B)4!59G#;4^L-R1M./+ MFQ]=Y@;7VC GBQ' 3&W*PYB 6--0A&I-81/S6;6N"MR5MGZM5A<8NE_IW(&6 MAMO&^KI?P/4\ET,\N;O/:.;$/4I<(\MT-0_[:I%K&+EDN H2@3&;0-&.!DZ9 M1/L+-YFTSJ)L[90]1,O1!YYWGGL#XQ*%Q) -Z)0D*$.A3^0A@RFF1D0Q1MXZ MG?8@,?U:ER8XN'ZDVX*:'OL'S6YE\WLAH/$M3(7EP]_V<]BIW, M%A<;4%$N$49JUPK-R2>6@EQ2'FM>,Y>LLE:E>?'*(^0BY[B/%8 M_V$CN[&-C$8FX_+1-^E&7Z3(%*D&G:KKF 30'D,;2F2>6=I;BFN=H+U-P='S MRG&Q0+QNJG/Y\!M@)B]%0NNAJ)KK5(5#,+GNG]QR9GP]9&_.WV,4]6LYEEL>THC2_$D@:TBD]60^;>X_%+K6&K# M@:L,V7_,QM/EW^B+B_D&LC(6C:QX(#$@;3>6D%7[')0HM3;.E&1Y:U]^/Q*/ MCF.V+[=M=PRE&":M@X*UA"<*!\'&""A4=-EJ[>*)A#$X;Z5+7-T+@+K1V'"M MUZHWP/[FZJ:EP/'VZ3X)C0Q2?? 6#U?&2 %KYL ][3TJ(6T[(FM@.1A%X:T/ MIG4IV79*CI_4L?G4&V1R%Y1#GVM]2IT,P52MDUB908/,A2//K"9"=F=[&;&Y6K) MC95H3_IWS.>W;IML02#ASF6F&4@7+"'0!8@!:?_0.>6@N'&I=9G/$>0>;Z;V M7GICE^5!:PH20/A/ZW,+G MZLALGBHQ=S^G$:&<@-*D\X) M<;'H5.<(H4^F7EYH?6;\&#W'6KAMS[X!.$4&V5CAP:&LA1_:@JN!0A36*..S M,TF?@-F!V*AFN+AKA-HI8 MGGQFJTS4?L0WS4O=8,PZ[T1*D)2)Y*H+!<$E"UG'6%BBC\U'$-^FX.@+*9M2 MNZPX>#=;;NRHVCD??,S@HZ, QV9'84GBP(2G+57RXEEK#I^B:0@9I(,0<.\B M24OA#S8J\;BR'$(9'X05P31\4EPP<\P:" MS9J50FIO7NG6UG*L>LK<$EO%[E:GO-[)%K* B\2@RH%#Y,*!9#ISY0/7MK4) MV9FX0=F2?3!Q[RY&)^H8L%&I_-YOI'. 8=G^H%;&90Z#V*XJ-3 M2;NN_FQS]9OW2!BI2V2"]GM=9_58 9ZG O3:6AYEP%1:6_ C2>XYH70Z?-[+ M*9U0U4,.^)[A%,MX>=FZ<7]3>>O/6]VH?9"D9KGU,IYBWESG;'H9,GX@O<]Q M.;Y,76W^QK9\@O$&=4J*PGP50"&SX%E44"S3:!5&ZUM7_;6B_>@>?)?S;Q]= M>VL^UOL@RC].49.1J]=/7WVU7F(;UEUVR!SY B8J56=^*P@2%:"U06EN MLVA>P;H7@?W:L8;8V3IDM1,U#=DD73+\.?PX\([)S5\WNV/R $'-[IBLG[_E M7#D*9[C4%J(K%I0/M,WQ.@&MF%"22HC-BY$>(:?!=/*[C]Y(_2KKC#,&C*AW M+)-S$'(.D(-%'7-4NK2^V_\8/7W?,6F#B2V#Q-MH8,@6I+8 'U^6GH9I?K[J MH'F.TP.[,#WVM$869F>"&UF(<6-C90S9Q!S3]+&G?I=# MZGO95__+K*373@K@L;9X-<&"]]E#M,8*#,BB:)U[[J[_Y4H![\N=!7Y>?KQY MY="C02,81&]JX37W0%X#O7?H%1/H"@;6F.?=*!ML_\M]4'+7"':@E $,*'BD M0=UV_E@@[]1$#5ZS#,KQ#"$DK,,CK0DF*>9:'XSM2V._LV0[@E^GBAINY<^Z M3=GG$"<'[:NW_[YM_\!M1)VXBZ#/P3:,:6=MXJIUHG# M$W41)!\SG)_/ZX NTM#[LBGSC;-(+377=0YW+9=5PE(,7?D7O,C"-9>F>5>O MG0C[-?H'[H.>+54VC?4S@-UPJ[06"UR>3?.;<8CCR7CY\PZ+C&$J.E+@XXT@ MH\X07#8.N!1,NAA1N-;]%PX@L]\]\12 [%IWP]TC[[6//'BW?.A)7?6Y[' ' M?;#+H?TA?,%Q-\7^ZN4(.5 MM)JB-KFH RYOPYX[53C7"GC1" KKG$0L!A(RGJTS/+O6:?P#21UHI\Q],'0O MF78"I0W75FTTK3S82MU_1ON.FAU:IL=Z* 9N+0J9 1-3M=FR@B@E!U%,TE@X M17&M^SMTV%?S!NK7BSR_F-+TP7!R$W44X&@WCLHKG5CK MZOI=:>N[%J(-5AXV0@TU,URKL^X?>*C!N?7G3;MP=FAF[G1CM J=JYG#.M(^76O3CI:?7RQAV$.I5YEDP#RA) Y>C %1^ HZ>? M4(!90B>,W2=E4-TW]]'W_>Z;QXMZ -'\MB:BUY'@V["\F-^/"*7R-6DJ@ M/ M8N-90PR"@Y>9D4!);AV@:6\R^XWFFR*M6Q4-=TNJ_> .WI V_KAA*\4.-Z,' M&NH)[;@L7$!Q6M>^X:O3BD+001&4M\G$UH%H-PT5;_RI:T%N1&Y!KNPNW[]/1]]^EH)#SLS!XI_"%;B\?:%!YA1W9X[$DZ M+79J>P[O;1>^BUNODA;B-@L]DI) MUSW7R56W+27!F1+!64.>@(S9^-9G'KO2UK=U.PW6'C.!S30W !?^";[^$L;3 MVOWK]71C_O>U>?F \U4A[C1MQC"2>UW;]XJL,ZA:!A%;#[MJ MSD2_[O] ,=XQ%H;K&VSMS'FP2_#8T[IL)=JA _!HXTBG,"OZ#Q1M:EVT]F00 M69VU6DP0+&=C3]%CL_T6?KW*ZA!\L7$*3J_F6O+Y_?0CIHOYG-[;57WC'>N,&W*P( ;ENZ#NX@#?CD%6B1/?(D,.G6IY&-VQ9> MORB/2O6R*.5:MIL=QI.1+$KR"*0A=T62MVRE!:>BT2+(VEF@,_MW$,F#:G&X M#WX>MG'=JVX @0Y9Z$E8+%;W:E8%E1?+G3B_P[6UV=!^DL"AB*"X(ZZ3C9!- MX,X$&8)N[A1]\5&>-@4^WS_+"43EF07-! MOJ TI.RL)'V)LA1R%-M?Y.IJG[W?F?9NR6V1)2I),;-+SL]ZFC46-"J4FBK MDQ03TKZG3+00 X'"RX NB,0$MKY7-)3VES>OSCN\6FO5,_:N@ZF=U-S4SAV9 MPF8;! 2+]+9F@S)%(VUJ/0QP1]+Z/@+I 8,/V[]V2ARN\;O?*O)@$_C@HSKK M:MFA.7RB/R$O(67C&1BG!6VP->=E" M<%<>52ZGPUJ>8W?2V)"UN('[K&L]^ MUIAC-KU?X5NR+:&6]/)42 JEWBNHO8%,]-9:1ZZ ,4^ YICU!]W!NYC >0V6\^H@-8GDIEP]TE[W?G.CP9\="C.FLDUN$N^6#+ M*,Y]0:\"P4RR6BNB2.T^0/&BD!-FN,/FMW(Z:B?V$=-LFL:3\?JV^G7%\8?Y MC%S#FC^NEY/7RR\^SY[/IHO99)QKRN[F14@&8]+*0> ID;N(IO;N8!"YY\:; MDH/L(+W:@/*!-B7;!V%;$JVG5NEP;=OZ@OWU/VEV/AW7Q[[ 91A/CNB<\O C MVS93V9'T$_=7R2XK F@$AO5N0U0:G.8(UAJ1''VEC $$!"2EAE=-JZ-)X M\8]G/Y_A-'WY&N;_./LQ7HQ*'1%"'B58CQH41TN",@&83:YVCTP4 #5&UU,T M]3XLJY'V[_=$::>*04+KBIL7LZ]A/!TA[=91H@>3;*'XFH8 +P^!8JQUB_?.UR^Q:\1YZ,BT24K"J10FV>; M2,ZA2J8.&:^7E3#QTKP(,K;0 H:(IHN:9' #F(%@2$Y,:A<_:<]EZQ-D3) T,4H>J_BZD&NIA +#Z,)_EB[1\ MB!LN4=BWAN>6=$Y&BE:H^IQBOK=\[H"54,M# !3?\'9^3Q\ M^S).#S$4G=56D2,8$M:7Q--+HC*"-MRF;)QTKO7>]R11.R%+_FK(:JN+'L&U MF"]';\-_SN97!GBQ\@XL\X9I+R"(&EP(K2&LFL!R4U3MC:[33A5N]/@-%-%7 M-PC:OG*_<&GN?#<0;\_@>!>^XOMRBX?U^\-E(:(CO36E5N!&KL#E;"$:QFP1 MAB>WTSRE)S#R( '].$(M-#IK+=X>,5(+>IZ-9Y/9^3@MKF6R-H+",\VL<5"< MK_@;=S:DK=53#SV_/P0T4MNLL0Q[QL%?<(KS+2PPGWEP M2H,0FG9:F1.Y\98$X[CS-FG4+NX @P<>WX_OV@T*6DBP9Q!\6)U@WV6@Q*2L M=A(PK.:MB P."=0F^DS2P1"TW $"6Q_>C\_0#0".EU[/ZK\Z!'X;IA>(,>2K:&>^>*,FP'(#SP^/X"D/8P:"'!GD'P B?C[SC_^0)7 KEBP,OH MF*(P6M?Z0Y:KL2P42SE&H96P+HBP P2V/KR_ *0] (Z7W@ #D"LQK;E1PGO/ MC 9O W&3-4(@0P;51T:7HHC*[X"%IU?J+_QH#XS&55FDX6KVCXA>!%)0-+2$A-642RO+7#&1(J _-[218F>M MI=PS5,Z^UB1NN#*+SAJ5G2 [6,=,*\4"^) ,Q)2=1JMUMBT.4V^OVB,HVJAP MUD2> ZC;>/GVY=E548!/Q"4%YB5@H0W2;6_9IY75]>K] MA2EM$7&D7/NV#8MQH."J=L!;$X\V>XJD-3@A(^VJY&5'5[NL<)N9S+6.N\7V M<6_A_J*6#BS$45(=@)%XP.]Z,Y[B:]IB%R.C0A U]F:KR\")%>),(63,LEB9 M7$FMV[$\1=-. #*_C*?:B2H& *U[%6H?<%Z_$0-PT/U/Q31?.'JF'P]^RO,@6+<*OA^M&7[9]X;ML; M]_LP<>)K]X9+9XRN\[4SUFE@M6\SLR!YUB5I3-*T;C_8\;7[S?S2K>?6OOT? M9Y/)J]G\CS#/(UL43\IP\-Z2?^"0=G7MR;B[4'B*QH2[HY ?S=P]MM:O<:U^ M'RQLR^8UD_8P-KKM/+W#Y<@)ISE'47NXTH=$3F%@JX:&(1IN@BW-V_4\1D\_ MZ.I&\_/GO*"D,W% 4PW.D M-X8)$A9R T$)H5+,*MA=*B=W7K"?M$"G .I.X ,YZ]QDZGI ]*;4A!?9RF@ MF:' )01/%K?0VZ&4C=PSGDHZ$$3;UNOW.F$?OM/14A^H_W3-UTA:@\8JLJVN M7A@7J3:<%AJ"-);)E!/]\ 3[W#5!P_*@CM?_#IO=8Z@%\B1,#N9/W5BF.VCC#8P.]:W MVHFOYU_"]!Q?3S^/OV*9AZ^X,?_T?9R,+_-_G^CCHHPQWVZ^^-^8ZP@DE4T( M]-+E" KI@\^N=HGBR*1+0ITDF&S&T+!\OM."_*1@^%5SM^_"?+X:*=Q5$O?> M B?)YC[.UHG3NCXJ^F]T(.IM3\6Y@E"L G1>>2D+6GWR MD>(AX&1+9409LH$(WFD)VQ MZ_%)E@707A@C$P57MD65[R]S@6P?G>YT@6P? ?=]:^@KA;8O9@N\Z@N5,#MA M1.W5J2\/*CR%.Q!+8B%&EEGK/-P3&H**@PD M*9!<>I; :YM!ZI(\LI *;^V*-2FVZJJ& "T'H]G[\6.',F-$ZX M2TJ"\CE#R*$ B30&SF20I?7(E/TH'*13JH0-QQ(@))P)M\(9> M5)6R!B^R!*]R$LA,D:6U@1M@EK5_F.VEB*&CZOG%O$I[)#/2>U(X6)5J<(H* M?""/TJ1@(PHI+;:>_;H+78-L+7@"C!VBEJ%#[=ULFM9LN<1 .5,YP<^/O5E4BL]71P"?ZV1%9\ +Z[6NDY/NN"+YJE 2:60VJ.A>+!$^A!2Y$HGKUJ[ MM0_1 WAFZZ!11.="B/9N*\:C(7D\U?UZ\IW@],2J' !X'W@S7XPG%_3=>R_H MB&4C<]8"=,*Z,V@/CKD TA#;/"?G?6ND[DEBO_[^*AYL$\+[[334"5Y/K] !6-)/RUGZQT?\=C%/7VAS M^#"O;16^WG9USBZ67V;SFLC^/'N&-[^<1\Z$X!6]HT9Y!&HU7GVBM.GL\6R[=(KTL> M:9,##XI#-ER3K(P"9T2 0F)C'+7VMK5QVX6NG9#E?EUDM5#'T"!VQ<[:%:Y< M70EPQ!/G)5HRO%CJV; JX((KP&-*EOR%4G1K#W!7VG:"FO]UH=9*+<,]?7@] M_4X/HKW_F!8J6Q[2Z,3A*?(:G35<+?/SQ7B1)C/2_PV8I(PEU)I%8^J=X.)) MXQ$UD NOM2:P'R3D^J[=^],?PQ]M \!J'R>(=+NL1W@+GWW$Q MTBP+IZV 4*2O=7L2HG""/E.17AU)P4KK\Y6GJ>KW;*(5/NXGYIIJ8P"[VC5' M?Y_-__%Z2M%&PL4=EA(K(M;A\K9>;%*&U9[_A1-?)F941<;NWJB'R>KW?*)S MA#72QY @]FH\'2^^8/[+;);OL)0=2]9Y#P69JKX@A\!X)-=0)\:Y%$SO-#[R M$(@]3%:_1PN=0ZR1/H8$L=K\)2(KP6D/%*IR4,D6B+4/?<@N2Q:B4QV<8MVL MWV_BOW/0["OA9HG]YJ[TF]K@9;'Z6 .%P]WI!Q[4R*7>AJ.".?I T"V! M4Q28E*CS*5R=G6F3U,SXW+I \#X5_3K'1VCYKE4X4L #V#D^?9G-EY]Q_O6& M@VR5L*HP\J>0S*2E73#F5( %QWW4F>>2&T/D/A7]>K<-(7*D@ < D;\%"O/B M!&\8D)B]\2D!VI1K*HF\(S06'%,D%JVQ??OM>T3TZYLV!,AQXAT /FX(US85 M:WV=/) KL*.&&"T#Q66*.B+RT,F&N3,>.G,[&^+A,''^&FYF6'QY-9G]$:;Y MT\4W3U:% H+41=.U:) M8(IV6EC9NDM=&P=VU0R))/DAC/.KV?RR$F7Q>GI9N?)Z^OD+OET=>ZS$^[ZL M5MUH97,M@>A=C'7HDLS,@9+,0Y#<@/"TTU*XIVW8:;A= UH&Y?3N@XQ;W1Y/ MK90![&^WG?QUL>EB)),VRI#TF,%JXT,>4"(14]HV3MFE_LVTY)C[T?3XZ& M1^.O@U0S (!]K&6E[\M?%[CJP?L^T@8QK3)\^2.M^K&1?&]S>G-EUC(CG)<" M:L-PJ!.((3K#R5=$SS573OO6'2*/(+?'_I%]0_542A[NT?V&EW2GDKJ)U_? M,]N[>+L0WXT_)[R6*+,#4_N.*A<2^, #A"A8T*7>5&W=7;_+A.0=07[$VH;G MZH0@R9+3F\;>);I!?0^&*[0V=*ZM^B^- [*K]L'(8]OIHV5 M,X!M]E'^ZG%1W18^AB6N9U&1,',R!CF@=Q1U1Q4H_BX1A"'&A',QR=:)T'UI M'%2:M#/P':N^);\-R?3EC5K;[ $>5NQVP2--=\W#VNME&)7>8T)/)0D_! M;Y097'8%&? >&21N*+"*4O+8^F#Z4%H' MM>EV#LMCE?4+@;*^<)__F(VB*9G>.P%U+D-M %LG/20-4LB84XB>D-03%M)7)0 M9ZTG0]_>ZOG%\/=J=C&OM=6N2%WG?I5ZVSM;"$EJ,)JGH*W7GK7.)^]+8[\W M]7M"W][*Z;F-^*.\U4O;-1E_5FBQ:^ZBI0&_I,Z0!,F*B\D,[) M.]RAA -[!'^?KK-*^/9#"__%%O:*Z;1=$;8Y,4M8D!1E R,G B"C 4,L7D MO,OBI%F\APC=+;/,?G7\-='3L;-,.SB\O2F-,3K)I'(BIS716\6(FV!-%6+6 M42)+J;2^FWU,;1/_%4XK6LCZ_Z0CU]$=1[2C0]<1[^_8]2Z+UP>OOQ\NZ+-2 M:)%J 6J;P3 ]Z@S[D8+%\N5IW VS?\Q&T^7 M?Z,O+N:;5TH,EYY\"!)+)*?!6@M.2P.EQ**UY3-YY$1J*$TR1?RY<;GVKZ %2>FXXWR%B[FX!+70Q@$CIDHV;WJ=U M0L?L8OD10QY/?M+KC?.OXVF]??7C=K674^-JWVQ:-<,=5:'* Y<'2R+ M.ME:=,N\:IT[.IC8GCO5GQR67>NSY]3YAW4STRK"C[.?87(31]:>O??EC;@8 M.<]L\1J!F*J]>5&!4]E#BL2A"P5)K#LDSP]9N^<&]"> WTFT,@!S^>("/\^N M_:#UJ"SB=V.&DIJKG7O,G-("- M-=3WK.$PP<7GV?9WIS#!3>V2( L+=9!JA*@YA\0%^B*28ORIH.&I-7KN^7XB MR]5,RL.P4-7:7K\!9&)E(DF$ ,A-':JF.'A9.W5AR:)XH4)H7;!PCXB>N["? MUOX<(?_A)H5>8%R^F4W/JP-9/S\\4?'0DQIE*78BM%&*8O7\^VW44N2H2]#D MQ21?\1/ YUPG[6C4G$64J74\OIV2HXT)/?7UE)YU45^8R_'=4HB<52Z ,<=Z MU;) P% [,UMZ,:(,:%K?ZMY"1L^#IH_7^SV[<:2H![#U;+YUG^EOSGZ,%Z. MY&6Q$,$D:2FLS +(("+()*0P);"BFY?+;:&C?[P8IUW,TK.8Q0F XI4;SEZ PZ=!E0EIYA#8;A+6F?KPX<%@4,T M-FLIOKYC89R.9_-W,_*I+WD0:QZLB4G[LIK J:".I0'GB1&=5'3TDVAYV@$" M#SV_Y\M,;5'01(B# ,*S#2:NT*RY+L)* 9AKR60@T<3:SI@S;T2A6 M%WAD) M6Q;H^5)1%U X5HR#P,+S#2;LFHG,D5ORR"'I5%$=*.Q6V@!W0EBEC"#_?&TI-QL>JF\6E9"U[6/37".8X"LQ@4V467 M';T0SB>(6=)&*;U,W%L=$#M%TF/4#2G,/1 ,CP*LF68&A[GG83[_.9Z>KT_C MBU1)8XG =-&@I"[@2\S@I6-)%O+:;>LRXH)EC4@R:U7V6=68NL688]3 MU*\;W06:&FI@ 'BJSN7GM7,YTI'9'%"0 ZBK6)2$P -"G8:8R?GSV;?.]V^N MWZ^;W056#I;N$.Z\;-#^_*J<@@<9E;!@T=6*1TO1(F8-6?F<+5+,V+SN=@L9 M_58J=(V30V0],$.R68#CLHE"U^&'Q=:[-0Y"H3U6"Y6BY<:%]AT\ME+2;UE" MUZ Y4.('X^8[SN.LERJ$@^Z?//RL;BL1NKA)LE(W^;!$Y_+<6MAY"\ )Y5YL9KE7QKH]--448U%._+.&;1)W@H5 RO-VSD\1$S_F8@C,7#/LC81^T V MY7M'RTQ[YI4KX!QYGRI9 ;&V*^:9G H?1,FVZV/W_LLT&JEXEV*-?>0]0,RL MCQN0(XL\4R"KLJ2XEF03.1,@2M2ZD'/A4]?%/8,MUMA+P[L5:^PC[I[/Y3[B M]]GD^WAZ?OMMNGW.B#*A9W6N7[U9KZQ#"#)P0*:\4_2;ZNX!G;JJH]# MX7"\^ ;@CMRV>ZOMUF 2TB$"*Y'5UANU\R,JP!(,(T.(T;=V8.]3T;/AZ,1] M/5+6@T/+^OU)+$:=/(*C]XBV1\W *6] U)L_MHYGX:UCY6UT].N7'*O;1Z%R M@* ' !:B&A?+<=I\F=9&DFP@BE2O=\AJI&1)P M#M'TW>/X-F(? (!>S>8X/I]N820*GIF*!G)MKJ BITV6Q0R%<<6R%9%X:XR? M!XGI=Z=J#I\V0A\ >M[@91]V^ M3>]].OKU@YMCYFA1#P N?POSPS:W+T.R MKUY#--* C<*CC%&*?"?!OS6MLOWIPU'^(?J:-17> &S$*R2!A\FKBVE>O"P% M4SVH__1'^%8EM&9)DB=5:D-<(KZ66)-7'C,3H+2(,:)/,K3>7G8@JU]GMA&0 MNE+# )"U:D>'^?UWG$_KV-)7XVF8IO'T?%7&/ROSZY^\GF;\<8?93/NSD'6$ MJ=8D3&09 KU1(*.S(GF52:J-,7<4P?WZ/XW1>#K5#0"GS\("-ZC7LJ2DA0/D MM3;7U3"CJ%HMPHNQR7IY=]S.T<"[34&_M<^-D72$<'N$QF*^''T,T_-+_U P M)12S"GC=QY6*A&<>)02D:%/98H/:Z28%/74##?35#1)N+=CS'=.FH=3ADAR" M^M>H):HS1ULG\2AB/' #(=2RVH"&9[0FVM(* 'TZR4(/EM\ MG+]MN]V;ZSL9*#19/.4I>(\.E(D:7)8<(@\R21T9:][5]U&">A[QV4VA;#,- M#!1.ZUMR/6KX7OM%/EC]'P:B,,B*(VFM4<6? :F^93 M\/:@;WA5V0?"8@? -=%1S\G7RZN)+FB%X S[+24&+U\XQ)M8%8HNV>Y&:L\GY!YR/9WED,4HM30&37,U) MB\ID-E"L2091%0IZ=@#5GLL.SU\_'E1=2GX 'OQM]IZ%Q7CQB6@)^?UT,S7. M1QF3E"90D)QYE9^Q$&2AP"<4;URTN>36!U2[TM9O@X/N//=.=#,H0W:WIN!C MU=K(\,22,PX8=V27BW7@4\X0F0R6ER"EV^7&W Y+[80<^^L@IPL)#PHP*_+? ME]4UH=G+9Z\_OS@;6>\95]8#2N9!,1' *VX@95MRY%X4M\NMJ"<7V@DL[E<& MR['2'114WEW4!.W[4K]3@XK%%N[J,&S,F$>>C*1A-41=[=I") C1:D#40JI8 ME-9N;PSM0\%.X/*_,K@ZT\<@4?=JO$AA\C\OPKRN\FHVF:QBC[/T7Q?CQ2HB M&06-THOLPT.\26"&(RAGR%/4**!()[/__\O[KB:WO&R$3/=< M;?1("DES;^P3 R:AYDZ)U))5FM;\^DW0E&55T>#PH+HC)GI*CDSS92(32,,4 MIR2XQ0EY_XOW@]@+NE,?7OP=I(2WQ4;IK/,ZB @IDJB45@9B]AF$"P*SLD&4 MYB-S;GW_?@AZ03?I)PNY,X!LI?():^T<.=6'UVPJAAAUB:!#;5_*68+7B8$5 M.;N$5A?1NJ/T, KW ]D+NF _@Z(Z@.&3PZVCX9PY;B%QFT!%*< 5JX ,RLF" M(00[[ *_(T:+\Q=TW]Y<"9T :CN#5J*7):M2%\/0?^K3DXN. Z?C&K,S/-CF M"ZX/G//+7]!-^JDB[@ =CPR=C3$D$06#J&K_4Y (WCD)DI62,RL\FX[&_/(7 M> W>0/#-X#/ K-_%],=J6NRFZ21]G^:+O\99OG- M_-NW>5Z]/TW3ZC=/&8C;FH9FTW0'%4ZS4;Q;*F\1]VJ6_Q/SU]4M _T1)8*X MW#6K-9F0)3HHCNO:VE_?<)(&$80E!-/Y:%H//3B!W-,/V.U7K^LHF;&I2"9 M9U=7"5-.[#6Y!IMUI%2(1[S?>-N0^RX&^)X'.0]/X>/U,'+U^CIX2.LQ3M+5 M'BHZ JRU= 1$9RF"B &RC,AE"%+&O8*T9XK7;W]G+X Y0G'S!E(<4?MI0_/D MU<7%AOYJ&>N>/9%$PN*P#IZE3(.E"#XR!YH+'I5"'9[L8EQB^I]?YS_^8_L= M:S1L?W6#AJ=H&*^=Y7AMSAN+M@=X?/[;VXG3)7&3"Q1>(BAA$!PS"9CR1NHL ME?)/M3 ># ?ZSG'4WTYS]Z%PJ!A[4/T_/K^=Z.)YDJK.=Z5<4NDB(%@3@;$< MM-*)"_;4_+6_?.4ZU]W"J/U2,/:C^?W_\/Q/M4/NH'##I#3$M,SC'"ECN MBN51%$Q/];(=K'KZSG%*LX=3_:%B[.!>9E<075.^U6FHB.#,*#:6A5E0M;/7 M:9$H2@I:QX@EF_8;<1^G9^P-DZ='C\VEWA6"WLQGJ^SJ]@CJPH3)?K7&D('R MLH +-D&.-G!!@L+<>O';4_3TDG^C!%\.QY,$JW?I1ZBIY>3K/V0&JC@@[@]&8Q7RZW M]P.W]XIO9;8=()S0%I(,>%%GK45.;CL0ER&ABTFES%CK.9E[DC;V&N6!0#:$ M8CK VX?O53/;Y3Q1)&.% 0RE3M1A%!#4IUZ>D'D151"N-:AN?__82Y4'0L[1 M(NX 'A_GZY+(5;R8N;8L$9;+:LTO)2%T*&>2A)5!ZEISA*TGS]W^_EXO4O!N,'Q\9I\!!)' MB+4#4-2*CXV#XU%;$VM-(G=U+P992%#.07!16B]]E+C7,,(#RVMZR)1.T>&. M$IHC!-H!%#[_/E]XB,DYV8$$3S ^/6UX^;[30$ MP[$B[0 -F\*(M[BD!"U<>TK&/6/:,6"*1*)J9A8$A4*$:9;(3UKF6E>8[Z:D MEY#S])BB@:2[Q,O&?K*P42JA0&I5=R"@@J!3+4JTCE(J:P*VKMI\C)9Q#YD6 M>GX6.D<(O0/P;!G _&JYX>GFUGOC/[W5A6JW^7+Y^N>&RT]XL9+A\O?I]Y5I M6E&8*;5],-1-<3Q0[!:-!\E3,"*%4'3K!6O'43KN-*"A'SL;:ZH#/.Y@8[N M#!D:[UGM6*W[PNJZS) <9&])D*A<3*TO\AXEII?7J^&0L/LX/5$M'>#KUS!= M_%>XN,(-1]L'.D.QAHT:J:[[]E MG2[S#I#S'B_?S7[@\K*:VUU.G-2!0HI$F6^A!-:I"-%I#ERRI-$(G43KH<*/ M4S/N%<$P"&HD^PY0=..[?[ON2XL8(]&=H"1/48$D&_!2)T!1I,>@F#+-MQT_ M)&/< 7;#1$K'R;@KF+R?KR>';KJ9-;H27:P#_@VE%X)R8F<2 ^>,RCDH57SK M.X/':.DE"#I2R8^"Y@2)=X6__.4G*21'(CGCPY(%E\1",X>!9Y$I'[GT<+CYZEKQ>GEM: ZZM7E[J M\(/U7MCEO.R\=)G//KQY%V;YE["HTXR60XT_.(Z*LPQ :""@'D8@L.!X$60M MJMZ-R9J<\E27J+$H6#+%B'.TZ)Q]!,*^%XBO?[Z;$2#P,T$(ZU__K7X)_>'K MGX^U8ZSSN!"T$C&+6E58*]^9AD#G$91B2W8%4?/V([#.Q5TO&="P>#_](>(L MZ.D@J'F$R]7MNU&:(C 9(+-"\9FFT,P;#("Z)$H%A"QBKWVF!QC"$^1TB-P. M$#0?1IW](G-S-1N3+HPQ"QKKUEFL6R@+$\ 8.A^X+C*U;NEYDJ!QT=E,[?O! MZ0@== "H37_2MGED:[S7"TD]SQ@5$%=F?;S$1+)"5X1"RXB?UJ?^DP1U":AC M%+^[2ZR!%D8>)_X>+S^'"]Q2GF14*5/**IVN0V %@A<6(5C):O6.344_DU ] M_-1Q;QW;@^!$N77@1-[,EY$QNM8G MT0,BQKU!',Y9G";M#N"R[5#\Y8_O.%MN5VBG)+@6-D))J"F!L0DB2@M">:\% MEB!RZQ>QG82,>P\X'&Q.EWH'T#FR9"HJ)XT)"DSF]8;3%HBF!* HSV?//3=R MN)OGYF6.9WA1ZSJ?.P,(.H#ZXQ4X%KFW3I*3#V$U24U#]+P6Y"C$(IU%/U"' MRI^D@O(@).Q=07F(6CK UR/5?,2[CW5& ).R@'*UI2_03U*KH KG43:O@7M9 M%90'J7F_"LI#9-X!^_7LS_=9<))H.1G(P*-0N4LP0'+F2VJI(06=E< M4NO95CL)Z;5N\A32LR'Y+R>",URLA!<=1%C%:+&OYX MD-8/&?YXB HZ@-.]X7'WIGEQ+#%F;<'RHD&A#1#0<\"(NNZW=3+DUI'Z4P3U M JA3]?[T!+\3E- !HKXL,"RO%C_)L?_SF@/T/I)LHJZ--P810HT$;'2Q!*_K M5,O&,'I(12_W7HVQ#H!06*SO+6 M0]OZGL?4=3;70(E=0G%CI,&CS+9>M+%41Z4E!AZ-@N!EW7?,!#:?E_*B1CT= MI.=]1ST=(O0.P/-^/LO7 X:V)5S1!BF3 O+MGN3B'7C) GGF%'+41F;3>MK@ M#C)Z@\PQ^KU_L7FBL#O RY.>_;?K;C!IM97.K88[UUUL/E,*08FGR9'D%[U M,]SND*#-8:!RI$ 3%:!S8D*XJD0#BW;M,ZDM1>+K7:H>9^ZG &%1Z. M5+]&Z@R_5K_^Y2R O?\X?TOD?%*,Y$D(A"A$W3E.C+LL-9 44*'S7OK6!_BQ MM/9RES8*9)LIL1_,;IG[E61-B?[W^6S5K_M'NKC*F.OOOEHN<;FL3'XH=^UT MW=5+RIC17WB/EQ/C94ET5@'/KCXB1X2 K/:4"_H=[SF7K;/IEO3W+]GS+C\A&G^=5;M_=ULVX@^T88Y4VP$N>)1U;D%=9.YD%'G8+B4S3N^ M#R*PXUNCMHAMKZZ3(3F_#!>-4[2M)5[;YI;]G=Q29EN4$W5TL*/,5NE46W@T M8&0>DPY.Z-:S3H\DM>,DK@U,SZ'"?GSHA\O?<5$97.#O.%NN!%MSWLKF@UHP MO$Z7L+$@?& 5/9+G1*0L,47%KDPO8 MNMR@/1>]#$<<#.8C*[Z#.XGC)'"?][5$*OO>,HG":1"BU"E,08-SM>P2+9U5 MW*G@6P]):\S"7J"W?SG0MU'YR_#YMPO(][1Z33FQHS29D@J203$*7*QEP4IR M4UQ))K8NI6W*P%Z@=W]2T ^K[LZ=_!WF[[/[ZWQ1QRC-9Y?3V568);RQ>HU2 M&94%J)1-+9?(X(HCB7B14PG"%-&Z9WT -O;"O?\KX'X@U??C\&\R[YUBIY/O MXP(OB3W.0C1)&8BYS@U]A+QBO@VBI Q>\ MFYOYY9/+E:YE6Z\G<^ H&>>@A5646B,QG*( 8[WDR+,WK/6;RLE$[X?7E_P@ M>%Z]]CM/]OHV\^^K&FY?,GU/,SE]4#,(%U2SE?8"0[*R4CNU%APMCB)63LTK:?( M/$5/LR;]M=Q?W9'[1B_YPXPT<+58U&&AL_Q^/EML?_DZ+*?+=?&**LSI4#%S:/ M@;>=#GM"YNTS[R%_V\79+AGA%0=6]QJI5!(_![42-= HNL6%%V61%X IB0(II/!<0O L@I4\E9*\S#K9$\R$Y MXY8SC@NN8S32*;CD=ELHDTY*SB#'NE>;%P8^<@\B):VLBX$Y>09PR1[:B,<% MUS$:Z0!<3TX.D)! X"&]UVC)@K- M]-45]G8T< =.V7XF)ZT$6:6*WH#36H#AJD14QHO4VK.]T/D^!VG]D/D^AZB@ M S@]/5K&<*:9)MD(1L&D0H9D;Y&#Q62D+]I0+-#ZI'RA\WT.TOM!\WT.4<+1 MB/J!BS@?;F +I=>AU,$/JZ&BRFL#/FA/OS24K$A.QWSK._$C![:,,^'G%/2< M*.X>G%"#*.'FY9&1P-#:"**&ILK6T M'1$=F,.:YQUO/M=//D[HHCBOVQ+8JEC( 65EZR:KJ**T 5M/R'Z6J$YNX,X/ MF/F0VNL CF\W7UL+WG"V7*GTXT68K1F=:*XSM]K2T44'CI*:$S/L41>,"L;'Z'Z0>S731 ;+N[1S;QD4K9G9(<*(BCZL>J+J@G-A+ 6(D M'J7-L9B"V3:/(@\D<=P0L_M?)V-QW( BF,*!.$L M))9UH'#:H1RD!^=1BL8-$X>%6D-==("LQQGQ6N>844$="U77WM?U"93[>58, M,[7)I[0^.T_#TV!=XL/BJ8T&CH=2LR[P6T'M4[)"41BK#318++E>K@4$34E8 MEL5ZM$(PU?KY=#_*7OYK1)LD80 ]=N#H7E\MIW7P!T6G<;J>K_=FU>ORE91# M/RVGI-]-(?":_Y^3(*V)G Q0,ROJI#Q)48)AQ&).S#%A@FU=%'H$F>/F%$.@ M97Y>U76 SE50L2N!>K58U&OWU=/W-7=O-HU;6%U 6L6\EQ/IA,EUDG&V%,TJ MAPZB2 8"A2#.&YYD&B0(/(GJ<7WN&;![9L5V .5'4K$;)G>%.D%RSA$+&%U7 M#GK,X+B*H!,342AI96H]">88.L?-:\X U\&5UP% GQ;CI(BHO2 CXUD44*%N MBRXV@)":)1]U5LTG9CU-T;C)SQE UU AS=*@L_3+K0Z'7RFDF:5IN+C5+MBV M0>[9KQFP(^XP%L_1 B>*CPP%AWH? \ID0\>IID QJ\ I-[(\M+[7&+(%[K?Y M[.L77'Q[B_'FIG.2G,Z:?"_H4'=?:C(7+[('5DJ0S$IK9>MIV#L)Z>3A[50< M//!8)PN]BV*8VVS<"CB=<\IXI8AZCS7@#!!*BD!YDU.*"^=BZ[Z=W91T&O4KKZ=G51&^$?CB)9#2&Y'MLZ+T_^Y?7/ 0,I12.L@Y MKY=IK.5U8]JK@F]KI%6J[LN0=2((DW6JCSQL:G<-A2+>"P'9: I)2R#Q^#J)(?-D)(]!\-8O&#L)&1=1#14] M;RWU#J"SA\%M:K>]S#8[5<#KVF.G<@)G P=,S'CNLL74>K_;WL3U< Z>!(3# MC\,CM-(7W&Z-Q;HSF_#C2N8;]G(T427M(#I'[ E*M8+S#LB]4ZH5-).N=;1Y M((G=GY?' .5Q.#;76E^@)+9N5N?<#$?>2"SW/#LKW>^L+E6RS3&>;7.*,?+FME]?)5_K]7:RXWW#'E MHH@.(=I$QTS1C"+AZ*%DSH/5,07=^M[W, I'K@P]-R9;ZZPO1'Y9$#_KS9$/ MN')))QY\!I]JZZ N"8))""PK)S3G%D/K=N_]*!NYEO3<"&REH[Z0]]3%P&_7 M59 ^:<-X?90.S%/0+1AX:Q"L4)')D(,IK9_R#Z6Q^S.ZS57+H*KK 9H?WKQ[ M=7FYF,:KRRJL+_-U,$PQR8?R)?SQ:7YQ\>M\\:^PR).4)5I6(LFQUC-86U]\ MH@%KG60^:U="\R1Z?_*ZSV5.P,E]4 ZDM"[>=C]?SM,_?Y]?D+Z6Z\N)"8^R M<*-SC3$2R:H.3]=.0V$4]OK@4,?6[O A%2/C:RB5/[A:/DGZ1R/H.RZF\_SY M,BPNV]0EI^GNO2C+K<1V27."4MIL1 !7K*RKP"EV4?23R,S[("3F]K7(1U$Z M\O%[)C2>08L=G,$/%IK4;;#S-%T7LUY^7)G&DPQS75NWL@"9DZ-X.%/PS4RA M""=IC,DQ[5N_EIQ,],@)]9D0?%[=GKK#YAR+^E:Q3 C6PW(*+F+ MB<+U7!^XG.,4'ODDDG24WIUS7],>)(^Z(A P*DWC='ZAB MK".M(_A$ENFSB(4'YY4N?<2A@VWT'3$./43Z)\:AO\QNN\+SEQKN_MT'0=" M)88'4G"NTL)3!#-,2:&7Q1+Z.!B>L$[E4A"BHM"3O)F6)3-LW@#6MJ3POO ^ M7)$E[W&=L;Y;XR)Z;[FKFZ H.30N0.'2Z=9%BJ?0.RY"SPBK M1H ^6,#UF-('V$ MFE\PJ#=ONL751K/L(0O.0)7:3Q1=@2A-5H$RAA):SZ$[C>*7">ICL-4(UDA\DS$(B#JS6I6%$#%3'&>4LHX+473K:I'3.R &>Q<8+WIHIZ4. M(+>[)MMSST.2!DP@TE4B"XK!91 VBAB#MBG\Y5LB#E+T7BT1ATB] ^@<6NUL MI3.&DE!(L:CUDB"7-8.HK)#>&Z=S\Z'7+ZE&O0$H3JQ'/T1#711P'%A%JHU) MWA4-"7UM-2'^HC8%I$47BE>8[8"M.:TJ?P<[4@<%8&O]=(&_IU<4J4!1)QT+ M)M>)WEXZ\ 49""V$CKR(E%MG&238O=7G8(5H_9'G8(2KH $Y/[ZWBD2F13 +KG 2E MR-Z\\ 4*)N5Y%,JVW^'Z0I>'':3W@Y:'':*$+H[$+XO58+.?O\W3/[=MC@K1 M:R\@2VGKG%E*DIQ*4"Q/3"299&E=R_"0BHZ7AYV"GA/%W8$3NA\9W$2%^\8( MOUU7NHODHN"4DULIZIB"XB$DFX'I@-QH;2A:'?AB]P3RQZWMZN*^F2])4'^;SW/=B/ 9%S^F"9>?YQ=Y8KA+I>[$X+JVH]6?/)THX%SQDB$R MU]P?/DY-7^\%8^&LD;9.+;_^TG8L_UI"$Q5B*$D42-X9BE:M@9 I"+%D0-PX MHS)KO3O]UM?W=<,Q%L".U4<'I^&[&7T6+B]_^:.N *@;2+-!2]DY"AOJP&RR M!10"N'0!(^$OD*RL2!UBE[Z<50/;Z!??:L]!/]>A[OEXV(Z7VP< M5$.U84SP(*A0%U69D$CX[81AY34DZ7V/Y:[1A*QZW6[P6K9]!R MUY!.EU=A,0T7VP>_"0K'D[<(Q=>=HMHA!)T\""1)LJB"]ZVO\?8@:R^PFK\@ M6$_27P=G^$.62-CSK[,Z<.H]7D^:>GN%7^:?\?+R8KW>AT\*QVRS9: $*V1W MABQ06P7,UCO.: 1K/L+N6%KW J_]ZX%W $UWB>B-7)>7RTGQBM(V%L [1^=& MY 5<" 6R1S0LNWKQ-3AJ;^C9"YGNKX?,(S76STE_T_]:V[K7J_VNIK.O'[YO MUOHMU],+MG>R?^#R[]/9?#&]_+F-WE_-\MU/6==[_!TO?Y_?F@6XI*R16\E5 M 1YKQ0?6L6M:T'\*'4/(2^"E]5WD&=G;RT3\G]U$>L53!]W8URQOTMV-&YG$ MNBZS%D(Y7]_51*I/'-R","8G5TGD*F&W.: M:%8BEDQ1?RP1E")&/&,"8J!\H""WNOG5UQT"]H/8G_Y5Z'BE]+ME[S/]&N_, M.WBSJCR9SA[^R?%M_\=\2Z/6_I,9'*9]'P-W,MM:RE-7GP65(5AM(0@M"%") MXL_693!MV_<_I]\Q7UW@A[(:F?%ZO8IW\_X?2@S6Z@ Y1*F] MD=GSUGVB3Y#30R'_47I_T&O42.0=I-%/=]-PH0U/+))H%((RD4' 1#Z;"2.D M<<;PUGETQ^M]FJG]H-:U0W30 :!VMRLP.M(C5AO#U6GO(OA"N8>3P0GE3!9^ MF+UK+ZAU[2!%[]6Z=HC4.X .D?]M/EO9UG;E@4>9*&\ EDSMYC,.?.8.HB\^ MD7 PI=:P>4!$#Z?628I]4.IRBI0[@,FKG*=5_.'B8YCF=[,WX?N4@O-MMU)1 M-K-"LF#:@9(AU7.=@V8YZ%20_K]UR/,D03TVCYT"GW;2[P!*VSKME36L#6,[ MHX!ED5 Z2!G))KRQX)*GGQ3S5I@BI6Z=Z3]*S+@55.TAU$;J'<#G4TU39YA_ M"8O9=/9UNZA'992:W"9X6^=;Q"3K@KX ED2E6"Y.Q?;3>791,FZ=5'O@-)!W M!ZC9?U!*%,Z$.CK3I5!'#ZD D4L-Q5&4P[8NW&P[_&:PNJ8!SK5!M-(! MW%9)ZB9EO;E^Y:((KTJ&: O6H0(:O"L)A,LAZ'H'HEMG]CL)&3<\&BJC/UWF M'0"'0%\/:GR+Z_]_-WLXD_?VM%]AR>"TM\#KM;[R5H%#GL$;+8OR 9TWC2%U M((GCIG(-0/'PJ6TP#74 P%N9ZNJ)8/ENN;S"/,E6N5(W'ALN BB!&@)'!,:L M+)QSP6QSW[6;E'$!-:CZ'[\U.%H7W>R&V;7CQF%QQ6KBH]8?94^'NF!DD$4* MJXC'G#N9[#[887A..)VH@6Z0M".579O'1*)&5*: +3*2=(*!6/N]F0_D\C$% MW7SNQZ/$C'N!<$Y,CI=[!V'32BSKX_GMU6(Z^[K>,?1?X>(*5\;PFJ27:WY+R>U* M?1.+W-M$+ 6N8]WP1BET%AIB\LR;(#WWS>L$#J9RW!N'LY^.PVFP7XRN??4C M+/IH78DJ@RRIEHB'1 &"R%"$S,:6$IEJ?:(>0>:X+50=H+29#CN Z9UP8LW8 MJT1")$HFW(2<4M)D;+R DCJ RTY +#8A!E:,:>TSGR!GW.:GT4*\$W32&[Q6 MWGW+26V*69?L3Z30+B>2$'**654.&2(:!!.C9IA-"J7U;<<^=(W;TS0:X%IH MJ9_J]K?3'].,L[R\=;U3!Q%/&"O"Y,@ +9(A9<,@6HHIT&GGE-!)-Q\U_A@M MXW8&G1-H3;31#[A.71>9HLTVUT6GUM0*74K 0B3C8LB*_^S/]&-W,S;Z3)=S.GXP@_E]G=^PE6![&IDSPH>L5+U,?Q[%43!"\0TB&$F9%=NUR\T>N5L2/O KD?)A]HA_\ MC.KOX%ID33G]Y74#JRS<2YM !(R@)"]U49@!(;(5V@<16.MHY X!W72'GQ,$ M]]L8CM9(!W Z7G W;,]RG2SW/EPO.K:*:4Y'-C"C.$FSRJ!..'3&TV]K3DE] M\_N4 ?@8%]PGP.J^KQQ;QQW@G(+K5;8X2^MRGFTC6\R%$F0427C6Q_^CY RLBL='2/S]@KK '>?*+E83!-%0ZN4XA^SZ>7RT^=_;)C! M2(=.Y(RL.BE0-B%$QS(EDZ)@"*B5:.THGR1HY-:PWC#83GD=(/%9Z3XFW-^N M&Z="-HA%.XA%65!:*7#>:-"Q).:=$J)YE_7I5'?3[CABB'IFW;]DM+^_JL:] M4=?RU8\PO:CB_W6^^!O]6TI:'5/",PG,QSJXFT3@B_3U4<'P$(LULGG7TD"\ M=!YQ-,9D*Y-H"9"7;"@?OJ^F(Z^87KZ;K2N1)\PPI7E0%(]Y RJA <^3!TE1 MFW-1F=)\\55;#CH/@3HUBM/!\!),X=$3>B?[_XW3K[]3[/CJ!R["5_SE#URD MZ1(_4D2)$Z8=G=?2@54WZ:Y@1!M2KRN,FG>JWA&]L;M?NS=B$:"T4NP ML%,DL_K#M^$2?PW3Q:IH?((Z&E:0@[=9D .RG-28#,7,B:$-V9K,NSZ-GF5Q MW ;1WBUM1#B]9&N[YOC5W!ZL9GR0]&(NK?S'5A+_ M-;^@C[FHE<+5@\C$>7)1@K"VD >IFM)('L04:[2+Q6(WM]#[LS5N-W$/!M01 M;/ZLEK2M-5V?Q)Y'4POL#=:B^(06 A8/*6551Y!GY;H.WG8Q-6Z+])_1BHZ& MS$NVH6V#P?)R<;6ZL5GU7G[Y/16()G"G6";7 MTWH.Y[EX&[<7_*5:U) ^@L9UO-7,A+1:Y<-,%=KB*7+$%F=&XS(N8R1,]G- M>U-KYD?N??^+V&9;#(YHO/]:7DX^_EB2*.97EW^?SJ;?KKY-%+,J9UDWL2E1 MFY@5-\A#]6U#LI M/$JCH 9XA&WAP3%IP&..BIE4+$L'X6/]N2,WNW>!CR,D/"H^K@O3+U9_!_-N M*6YV$$^,YR[JI,$$(T$9CN#JBBNF2'!8^7ZV-^FC9_N7:M'=^=>NHW-NI?;X.5TL3: 6W_CIL7PIF\PQ)",D(3WPC-Y3"8A^! A:28Y MJFBEE(T]2RO:3YX>=R(=ZU)BF:U%=!)DUHD$6&?8:JLI+@DE&R=85JUO_IH0 M/G*WZQCX?3"P[NP Z."ZX=,U5Y6=ZYZX%$0H=2L4G54!%/($(7 ++ C"6GG^J< MY-J,IH)'9KW+@K?N&WF.IM[ =(SF'W2--E1#![!ZSHOO8C$KB0FU AFR T42 M@^BUA\)YM-FSS$3K8_$(,L?MLQ@$?$,KJP,\WI7;9\HFE_/%;_6?5<75PR K M#-(Z1]&L,Q1'2%:7_D10*KE@0]"&M=[B_"Q1XV*MM_CL5*WU#L.-)4NM"F=U M*%LJ9,F%N'%1., 4"HO,%$RMD]P]R.KIS#T9"(? [ BM= THAJ7E]-4&=IX M;!,ENNPEQ! I;DB1@Y>* W<^ZY"#E[9UY]9#*CJ&T3&*OG_)<9K41\1-FE_- M+A<_)__X/-$LH;2)@2RVCH=T'IPV"#9AY3[D;)[R/TM,__/K_,=_;#YQ#9/- M+VX0S=QFLP[ ,U1D>$J'/R"?UR^OKBSU3KFX&3D";C7Q'&( M ERIF6W2.K.HT(G6[ZTMZ1^W97C\&'TT+'1I!Y]Q\6.:L#Y)3IPF9C &2*). M5Z+T'.@C-%B9T.H0@E*M'>F3!+W V_XF.'D6L, IREZ@3<:Y\'@T6KK$H3;)@R*I*X6LP^K4.?5 M24B #$QZR8]P&HZ63PT/RX'%^'H V4NFI.^<& M NRK;W4!V;]7BOY0/BZF\\6M4^$-$3F]G$0DHZ0P'3!HXI/. J"0WP%S3& 0 MDKOVFPZ/HG3#SG[A&G^=3;]-^;W>+GE[NT5 M?IE_QLO+]9ZD)9\89X+W6H(.Z.E$88),4%)JZC*:5.J=_O!XW8_6<0=(= SB M 53=:?"PNR1YXE-B&#V')$5]DF<> C(.KK[(BY13=&QP$.^F;=RA#1V#MH$J MCP\)YI?AXEQ=!>_#8D$?^0/;M P\^+@!^@&>)KFW8O](!S5'*T%&;>LXW0S! M:PHJ"4@ZR.01FR^V^E,5^Z=L@_8\@DN:#H;L* S7C$'D3JHKZTR ?Z9B M_T/P.TRQ_R$ Z" />Z3(&)-7IE! 8TW*H'@.$$H]J8K(/C)%3+2NG_WS%OL? M!(G]BOT/T4^7*-L^2"MO1%H-TS6A-CX:<)PD59!G[14:J5M/Y7M1Q?X'Z7G? M8O]#A-X!>)ZM,G?6BT@1-;A5,J9)4D%;8JK(:)A).L36M8B35VOZS=D\8DY2QN@YQ9-5[D(&KK" ([IUBR;K8 M^K#>F[@7&"=*\.]F]&O<3(E9_<[FY_4?''\+>LBG-[H4 M/9JA1G>DM[Z?<+WYVELW1T%9D9($X3.%#]P(""X5"*&$S*U6W+9^O'N:HB:[ M4*_2Y=5B.OM*GW]K33Q]YU4%_.J5("<; I,.Z8WQ,O.3:>-5=/%L+*M;_XP^QPN\TE(203#$K@<(N6?4I,JM(1$!AR<$M'9UB\_9V)MW.K2 2V@1VAT MD&MM.KW>U(-HEGY^(=:7)&KB:>LR7F.AO_,E_#'AR:O"A03-ZC0:7^>M1A,A M9L>#+ZJXW/K!^ #RQBTI'1"Y0ZFH'[>]$MZ'[RMCFGV]DS=0$C@)GG/!N 6) M@;+,NN+*2V- L<@IR?&%Y]9I_=,4C5L6.B#4&BIB?'35F< /$U$*M"4+VGD( MQ3B2#U<0*9P!J1S#DGDJY9X7VSEW^>$GCUMG.0 J&@CP9!0,77'VD+\&=6=[ M?.A@%RUGJ4%[!FPF*&?('P"65;>NS>MHJ-#QDUR.2>K6F=ZP]RO;0;\?RA/I M_.9M*LJD$SH%R3M*Y&5P$#US8*61P3);765CY@\@K^M[ED-P\V!IQ4 JZB!& MO\/0JONBEHL$PSTK08!TM:>-DR\.*EN(*7M=C)3,Y<8XVTG(N(@:3.U/7>,= MI8,>@;0I%;':J"2L@R)#JG&= *^2!RZ=%:O5S++]0*^=I(Q=2W.RDI^#S1$2 M'WFQS2O2'7O QW;(HA3*:Q$AY%(? (L%7\AC^Y2E%C:KH,T>P?13W]$9)(Y1 MX'P :8Z(BN7B"BO"[-4N3Y]Z MRW'0KVZ.?NCSYGC9]@"(#8Y+B89'5&!LEI5L YZINH+/!N&TER;O M]ME"'@ M7J.1GU'YG2\=6>G'J&S>0GYC*WZ]7FM#>!T\8%S*1*EW0$>@A: SHX-+6Z^T MEOG^&K/C%'_[2\HJ&'#A=)9.T M(2>8"FCEF<[*66_:KP]YGJYQWS9'R51;:&CD_.,1:;U*E],?T\LI+M?MT!_* MNWHS^VVKTHED/G*-KA:]UK9]Q2$J,BQM1):,%NN@7Z>\XW6W,BZ MK"K7_!Q)#$XJ"X@4P&:F@VS^S/IG>G/.CN&[!\?J'EE9PTAP M$5(6Q$ZPQ%A=]!&4]$7F8E@YX^W)RWKB/P@*^U^<'*R7#F!61T'<$]GF[3(+ M^MM!U]7VK#9L!@I*#/<0N)22;+-(VSJ#>)28;N])#E?Y? CY=P"D31LY?L8? MN BSM+W_1IU\9@XA\U"[RHT$[ZT$G0UJ"C8UYZWO/1XA95P0-5+T_<2S@=0[ M ,\J1+@CF^VZ6*N2X@E!ICJP4KI(5A4"2,.5-LJXW#RN>HR6<6_)AH%/$[EW M@)_=)5E&:&%,X,"\Y73,2P;..0N:PDH?K5"(K6MLCZ]][*(6I5E@=)0.>@32 MQLBI,!]:Q\/D69O[N2QVU]>?#:2 M:,TU!OJ-LQ\FE]<_#I?_"LL M\H2R5:[KJH*0K2++9 SJ=J/:KZFE(C/2MO5 _V=(ZLB#-<' 4R [42&=XFL2 M<]0A% O!FNKN;0+/I:$80%AM.-D@;]W-MXN.CI!TJJ+W -%!4C\:.=]7E3J? M+\/B/[],KN]=^MLA01C8NROH24& @AU<7D M(,!P2R>8=2&EEU&64N]&WN(/O)A_7U5+S_+%--4)_+.OT]5WK9-ARY,TN;I4 M$>E@=D6!9R8"6EE"*E%9(YX!S7[?U'51R2%:OWWYU%C '40^;\EY_5B->GDW MJPZTLO9INOSG^N7:)Q]- :@B] M/QA@W4@)70%J-4B>K.W6.I%BI:V;"B&6NITF^TB9:6;@##*6M3+!M]^*_C@] M8^\ :*7U1^%TH@HZ@-.;^;=O\SR]_/GA>]7+YIX_"&.5J>7RPB+Y[Q3!U968 M2A>+Z+GFK+5CVDE(+P Z5<_SUD+O #G_B?EK+8/ Y?3K>E3KRK"\02^,TH"Q MCL?@L79%1@7"VB)%*847U1@ZNRD9YY+H#*=9 \%W"9^-845K@_+%UC?&.K3% M!3(Q)2&Y.ELE6[*+UM>.C]$RKOMIH>=GH7.$T#L S_LY9:YK'C!OW:>/A0M5 MH"!Y9<5MO8L@XV(B.YN\(,-J79&]@XS>('.,?N=MA=T!7M:9ZF=2Q*K5^;?Z M#[;V9+0QDGL$Z[6C@SQ1$%C0 N-9)6]XS*KUF/@GR!GG%OH,IU8K%?2+IHVI MF2CM:C.(\"0I%2F,"SIY\%$:&7EQAK7>U/LD0>-ZI&9JWP].1^B@ T#=&QZ_ MG1B_\;6,.R55(>>::J8AD$.,S *7*?"2B@VFM8-ZDJ N 76,XI\>X7^"%D8N MB'S2D_]V75(CN5)>&D=9IJ5 ,J, 1TDFR!AT04>'N-QG]LI^WS;.P]B Y]I M@N[ &^VZ-UN^GU^^O0X"7RTW@>:MO[ UE[J"(.4BM'$%F*VKL1'KO5HV8 (R MK80-VK8^ D\FNM/+[R-1M,<%^' J[6+SV2__[VIZ^?,SIJO%:M[1KS_>3S]A MN*A+*[>,3;363%N.%'?4B[909YE[)4!RQAA1C@Q;3\_8AZY.KZ[:8+&Y8CIP MF;MX^L=L<9\K4^<1!Y'!9FEJI;2$X&+M#4P6I3,EE-9^<3_*.LTZAP/[Z:]+%*3+5DL; ,2HIPA#Y-R M'15>6*J+MVUSU_\$.6VN).BC-Z48FUW-DV2$B<62H>A0*_P2@E+1T!%L*0]6"I0LY).=,& #XZ(4S1)K?%UGWU]+#<<&@;>V,U2F 8R6#\;(*(K&$^^Q8:4;0N(7H8V&SO:[&Q^G-'<[ZVQ\+.00/ M7"LO0.O5QD<3(=01-,445*)X9*%U!\0S)(V[@76HT[BE'KK/(S_CUYJ:OYN5 M.?W^ZJ'EZ'3R\<]JE%7N26RCY'+S;9_P^WQ1%_%>@TMKQ$#Q%I0H; 4 N9<4 M.,5@SF<>H^7D.INK^O95AP#4#ZYO)9MO6DYR\8EQPK5'R^IN+0V. M.PD84RHV<<9C:RX?IV;DV8T1_*]>KJCXLY.#GRG M5"G&\:#%7GN5#G'U3Q$T]OB%\Z+C_C3B9JKJ 7=KVK?EFX4IQ82#:#UEUMY% MB,IH"%R)4*)G.K2NB;Y#P,CG:SO%WH?,T5(>^?+L8TC_#/6Y_O//97T@VQ0I M69X#I\P&1!&%S*/LB(=F".05M ^9GHO3'/[V+(.L85/MRVVA4Z? MA,@1 NX@#KVVJJT=;2=4*X5:0. =X.;=;/59*Q9^N9AN7V4VS%"D7D0*"7).=8ZL=G4!MX-L?)2E MA$R&U;PLY0F"QMM5/ B&V@F_ R2]F2^^S\DD\/U\MK&)#2-":NZM\\73< M>#=L_.VZ(-7Z**)1'IQDY(Y51@@N45R@/,NY+H+?+TXZX9&G$2MCSST<]\ZP M WAT8"6?\ ?.KK RMAUU\M_3R]_?7"TOY]]P\(JUT>$Y1+I?R3X/R:2 MDF.6B#%EJR/(68)+7H&1C*2??,RB_7J/@\GLXM)J7'@]>,,95M<=P/E:J.L: MC55Y/ZIHC58"%"L4]3B9B 59Z!CCNG K V>M)\WN(*.+N[2NX'BJKCJ V^?? M2?JOP[+.9OY6:X%6"IVPDE,PR8"VBLZEP"U)A9<:+G%K*8YBJ76'P6Y*1EXE MT2'H&FBLG\+ O^&,Y'?Q:I9?94KUIO6=O]9);NK2)BF;&(*UP(2S=9F8AIA) M4-8+PUS.I=C6:=(S)(U;G-HC(%OJL!]DWMWLL5Z1/5$8D"=7YRT611[>K*U^@/?J6Q7KOS^+UAMXGJ9H+S":OQ(8&VKP5%B>_&2_ MWM[Q@\QK59[\[7N8+NI/=8:H4G.1P*-+@,:9Z+/,^GX/ZLY7^\<^ M?R]4V;\"JIIIH1\7]WX^F]]-G;:Q M=<:9LD1*Y(0,AK+913X+2KDQ.T";'U M!-9'B=D+@NZO ,&V>NL'AS=I^_9&Z7Y3ZFLL\P7>:OG_^W0V7TPO?ZZ>J7"U M[^WNIZPG-OP=+W^?YQN374XB"EU"26!DXJ!*7?*>!0)%(NB$])J+87KVS\+> M7K;B_TJVTBNVCK]SFE^&BWWZM39_4/\3PQ+_U__X_U!+ 0(4 Q0 ( *Z" M6U4Q!PXI1@< "8B / " 0 !E>#,Q,7$S,C R,BYH M=&U02P$"% ,4 " "N@EM53G8P1$,' L(@ #P @ %S M!P 97@S,3)Q,S(P,C(N:'1M4$L! A0#% @ KH);5;1?G0X ! QPT M \ ( !XPX &5X,S(Q<3,R,#(R+FAT;5!+ 0(4 Q0 ( M *Z"6U4+W8BL 00 . - / " 1 3 !E>#,R,G$S,C R M,BYH=&U02P$"% ,4 " "O@EM5H<6[SL=M @#M!B( $ M@ $^%P =W-T+3(P,C(P.3,P+FAT;5!+ 0(4 Q0 ( *^"6U4O#(3+'! M !&L 0 " 3.% @!W'-D4$L! A0# M% @ KX);5:QVSWM-(P M5,! !0 ( !?94" '=S="TR M,#(R,#DS,%]C86PN>&UL4$L! A0#% @ KX);5?:$P-P.2P (CT# !0 M ( !_+@" '=S="TR,#(R,#DS,%]D968N>&UL4$L! A0#% M @ KX);52QO%>@1[ OF$) !0 ( !/ 0# '=S="TR,#(R M,#DS,%]L86(N>&UL4$L! A0#% @ KX);5>CD0>P-B@ U@T& !0 M ( !?_ # '=S="TR,#(R,#DS,%]P&UL4$L%!@ * H *> ( +YZ! $! end

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Ǯ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